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Abstract 
Introduction: Obesity, with its associated co-morbidities of diabetes, hyperlipidaemia 
and low-grade inflammation, has high prevalence in women of child-bearing age. Of 
further concern, it is associated with increased risk of adverse pregnancy outcomes. 
Considering the key role of the placenta in fetal development, alterations to its structure 
and function in response to the adverse metabolic milieu of maternal obesity must be 
important. The trophoblast is a key cell within the placental maternal-fetal barrier. The 
research aims were to evaluate the effects of elevated glucose supply, in the absence and 
presence of non-esterified fatty acids (NEFA), on pathways of glucose metabolism and 
trophoblast morphology in human trophoblasts in primary culture. 
Methods: Trophoblasts were established in primary culture from human term placentas 
of normal pregnancies. The isolation protocol was optimised to improve trophoblast yield 
and purity. Experiments were performed at both 36 h (short-term) and 5 days (long-term) 
after trophoblast isolation, when most cells were, respectively, cytotrophoblasts and 
syncytiotropblasts. Syncytialisation was promoted by adding epidermal growth factor 
(EGF; 10 ng/ml) to the media. Metabolism experiments were performed over 2 h at 
diverse glucose concentrations in the absence or presence of NEFA (0.25 mM, palmitate: 
oleate ratio; 1:1). Pathways of glucose uptake, glycolysis, glucose oxidation, total and 
partial palmitate oxidation and glycogen synthesis were assessed using radio-labelled 
tracers. Lactate production and glycogen content were measured enzymatically. The 
effects of EGF and NEFA on trophoblast morphology, lipid droplet formation and 
triacylglycerol (TG) content were also assessed. 
Results: The improved protocol increased the mean (± SD) trophoblast yield to 266 ± 
141 x 106 cells, and purity to 98%. In short-term cultures, rates of trophoblast glucose 
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uptake and glycogen synthesis increased linearly with increasing glucose concentrations; 
whereas, rates of glycolysis, lactate release and glucose oxidation did not increase with 
glucose concentrations above 5 mM. NEFA enhanced glycogen synthesis, but did not 
affect other glucose metabolism pathways. Total trophoblast glycogen content increased 
minimally with increasing glucose supply, which was not altered by NEFA. In long-term 
compared to short-term culture experiments, glycogen synthesis was lower and the 
trophoblasts were able to increase glycolysis and glucose oxidation rates with media 
glucose concentrations above 5 mM. NEFA increased glucose oxidation at the media 
glucose concentration of 1 mM. Palmitate complete oxidation to CO2 and partial 
oxidation to acid soluble products were significant metabolic pathways in both the short 
and long-term cultured cells. EGF promoted syncytialisation with a lesser effect of 
NEFA. Neither EGF nor NEFA affected trophoblast lipid droplet or TG accumulation.  
Conclusion: During acute exposure to high glucose media, human trophoblasts divert 
glucose uptake to glycogen synthesis rather than glycolysis and glucose oxidation. This 
diversion, however, is less evident in more differentiated trophoblasts. NEFA have 
minimal effects on glucose metabolism pathways, but are a significant source of cellular 
metabolic energy via oxidation to CO2, but also by partial oxidation to acid soluble 
products (e.g. ketone bodies, short-chain fatty acids and tricarboxylic acid cycle 
intermediates). Further analysis of these pathways, particularly in placentas of obese 
women, are warranted. 
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Introduction 
1. Introduction 
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1.1 Obesity overview 
Obesity prevalence has doubled from 1980 to 2008 worldwide and reached epidemic 
levels in both developing and developed countries (1). About 1.7 billion adults have 
overweight or obesity making excess body fat the sixth most relevant risk factor to the 
overall burden of disease worldwide (2).  
Obesity is a complex disease that occurs owing to a disruption between energy intake and 
expenditure and it is characterized by an increased amount of body fat mass (2). The 
aetiology of obesity is multifactorial, involving genetic and environmental factors. The 
neuro-endocrine system is affected and the physiologic regulatory mechanisms that signal 
caloric storage and control hunger, satiety and basal energy expenditure are impaired (2). 
Obesity diagnosis is made by calculating the body mass index (BMI) that is calculated as 
the body weight (in kg) divided by the square of the height (in meter) (3). Thus, obesity 
is defined as the BMI ≥ 30 kg/m2 according to the World Health Organization (3).  
Obesity is closely related to the metabolic syndrome. The National Cholesterol Education 
Program’s Adult Treatment Panel III report (ATP III) has identified the metabolic 
syndrome as a multiplex risk factor for cardiovascular disease (4). According to the ATP 
III, the metabolic syndrome diagnostic criteria include at least 3 of the following 
components: abdominal obesity, hypertriglyceridaemia, decreased high density 
lipoprotein cholesterol (HDL-C), systemic arterial hypertension and/or hyperglycaemia 
(4). Besides dyslipidaemia and glucose intolerance, the most common pathophysiologic 
alterations observed in obesity associated with the metabolic syndrome are 
hypersinsulinaemia, cellular lipotoxicity, disturbed adipokine levels (i.e. 
hyperleptinaemia, leptin resistance, hypoadiponectinaemia, elevated levels of resistin and 
others), impairment of endothelial function, higher levels of pro-coagulant factors, a pro-
inflammatory status [e.g elevated levels of interleukin (IL)-6 and IL-18, C-reactive 
protein (CRP), tumour necrosis factor (TNF)-α] and elevated oxidative stress (4). These 
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chronic pathophysiological factors lead to obesity-related diseases including type 2 
diabetes mellitus (T2DM), psychiatric disorders, asthma, sleep disorders, renal diseases, 
cardiac, cerebral and peripheral vascular diseases, non-alcoholic steato-hepatitis, 
osteoarthritis, cancer and many gestational complications (4).  
1.2 Epidemiology of obesity during pregnancy 
As for the general population, the prevalence of overweight and obesity in childbearing 
age women (20-49 years) is increasing globally, not only in developed countries, but also 
in low-income countries in the past decades (5-7). The highest proportion of these women 
is in the Americas, where the prevalence reaches 70%, Europe and Oceania. Africa and 
Asia also exhibit a high prevalence of overweight and obese women, being more than 
40% in Africa (5).  
In Australia, about 45% of women aged 18-44 are overweight or obese (8). However, the 
prevalence of overweight and obesity in pregnant women has indicated a trend of plateau 
and these conditions may have become endemic in this country (6). Data from a study 
with an Australian population of 75,000 women, who had a singleton pregnancy and gave 
birth between 1995 and 2008, showed that, overall, pre-pregnancy BMI has been stable 
for women with BMI < 35 kg/m2 (6). The percentage of women with pre-pregnancy BMI 
between 30 and 35 kg/m2 reduced from 7.7% to 7.5% and the percentage of those with 
BMI between 25-30 kg/m2 remained unchanged (20%). Nevertheless, a small but 
significant increase was observed in the prevalence of women with BMI ≥ 35 kg/m2 (from 
2.5% to 3.2%) and ≥ 40 kg/m2 (from 1.2% to 2.0%) over the years (6). These data indicate 
that obesity is still a major burden for maternity services and the most severe cases are 
becoming more frequent.  
Gestational diabetes mellitus (GDM), defined as a degree of glucose intolerance with 
onset or recognition during pregnancy, has a prevalence of 1-14% depending on the 
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diagnostic cut-off used and the population evaluated (9, 10). GDM prevalence increases 
in overweight/obese mothers (11), especially in those with higher weight gain during the 
first half of pregnancy (12, 13). The prevalence of hypertensive disorders of pregnancy 
also increases with high BMI, reaching 1.4-13.5% in obese women in comparison with 
0.7-4.7% in normal BMI pregnant women (14).  
While some of the adverse pregnancy outcomes related to obesity can be attributed to 
hyperglycaemia, maternal obesity has been identified as an independent risk factor for 
complications, in particular for macrosomia, preeclampsia, stillbirth and excess fetal 
adiposity (15-17). Other components present in obesity such as low grade inflammation, 
dyslipidaemia, sleep apnoea, hormonal and adipokine alterations (4) may also contribute 
to adverse gestational outcomes. The detrimental roles of non-glycaemic factors 
contributing to obesity related diseases are well known, but their effects in pregnancy are 
not completely elucidated. In addition, there are not many studies that have investigated 
the possible synergistic effect of hyperglycaemia in association with these factors, 
particularly dyslipidaemia, in the pathogenesis of pregnancy complications.  
Before discussing the pathophysiological processes involved in gestational complications 
related to obesity in this chapter, maternal metabolism in normal pregnancy is presented 
in the following section.   
1.3 Maternal metabolism in normal pregnancy 
1.3.1 Glucose metabolism 
Glucose is the major nutrient during pregnancy and maternal glucose metabolism has 
been extensively studied. Basal glucose and insulin metabolism in healthy lean women 
do not show major differences in the first trimester of gestation in comparison with the 
non-gravid state (18-20). In early pregnancy, post-prandial glucose is normal or a little 
lower than in non-pregnant women (18, 19), and endogenous insulin secretion is 
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increased in response to oral or intravenous glucose (18). A study that evaluated healthy 
lean pregnant women pre- and during pregnancy showed that at 12-14 weeks of gestation 
insulin levels raised by 120% during the first phase of insulin secretion (i.e. 0-5 minutes 
after intravenous glucose injection, an estimate of β cell function), but the second phase 
of insulin secretion (i.e. 5-60 minutes after intravenous glucose injection) did not 
significantly increase in relation to pre-pregnancy (21). Another alteration observed was 
a higher insulin clearance in early pregnancy in comparison with before the conception 
(22), which may occur due to a rise in glomerular filtration that starts in the beginning of 
the gestation and peaks in mid-pregnancy (23).  
In the second trimester of pregnancy, a progressive physiological resistance to insulin 
initiates secondary to placental production of insulin counter-regulatory hormones [e.g. 
progesterone, human placental lactogen (hPL) and cortisol releasing hormone] (24), 
alterations in the growth hormone axis and increased leptin synthesis from both adipose 
tissue and the placenta (25). Thus, as the gestation advances, insulin sensitivity decreases 
by 45 to 70% in comparison with the non-pregnant state (20, 21, 26). Consequently, both 
basal and post-prandial insulin levels progressively enhance to compensate the insulin 
resistance. It was reported a significant increase by 65% in basal insulin and basal C-
peptide (22), and a 3.0 to 3.5-fold higher response in the first and second-phase of insulin 
release during the intravenous glucose tolerance test in the last trimester of pregnancy in 
comparison to pre-pregnancy (21). Also, the metabolic clearance of insulin is increased 
in the last trimester in relation to early pregnancy, possibly owing to placental action (22). 
The insulin resistance of pregnancy is more marked in peripheral tissues (i.e. muscles) 
(21), while, insulin sensitivity is preserved in the liver, where insulin infusion supresses 
more than 90% endogenous glucose production (18, 20). Moreover, late in gestation 
hepatic gluconeogenesis rises mostly from lipid sources (glycerol from lipolysis) than 
from pyruvate (27) since insulin resistance promotes lipolysis.  
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1.3.2 Lipid metabolism 
Pregnancy is characterized by maternal metabolic adaptations to provide adequate 
nutrients to support fetal growth. The first two trimesters of pregnancy are marked by 
anabolism and an increase in maternal fat depots (28). The maternal fat accumulation 
follows a rise in the appetite and food ingestion from early pregnancy possibly owing to 
enhanced levels of the orexigenic hormone progesterone and a relative lack of the 
anorectic effect of estradiol (29). At least in rats, this hyperphagic effect is perpetuated 
from mid-pregnancy through a transitory hypothalamic resistance to leptin, which is a 
potent inhibitor of food intake (29). Prolactin, progesterone and hPL decrease leptin 
actions in the brain by inducing leptin receptor mRNA down-regulation and suppression 
of leptin signal transduction (29). Hyperphagia associated with changes in insulin 
metabolism such as higher insulin secretion in response to glucose with maintenance of 
tissue sensitivity to insulin (20, 21) contributes to maternal gain of fat (30). Insulin 
induces maternal fat deposition through stimulation of glucose uptake, increase of adipose 
tissue lipoprotein lipase (LPL) activity (31) and suppression of adipocyte lipolysis (32). 
LPL is found in the capillary endothelium and, when activated, promotes hydrolysis of 
plasma triacylglycerol (TG) rich lipoproteins [e.g. very low density lipoprotein 
cholesterol (VLDL-C) and chylomicrons] (31). Non-esterified fatty acids (NEFA) and 
glycerol are then released and taken up by maternal adipocytes (33). Concomitantly, 
maternal adipocyte lipolysis is inhibited by stimulated Akt activity, which down-regulates 
protein kinase A, the key enzyme during lipolysis (34). A decrease in maternal lipid 
concentrations is therefore observed in the first 8 weeks of pregnancy (27). Subsequently, 
other lipid alterations are observed mostly due to the actions of estrogen (27). TG levels 
begin to rise from 10 weeks of pregnancy (35), whereas low density lipoprotein 
cholesterol (LDL-C) and total cholesterol levels progressively rise from the second 
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trimester (35, 36). HDL-C concentration shows a peak in mid-pregnancy decreasing 
afterwards (35, 36).  
As the gestation progresses and peripheral tissues become insulin resistant, maternal 
metabolism shifts from a predominant anabolic to a catabolic status. Adipose tissue 
lipolysis is increased and, consequently, higher levels of circulating maternal lipids are 
observed in the third trimester of pregnancy (35-37). Insulin resistance contributes to 
amplify the rise in maternal plasma levels of amino acids, glucose and lipids during the 
post-prandial state to nourish the fetus (27). Insulin resistance also decreases the activity 
of adipose tissue LPL in the third trimester of pregnancy (36). Thus, less NEFA is taken 
up by maternal adipocytes from circulating TG favouring the breaking down of the 
maternal adipose tissue. Moreover, hepatic lipase activity reduces after meals and 
increases during fasting to provide NEFA and other lipid products to the fetus when 
maternal glucose is scarce (27). As a result, the hepatic synthesis of VLDL-C is stimulated 
and the VLDL-C/TG clearance is decreased (36). Thus, maternal TG levels are 2 to 3-
fold higher at term (38, 39) in comparison with early pregnancy. Maternal NEFA levels 
increase later than the other lipids (40, 41) and are 2-fold higher at term than in non-
pregnant controls (42). NEFA enhancement, in turn, contributes to insulin resistance in 
healthy pregnancy (43). As a consequence of increased lipolysis, notably in the state of 
fasting, NEFA and glycerol production are enhanced as well as hepatic ketone synthesis 
from the NEFA (44). High NEFA and ketones can provide energy to maternal tissues and 
spare glucose and amino acids to the fetus (28, 44). In addition, total cholesterol and LDL-
C are increased by about 60% in the last trimester in comparison with early pregnancy 
(35, 36).  
In addition to changes in lipid concentrations late in pregnancy, lipoprotein qualitative 
alterations are also observed (36). Lipoproteins not usually rich in TG in the non-gravid 
condition (i.e. HDL-C and LDL-C) start to assemble higher amounts of TG 
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(TG/cholesterol ratio) owing to increased activity of cholesteryl ester transfer protein and 
inhibition of hepatic lipase (36).   
1.3.3 Other physiological alterations  
Maternal plasma levels of amino acids are usually lower during fasting and the post-
prandial state during pregnancy (24). This is mainly caused by maternal and fetal amino 
acids utilisation for anabolic needs than amino acid metabolism for energy production, 
since the nitrogen balance is usually positive during gestation (24). Even though, amino 
acids such as serine, threonine and alanine may be used for gluconeogenesis in the 
maternal liver after prolonged fasting (24).  
In addition to the metabolic alterations previously discussed, healthy pregnancy displays 
changes in adipokines and cytokines leading to a pro-inflammatory status especially late 
in gestation (45, 46). The placenta expresses leptin, resistin, IL-6, IL-10, TNF-α, 
monocyte chemoattractant protein (MCP)-1 among others inflammatory molecules which 
act locally and systemically (46). Leptin is highly synthesized by the syncytiotrophoblast 
(the main source), amnion cells and the fetal endothelial cell (47, 48) and is distributed to 
both maternal and fetal circulations (49) with functions not yet fully understood. Leptin 
is directly related to insulin resistance (45) and serum leptin correlates with lipid oxidation 
during both early and late gestation (50). Adiponectin is synthesized by maternal adipose 
tissue but not by the placenta (51) and its levels show progressive decrease with gestation 
age with the lowest levels in late pregnancy (52-55). Studies have also described higher 
resistin levels in pregnant women than in non-pregnant controls, although with divergent 
longitudinal results (53, 56, 57). Low adiponectinaemia and raised resistin levels are 
similarly observed in non-pregnant women with central obesity and the metabolic 
syndrome (58, 59). In healthy pregnancies, decreased adiponectin concentrations have 
been implicated in insulin resistance development but not in alterations in maternal lipid 
oxidation or lipolysis (52). Fasting insulin has been negatively correlated to adiponectin 
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levels throughout gestation (r=−0.66, p < 0.0001), and adiponectin concentrations were 
associated with peripheral (r=0.55, p=0.001) but not with hepatic insulin sensitivity (52). 
Supporting this findings, lower adiponectin levels have been described in GDM women 
(60, 61) and in non-diabetic overweight/obese gravidas (51, 54). Resistin has been also 
correlated to insulin sensitivity in healthy pregnancies (62). However resistin role in 
GDM is uncertain since studies have reported lower (62), similar (53) or higher (57, 63, 
64) resistin concentrations in GDM women. In addition, resistin has not been 
independently related to insulin resistance in GDM pregnancies (62).  
Healthy pregnancy also increases CRP (65) and pro-inflammatory circulating cytokine 
levels (45, 66). In non-gravid conditions, TNF-α is secreted by immune cells, fibroblasts 
and adipocytes, and is associated with BMI and insulin resistance (67) as well as 
insulinaemia (68). In pregnancy, TNF-α levels gradually increase from early to term 
pregnancy, mainly from placental sources, and this has been an important contributing 
factor in the induction of insulin resistance of pregnancy, since it is inversely related to 
maternal insulin sensitivity (66).  
Besides, healthy pregnant women seem to have higher oxidative stress rates (69). A study 
has shown that rates of DNA damage, which is an indication of oxidative stress, were 
increased in the third trimester of pregnancy and that these rates were positively 
associated to maternal total body fat, TG, total cholesterol and LDL-C (69).  
Therefore, major physiological alterations affect maternal metabolism, hormones and 
adipokines/cytokines in healthy pregnancy. The normal pregnancy profile resembles the 
pathologic features observed in obesity and the metabolic syndrome. Hence, pregnancy 
represents a metabolic “overload test” adding extra demands to susceptible women with 
overweight/obesity and/or the metabolic syndrome before the conception. These 
conditions highly enhance the likelihood of adverse outcomes to the feto-placental-
maternal unit (70). For instance, even though obese pregnant women have a reduction in 
 10
insulin sensitivity late in pregnancy similar to that which is observed in lean pregnant 
women (71, 72), the insulin response stimulated by glucose infusion appears to be lower 
in obese women with normal glucose tolerance than in the healthy lean controls (21). 
Glucose and insulin metabolism changes are also even more pronounced in women with 
GDM (20, 72). Both lean and obese women with GDM have lowered whole body insulin 
sensitivity and reduced suppression of endogenous glucose production by insulin 
compared to controls matched for BMI (20, 72). In addition, insulin secretion is impaired 
in GDM and, as insulin requirement is physiologically increased late in gestation, even 
minor reductions in pancreatic β cells can lead to hyperglycaemia (26, 72, 73). Women 
with GDM in comparison with controls can have higher glycerol levels (74), a more 
atherogenic lipid profile (75, 76) and an earlier (76) and more intense 
hypertriglyceridaemia (76, 77).  
1.4 Gestational complications associated with obesity and its co-
morbidities  
Obesity is not only associated with factors that cause gestational complications (e.g. 
diabetes, dyslipidaemia and other components of the metabolic syndrome), but it is also 
an independent predictor of pregnancy adverse outcomes. Higher BMI is a well-
established predictor of GDM (10, 13, 78). The increment of 1 kg per m2 in the first 
trimester maternal BMI is associated with a 1.12-fold [95% confidence interval (CI) 1.10–
1.14)] higher risk of GDM (79). In an Australian study, the adjusted odds ratio (OR) for 
GDM was 3.99 (95% CI 3.47–4.59) for mothers with self-reported pre-pregnancy BMI 
of ≥ 30 kg/m2 and 6.45 (95% CI 5.01–8.28) for the subgroup with BMI ≥ 40 kg/m2 (6). 
GDM is usually associated with impairment of pancreatic β cell function in women with 
an already pre-conception dysfunctional β cell secretion and insulin resistance (20, 72, 
80, 81), explaining why obesity is strongly associated with GDM. Thus, the physiological 
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reduction of insulin sensitivity that occurs in pregnancy overloads the chronically 
impaired β cells of overweight/obese women, which become unable to secrete enough 
insulin to cope with the high metabolic demands, and consequently hyperglycaemia 
ensues.  
Besides GDM, there is evidence that elevated maternal BMI increases the chance of large 
for gestational age (LGA) babies, higher fetal adiposity, fetal hyperinsulinaemia, neonatal 
hypoglycaemia, and congenital malformations (16, 17, 82). A large study has shown that 
a BMI of ≥ 25 kg/m2 in the first trimester of gestation is an independent predictor of infant 
mortality, particularly of neonatal deaths (83). The magnitude of this association was 
modest for overweight mothers, but doubled the risk of infant mortality for women with 
a BMI of ≥ 35 kg/m2 in comparison to those with normal BMI (83). Most deaths were 
due to congenital anomalies and birth asphyxia in both term pregnancies and preterm 
deliveries (83). Moreover, obesity was the most significant modifiable risk factor for 
stillbirth in developed countries (15).  
In addition, maternal obesity is a relevant risk factor for hypertensive gestational disorders 
and pre-eclampsia (14), which is a pregnancy-specific disease defined as new 
hypertension and proteinuria with onset at ≥ 20 weeks of gestation (84). In the 
“Hyperglycemia and Adverse Pregnancy Outcome (HAPO)” study, maternal obesity was 
the strongest independent predictor of pre-eclampsia, with the OR increasing in parallel 
with the BMI, being as high as 8.35 (95% CI 5.22-13.36) for women with BMI > 44 
kg/m2 (85). Interestingly, many characteristics observed in patients with the metabolic 
syndrome are shared by women with a pre-eclampsia history (86), with both groups being 
susceptible to future cardio- and cerebrovascular disease as is further discussed.  
There is also evidence that maternal obesity raises the risk for caesarean section (78, 87), 
induction of labour, postpartum bleeding (87), and birth trauma (88). Data from a large 
Chinese cohort study showed that pre-conception BMI is a more important predictor of 
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pregnancy complications than excessive weight gain during pregnancy (89). In 
comparison with women with normal pre-pregnancy BMI and an adequate weight gain 
during pregnancy according to the Institute of Medicine guidelines (90), the highest risks 
for caesarean section (OR: 3.69), pregnancy specific hypertension (OR: 7.08) and GDM 
(OR: 3.57) were observed in women with obesity and appropriate weight gain (89). 
However, the highest likelihood of preterm delivery (OR: 1.49), LGA (OR: 3.99) and 
macrosomia (OR: 4.1) was found in women who were both obese and had excessive 
weight gain during pregnancy (89). On the other hand, the increased risk of complications 
was not as great for women with a normal BMI who had an excessive weight gain during 
pregnancy, being significant increased for LGA (OR: 1.91), macrosomia (OR: 1.9), 
pregnancy specific hypertension (OR: 1.35) and caesarean section (OR: 1.34) (89). These 
findings suggest that women with pre-existing obesity have a more deleterious metabolic 
milieu during pregnancy that lean women who gain excess weight in pregnancy, although 
both scenarios add risk. Finally, a recent large Swedish study reported that obese women 
who have undergone bariatric surgery exhibited a lower risk of LGA neonates and GDM. 
However, there was an increased risk of small for gestational age neonates and a trend 
towards the increase of stillbirth or neonatal death (91).  
Regarding obesity co-morbidities, GDM notably if undiagnosed and untreated, 
contributes to adverse gestational outcomes (92, 93). Nevertheless, even relatively mild 
maternal glycaemic levels are important independent determinants of pregnancy 
complications (94). The HAPO study showed that, after adjustment for BMI, maternal 
glucose levels are associated with increased risks of macrosomia and LGA babies, 
caesarean section, neonatal hypoglycaemia and higher cord blood C-peptide 
concentrations (94). Moreover, the treatment of GDM reduces the risk of hypertensive 
disorders, macrosomia, birth trauma, caesarean delivery (93) and perinatal death (95). 
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Treatment of GDM is also an effective treatment for the prevention or attenuation of pre-
eclampsia (92, 93).  
As expected, pre-existing diabetes also increases the risk of gestational complications and 
more than triplicates the pre-eclampsia likelihood (OR: 3.56; 95% CI 2.54-4.99) (96). 
Severe complications such as intrauterine growth restriction, congenital malformations, 
perinatal death and maternal mortality are more prevalent in pregnancies complicated by 
pre-pregnancy diabetes, especially with inadequate glycemic control (15, 97). In 
developed countries, overt diabetes is among the most important maternal risk factor for 
stillbirth, which was 3 times more likely to occur in women with pre-gestational diabetes 
(15). In this meta-analysis, more than 2000 stillbirths per year could be attributed to pre-
existent diabetes (15). In a population without congenital defects, fetal and infant death 
were, respectively, 4.6-fold and 1.9-fold more frequent in women with pre-existent 
diabetes than in healthy mothers (98). The risk of fetal and infant death were similar 
between type 1 diabetes mellitus (T1DM) and T2DM women (98). In this study, the 
increment of each 1 mmol/mol in a periconceptional HBA1C > 49 mmol/mol increased 
the relative risk of stillbirth by 2% and of infant deaths by 3%. (98). Of relevance, 
recurrent miscarriage has been reported to be associated with increased measures of 
insulin resistance in the first trimester of pregnancy (99). Moreover, over six intervals of 
maternal first trimester glycated protein levels, the miscarriage risk for T1DM women 
was highest in those women in the highest extreme (100). Surprisingly, the frequency of 
miscarriage was also increased in normal women with the highest glycated protein levels, 
even though this level was 2-5 times lower that in diabetic pregnancies with the highest 
glycated protein levels, i.e. in pregnancies with the worst first trimester diabetes control 
(100). These data reinforce the detrimental effects that intrauterine hyperglycaemia exerts 
on the fetus.  
 14
As mentioned before, pregnancy is a hyperlipidaemic state with marked physiological 
increases especially in TG levels (28). Pathological hyperlipidaemia, with lipid levels 
beyond those of healthy gestation, is observed in pregnancies affected by obesity, in 
which it is common to have abnormally high serum concentrations of TG, VLDL-C and 
low levels of HDL-C (101). Maternal dyslipidaemia years before (102), or during 
pregnancy (103), has been associated with pre-eclampsia (102, 103). Pre-eclampsia is a 
disease characterised by poor placentation, placental oxidative and endoplasmic 
reticulum stress, followed by the development of maternal systemic illness involving 
endothelial dysfunction and systemic inflammation (84). Women with pre-eclampsia, in 
comparison with heathy gravidas, present higher lipid levels and a more atherogenic lipid 
profile including increased concentrations of small and dense LDL-C particles (35, 104, 
105). The association between lipid alterations and pre-eclampsia reported in clinical 
studies may be explained by dyslipidaemia causing the endothelial dysfunction, such that 
the dyslipidaemia is implicated in the pathogenesis of pre-eclampsia (106). Endothelial 
cells take up NEFA, when abnormally increased in the maternal circulation, leading to 
endothelial dysfunction with reduction of vasodilator synthesis (e.g. prostacyclin) and 
contributing to pre-eclampsia (107). Moreover, women with pre-pregnancy 
dyslipidaemia may have established chronic endothelial dysfunction, which can be 
aggravated by the pregnancy metabolic overload also increasing the risk of pre-eclampsia 
development (106). Alternatively, the endothelial dysfunction in pre-eclampsia could 
disrupt lipid metabolism and favour the dyslipidaemia. In the long-term, women with a 
history of pre-eclampsia have a higher predisposition to dyslipidaemia, abnormal lipid 
oxidation (108) and chronic hypertension (109). Consequently, these women have 
increased rates of atherosclerotic cardiac disease, stroke, renal morbidity and mortality 
(110-112). Also, oxidized lipids can impair trophoblast invasion contributing to the poor 
placentation noticed in preeclampsia (107)  
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In addition to pre-eclampsia, maternal hyperlipidaemia has been associated with preterm 
birth. The risk of preterm delivery was higher in pregnant women with hyperlipidaemia 
measured early in pregnancy, defined as total cholesterol or TG more than 1 standard 
deviation (SD) above the mean (113). Also, the highest concentrations of total cholesterol 
and LDL-C were found in overweight women with preterm delivery < 34 weeks (113). 
In the long prospective “Coronary Artery Risk Development in Young Adults” study, 
pre-pregnancy total cholesterol levels in the highest quartile was also related to an 
increased risk of preterm delivery (OR: 3.80; 95% CI 1.07-7.57) (114). Moreover, in 
research that aimed to develop a predictive model for preterm birth, the addition of the 
combination of first trimester total cholesterol and change in total cholesterol between 
trimesters to other maternal characteristics and biochemical analyses proved to be the best 
model (115). Besides, women with higher non-fasting NEFA in the first trimester of 
pregnancy had twice the risk of preterm delivery comparing with women with lower 
levels (116). This association was worse for preterm birth < 34 weeks, in which higher 
levels of NEFA increased preterm birth by almost 4-fold (116). Similarly, women with 
NEFA levels in the highest tertile measured at 30 weeks of gestation had higher risk of 
preterm delivery (OR: 3.49, 95% CI 1.73-7.03), a risk that persisted after excluding GDM 
and pre-eclampsia cases from the analysis (OR: 3.30, 95% CI 1.38-7.87) (117). Of note, 
a study in which maternal lipids were measured in the second trimester of pregnancy 
showed that the relationship between total cholesterol, HDL-C and LDL-C levels and 
preterm birth follows a U shape curve; whereas the relation between TG and preterm birth 
is linear (118). Women with extremely low total cholesterol, HDL-C and LDL-C levels 
were twice more likely to have preterm birth related to a medical indication (118). This 
association of low cholesterol levels and preterm birth may be due to (i) the presence of 
an underlying maternal disease, (ii) the usual increases in cholesterol is not achieved due 
to poor placental function, or (iii) a subnormal increase in maternal lipids is inadequate 
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for optimal fetal nutrition and development (118). Conversely, those with higher LDL-C 
and total cholesterol had a 1.5-fold increased risk of spontaneous preterm birth. TG in the 
third and fourth quartile nearly doubled the spontaneous preterm birth risk (118). This 
result was maintained even after excluding patients with placental vascular pathology, 
pre-eclampsia and gestational hypertension (118).  
Moreover, maternal lipids seem to be strongly associated with fetal growth and may 
explain why the prevalence of macrosomic neonates is higher in maternal obesity or GDM 
with excellent glycaemic control. In a study that included healthy and GDM women, 
maternal TG levels measured early in pregnancy showed a weak correlation with neonatal 
birth weight independently of maternal BMI (r=0.12, p=0.02) (39). However, this 
association was much stronger when the subgroup of women with GDM was analysed 
(r=0.60, p < 0.001) (39), suggesting that TG, which is also a marker of insulin resistance 
and the metabolic syndrome, may be exerting a synergistic effect along with GDM in the 
pathogenesis of abnormal fetal growth. The association of higher TG levels and LGA was 
also demonstrated in women with an abnormal GDM screening test but normal glucose 
tolerance test (119). Fasting TG > 75th percentile (> 2.9 mmol/l) measured in the second 
trimester of pregnancy increased the risk of delivering LGA babies by 11.6-fold 
independent of maternal pre-pregnant BMI, rate of weight gain and fasting glucose (119). 
Accordingly, levels of NEFA and TG at 36 weeks and near the delivery in well-controlled 
GDM mothers were independently associated with LGA birth (120). Besides, third 
trimester maternal levels of NEFA and TG showed a modest but significant correlation 
with intrauterine fetal growth measured by abdominal circumference at 28, 32 and 36 
weeks; whilst maternal glycaemia was not related to fetal growth at any assessed time 
point (120). Conversely, there was a lack of correlation between maternal lipids and 
neonatal weight in the babies healthy women (74). In this study, women with normal 
pregnancies gave birth to a similar proportion of LGA neonates as women with well-
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controlled GDM women and there were no differences in the maternal lipid levels 
between the two groups (74). Nonetheless, in the pregnancies of the GDM mothers, 
placental weight, neonatal adiposity, cord NEFA, insulin and glucose concentrations were 
all increased compared to pregnancies of normal mothers (74). These results may reflect 
differences in the placental lipid transport (discussed in more details in section 1.7.2) and 
the fetal insulin response in an environment of more marked maternal insulin resistance 
such as in GDM.  
Whether elevated lipid levels have a pathogenic role in adverse pregnancy outcomes, or 
simply correlate with other metabolic syndrome pathogenic factors, is unknown. As 
discussed before, in hypertriglyceridaemic states such as pregnancy, HDL-C and LDL-C 
turn into TG richer particles, whilst VLDL-C contains higher fractions of cholesteryl 
esters. Consequently, the ratio of total cholesterol/apoB in LDL-C decreases, LDL-C 
particles become smaller and are more prone to oxidation and likely to cause 
inflammation and atherogenesis (121). Also, lipolysis of TG-rich lipoproteins yields 
NEFA, oxidised lipids and hydroxyoctadecadienoic acid (HODE) molecules, particularly 
9- and 13-HODE (122). These lipolysis products promote the endothelial synthesis of 
reactive oxygen species, TNF-α and intracellular adhesion molecule (ICAM) expression 
contributing to inflammation (122). In the adipose tissue, liver and skeletal muscle, 
increases in NEFA levels can stimulate the activity of c-Jun NH2 terminal kinase (JNK) 
(123) and nuclear factor (NF) κB (124) pathways, raising the concentrations of pro-
inflammatory chemo- and cytokines (MCP-1, TNF-α , IL-1β) (125). Thus, because of 
fatty acids pro-inflammatory, pro-oxidative and atherogenic properties (126-128), 
maternal high fatty acid concentrations may contribute to alterations in the implantation 
process, endothelial microvascular injuries and a dysfunctional placenta leading to poor 
outcomes such as pre-eclampsia, preterm labor or premature rupture of membranes.  
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Finally, the effects of obesity and its comorbidities during pregnancy can increase the 
likelihood of long-term adverse consequences for both the mother and the offspring. 
GDM rises maternal long-term risks of T2DM (129-132), the metabolic syndrome and 
consequent cardiovascular disease (133). The risk of T2DM in a meta-analysis was 7-fold 
higher for women with GDM history in comparison with women with normoglycaemia 
during pregnancy (132). This association was even higher in a recent study, which 
reported a 26-fold increased risk of future T2DM for women with previous GDM in 
comparison with those without GDM, and a future T2DM incidence rate per 1000 person-
years of 115 for women whose GDM ended in a stillbirth (133). Women with GDM 
history have been demonstrated to be twice as likely to develop any cardiovascular 
disease, especially ischemic heart disease [incidence relative risk (IRR) 4.54; 95% CI 
1.88-10.96)] and peripheral vascular disease (IRR=5.84; 95% CI 2.26-15.06) (133). For 
GDM women with stillbirth, the risk of cardiovascular events was 17-fold higher (133). 
Besides, women with pre-eclampsia history have a higher predisposition to 
dyslipidaemia, abnormal lipid oxidation (108) and chronic hypertension (109). 
Consequently, they have increased rates of atherosclerotic cardiac disease, stroke, renal 
morbidity and overall mortality (109-112). 
Regarding the consequences for the offspring, abnormal hyperlipidaemia, even 
temporarily during pregnancy, can induce pathological changes in the fetus such as fatty 
streak formation in fetal arteries (134), which may contribute to atherosclerosis in 
adulthood. Maternal obesity is also associated with increased risk of obesity in the 
offspring (135, 136). Maternal obesity in the first trimester of pregnancy led to a 2-fold 
increase in obesity rates in children aged 2-4 years (135). In addition, T2DM was more 
prevalent in youths (aged 10-22 years) who were exposed to maternal overweight (OR: 
2.6; 95% CI 1.2-5.5), obesity (OR: 4.6; 2.2-9.5) or diabetes (OR: 5.7; 95% CI 2.4-13.4) 
in pregnancy (137). Furthermore, pre-conception obesity was the strongest predictor of 
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obesity in children in another study (136). Pre-conception maternal obesity was 
associated with a 4.0-fold (95% CI: 1.23, 13.22) higher risk of having an obese child (at 
age 8.8 ± 1.8 years), which was independent of maternal glycaemia (136). Maternal 
diabetes, on the other hand, was associated with an increased likelihood of pre-diabetes 
or T2DM in the offspring (at age 18–27 years) (138). Maternal GDM raised this risk by 
7.8 times (95% CI 2.6-23.4), whereas exposure to maternal T1DM enhanced the risk by 
4 times (95% CI 1.31-12.3) (138). These studies outline the strong associations between 
maternal obesity and/or hyperglycaemia during pregnancy and the transgenerational risk 
of obesity and diabetes suggesting that not only genetic predisposition and lifestyle are 
involved in the pathogenesis of these conditions. Long-term implications of an altered 
intrauterine environment of maternal obesity and obesity related disorders in the offspring 
may be due to fetal or neonatal programming via epigenetic inheritance (139), which 
contributes to the obesity and T2DM epidemics perpetuation (140).   
1.5 Overview of glucose and fatty acid metabolism pathways 
In this section, general aspects of glucose metabolic pathways and lipid oxidation are 
presented. Specific characteristics of glucose and fatty acid metabolism in the placenta 
are discussed in section 1.7.   
1.5.1 Glucose metabolism overview 
The majority of human cells take up glucose via sodium-independent facilitated diffusion 
with exception of cell in the gastrointestinal tract and renal tubules where glucose is 
absorbed through an active transport (sodium-glucose symporter) (141, 142). Facilitated 
diffusion is mediated by glycoproteins of the glucose transporter (GLUT) family. So far 
14 GLUT isoforms have been described in humans (143). Among them, GLUT1-4 are 
the most relevant and studied. GLUT1 (ubiquitous expression), GLUT2 (expression in 
hepatocytes, enterocytes and pancreatic islets) and GLUT3 (mainly found in neurons) are 
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insulin-independent and always expressed in the plasma membrane. GLUT1 and 3 are 
responsible for basal glucose uptake, whilst GLUT2 has a major role in the regulation of 
insulin secretion and glucose homeostasis. GLUT4 is found inside cytoplasmic vesicles 
in myocytes, adipocytes and cardiomyocytes and needs insulin signalling for these 
vesicles to translocate and fuse with the plasma membrane (144, 145). The main glucose 
transporter in trophoblasts is GLUT1 (146), which is coupled with hexokinase 1. Once 
glucose enters the cell through GLUT1, glucose is phosphorylated to glucose 6-phosphate 
in an irreversible reaction catalysed by hexokinase 1 preventing glucose efflux to the 
extracellular compartment. In the cytoplasm, glucose 6-phosphate can be metabolise via 
the glycolytic pathway to pyruvate from which it can (i) be converted to lactate (anaerobic 
glycolysis); (ii) enter the tricarboxylic acid (TCA) cycle to be oxidised (oxidative glucose 
metabolism); (iii) or go to the fatty acid synthesis pathway via the anaplerosis pathway 
(147). Alternatively, glucose 6-phosphate can be incorporated into glycogen storage or 
directed to the pentose phosphate pathway to form precursors for RNA and DNA 
synthesis (148) (Figure 1.1).  
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Figure 1.1. Glucose metabolism overview. Glucose can have different metabolic fates 
once taken up into a cell. Glycolysis is the main pathway of glucose metabolism, 
generating ATP and pyruvate which can be further metabolised to (i) lactate in conditions 
of limited oxygen supply (anaerobic glycolysis); (ii) acetyl-CoA and oxidative 
metabolism in the TCA cycle to produce ATP, CO2 and H2O (aerobic glycolysis); or to 
(iii) oxaloacetate to provide substrate for fatty acid synthesis. Malonyl-CoA, an important 
anaplerotic intermediate, inhibits the oxidation of fatty acids in situations of high glucose 
supply. Alternative pathways for glucose 6-phosphate are into the pentose phosphate 
pathway or to glycogen synthesis. 
TCA: tricarboxylic acid.  
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1.5.2 Glycolysis   
During glycolysis, the six-carbon glucose molecule is cleaved into 2 three-carbon 
pyruvate molecules. The yield of this reaction is two ATP, two NADH and two H+ 
(Figures 1.2 and 1.3 summarise all glycolysis steps). Glycolysis is regulated by enzymes 
(hexokinase, phosphofructokinase-1, pyruvate kinase), metabolites (NADH and ATP 
concentrations) and hormones (e.g. glucagon and insulin) to maintain a steady ATP 
supply for cellular needs (149, 150).  
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Figure 1.2. First phase of glycolysis. 1. Glucose enters the cells and is irreversibly 
phosphorylated to glucose 6-phosphate. 2. Glucose 6-phosphate is converted to fructose 
6-phosphate by isomerization. 3. Fructose 6-phosphate receives an inorganic phosphate 
donated by ATP and is converted to fructose 1,6-bisphosphate. 4. Fructose 1,6-
bisphosphate is cleaved into glyceraldehyde 3-phosphate and dihydroxyacetone- 
phosphate catalysed by aldolase with release of water. This first phase of glycolysis uses 
2 molecules of ATP (149, 150).  
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Figure 1.3. Second phase of glycolysis. 5. Contrary to glyceraldehyde 3-phosphate, 
dihydroxyacetone cannot be further metabolised. Thus, it needs to be converted into 
glyceraldehyde 3-phosphate by triose-phosphate isomerase. 6. Glyceraldehyde 3-
phosphate then donates a H+ to NAD+ and is phosphorylated producing 1,3-
bisphosphoglycerate and NADH. 7. The phosphoryl group from 1,3-bisphosphoglycerate 
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is transferred to ADP producing ATP and 3-phosphoglycerate. 8. The enzyme 
phosphoglycerate mutate transfers the phosphoryl group from the carbon in the position 
3 to the carbon in the position 2, converting 3-phosphoglycerate into 2-phosphoglycerate. 
9. 2-Phosphoglycerate is dehydrated to phosphoenolpyruvate releasing a molecule of 
water. 10. Phosphoenolpyruvate donates the phosphoryl group to ADP producing ATP 
and pyruvate. The second phase of glycolysis produces 4 molecules of ATP from one 6-
carbon glucose, such that the net ATP production is 2 ATP molecules (149, 150).  
NAD+: oxidised nicotinamide adenine dinucleotide; NADH: reduced nicotinamide 
adenine dinucleotide.  
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1.5.3 Lactate production  
In oxygen depletion or in cells devoid of mitochondria, pyruvate molecules produced at 
the end of glycolysis cannot be oxidised to acetyl-CoA and enter the TCA cycle. In this 
case, NADH produced during glycolysis cannot be oxidised again and recycle NAD+ to 
accept new electrons. Thus, pyruvate must be reduced to lactate to allow NAD+ 
regeneration from NADH. Lactate dehydrogenase (LDH) catalysis the transfer of H+ from 
NADH to pyruvate, producing NAD+ and lactate (Figure 1.4). Lactate can be utilised as 
a fuel and transformed into glucose via gluconeogenesis in the liver and kidneys (147, 
151). Interestingly, some tissues including the placenta, retina and working skeletal and 
cardiac muscle produce high levels of lactate in spite of adequate oxygen supply (148).   
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Figure 1.4. Lactate production. 1. In the end of glycolysis, 2 molecules of pyruvate are 
produced per glucose molecule. 2. In the absence of oxygen, pyruvate can be reduced by 
LDH and converted to lactate. NAD+ depletion from glycolysis can be recovered by the 
conversion of pyruvate to lactate. 
LDH: lactate dehydrogenase.  
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1.5.4 Tricarboxylic acid cycle and oxidative metabolism of glucose  
The TCA cycle, which is also called citric acid cycle and the Krebs cycle, is a key pathway 
for the production of ATP from carbohydrate, lipid and protein nutrients with the 
fundamental key entry point being acetyl-CoA. With respect to glucose metabolism, 
acetyl-CoA coming from glycolysis is formed through the conversion of pyruvate (3 
carbons) to acetyl-CoA (2 carbons) via the pyruvate dehydrogenase complex. Acetyl-
CoA is then oxidised by the TCA cycle producing CO2, electrons and reduced NADH 
and FADH2. NADH and FADH2 carry the electrons to the respiratory chain which 
releases H+ and electrons. O2 is reduced to H2O and the electrons flow leads to ATP 
production (149) (Figure 1.5).  
As previously described, pyruvate is produced at the end of glycolysis. Under aerobic 
conditions, pyruvate follows an oxidative decarboxylation by pyruvate dehydrogenase 
complex. In this process a carboxyl group from pyruvate is released as a CO2 molecule 
and the remaining carbons are converted into acetyl group of acetyl-CoA which will feed 
the TCA cycle (Figure 1.6).  
The TCA cycle is complex and extensive regulated by compounds and intermediates from 
both glucose and fatty acid metabolic pathways. Pyruvate conversion to acetyl-CoA is 
inhibited by fatty acids, ATP, NADH and acetyl-CoA; citrate synthase activity is 
inhibited by ATP, NADH, citrate and succinyl-CoA; α-ketoglutarate synthesis from 
isocitrate is down-regulated by ATP; and finally, succinyl-CoA and NADH inhibit 
succinyl-CoA production from α-ketoglutarate (149). 
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Figure 1.5. Cellular respiration. Nutrient oxidation yields acetyl-CoA, which enters the 
TCA cycle. At the end of a cycle, electrons are released and carried by NADH and FADH2 
to the respiratory chain. ATP is produced following electron transfer.  
TCA: tricarboxylic acid; NADH: reduced nicotinamide adenine dinucleotide; FAD: 
flavin adenine dinucleotide.   
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Figure 1.6. Summary of the TCA cycle. Acetyl-CoA produced from glucose or fatty 
acids enters the cycle and is condensed to citrate by citrate synthase. Citrate is 
successively dehydrated and hydrated by aconitase enzyme and isocitrate is formed. 
Isocitrate undergoes an oxidative decarboxylation by isocitrate dehydrogenase, releases 
CO2 and α-ketoglutarate is formed. Another oxidative decarboxylation occurs generating 
succinyl-CoA, which is converted to succinate by the action of succinyl-CoA synthetase. 
This latter reaction breaks a strong succinyl-CoA thioester bond releasing energy that is 
used for ATP production. Succinate is then dehydrogenated, donating 2 H+ to FAD with 
fumarate and FADH2 production. Fumarate is hydrated forming malate, which donates 1 
H+ to NAD+ and is converted to oxaloacetate. In the presence of acetyl-CoA, oxaloacetate 
can re-start the cycle. At the end of a complete oxidation, a molecule of glucose (via 
glycolysis) yields a total of 30-32 ATP, whilst a molecule of palmitate produces a total 
of 108 ATP (149). 
TCA: tricarboxylic acid; FAD: flavin adenine dinucleotide; NAD+: oxidised nicotinamide 
adenine dinucleotide.  
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The TCA cycle is not only involved in catabolic but also in anabolic reactions, which 
produce biosynthesis precursors for many other pathways. Anaplerotic processes refill 
TCA intermediates to keep their concentrations stable. Pyruvate carboxylase reversibly 
catalysis the most relevant anaplerotic reaction, in which pyruvate receives a carbon from 
CO2 and is converted into oxaloacetate at the expense of an ATP. Pyruvate carboxylase 
is tightly regulated by acetyl-CoA, being stimulated in the presence of acetyl-CoA surplus 
and inhibited in acetyl-CoA depletion. Concerning lipid metabolism, anaplerotic 
pathways provide precursors to de novo fatty acid synthesis (152). Thus, citrate produced 
from oxaloacetate and acetyl-CoA can be transformed in malonyl-CoA by action of 
citrate lyase and acetyl-CoA carboxylase. Malonyl-CoA is an important signalling of 
glucose and other nutrient oversupply being utilised for fatty acid synthesis or fatty acid 
elongation, and inhibiting fatty acid oxidation. Therefore, malonyl-CoA levels increase 
in conditions of high glucose supply, hyperinsulinaemia and physical inactivity and 
decrease in glucose depletion and physical activity. Hence, malonyl-CoA participates in 
the cross talk between glucose and fatty acid metabolism (153).    
1.5.5 Glycogen synthesis  
Excess glucose can be polymerised and stored as glycogen in nearly all animal tissues but 
it is particularly produced in skeletal muscles and the liver. Glycogen is a big branched 
polymer, with thousands of glucose molecules and one reducing end. Glycogen is packed 
in granules that contain the enzymes necessary to its metabolism (Figure 1.7 shows the 
reactions and enzymes involved in glycogen synthesis). When glucose blood levels are 
low, glycogen non-reducing end can be phosphorylated yielding glucose 1-phosphate that 
is transformed in glucose 6-phosphate and utilised in other metabolic pathways. The 
branches can also be cleaved by the debranching enzyme releasing free glucose. Glycogen 
synthesis is stimulated by insulin, whereas epinephrine and glucagon promote glycogen 
phosphorylation (154).     
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Figure 1.7. Glycogen synthesis. Glycogen synthesis begins with the conversion of 
glucose 6-phosphate to glucose 1- phosphate by phosphoglucomutase action. Glucose 1-
phosphate is linked to an UDP molecule, which is a sugar nucleotide constituted by 
uridine and a glucosyl group. UDP-glucose then provides glucose residues to elongate 
the non-reducing end of a glycogen molecule, a transfer that is catalysed by glycogen 
synthase. However, the glycogen-branching enzyme is necessary to bind new glucose 
molecules to the branch points of glycogen. To initiate a glycogen molecule de novo the 
protein glycogenin acts as a primer and an enzyme, binding UDP-glucose to glycogenin 
itself. Subsequently, glycogen synthase will add new glucose molecules to lengthen the 
glycogen molecule (154, 155).  
UDP: uridine diphosphate. 
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1.5.6 β-oxidation of saturated fatty acids 
β-oxidation is the first step of fatty acid catabolism. In this pathway long-chain fatty acids 
are oxidised into acetyl-CoA that will enter the TCA cycle. Lipids such as TG are 
hydrolysed into free fatty acids and glycerol by the action of lipases such as LPL. Long 
free fatty acids (≥ 14 carbons) entering the cell must initially be activated to an acyl-CoA 
by the action of fatty acyl-CoA synthetase at the expense of ATP within the cytosol. The 
fatty acyl-CoA, however, need to be imported into the mitochondrial matrix for β-
oxidation and this is via carnitine transport cycle. Fatty acyl-CoA is converted to fatty 
acyl carnitine by carnitine acyl-transferase 1 at the external mitochondrial membrane, is 
transported across the membrane by the carnitine translocating protein, and is converted 
back to fatty acyl-CoA at the inner mitochondrial membrane by carnitine acyl transferase 
2. Subsequently, carnitine acyltransferase 2 moves the fatty acid acyl group from carnitine 
to an intramitochondrial coenzyme A, releasing free carnitine. Fatty acids are catabolized 
by consecutive losses of acetyl-CoA (2 carbons) during β-oxidation such that a 16-carbon 
palmitate molecule, for instance, will yield 8 acetyl-CoA molecules. Four reactions occur 
in each β-oxidation loop: (i) dehydrogenation of fatty acyl-CoA producing FADH2 and 
enoyl-CoA; (ii) hydration of enoyl-CoA into β-hydroxyacyl-CoA; (iii) dehydrogenation 
of β-hydroxyacyl-CoA with production of NADH and β-ketoacyl-CoA; (iv) cleavage of 
the carboxy-terminal portion (with 2 carbons) from the fatty acid forming an acetyl-CoA 
molecule plus a thioester of fatty acid  in a reaction catalysed by acyl-CoA 
acetyltransferase (thiolase) (156) (Figure 1.8).  
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Figure 1.8. β-oxidation of saturated fatty acid (e.g. palmitate). Following access to the 
mitochondrial matrix via the carnitine transport cycle, β-oxidation involves the repetition 
of 4 enzymatic reactions. The aim of each passage is to remove 2 carbons from the fatty 
acid producing an acetyl-CoA group. Complete β-oxidation of palmitate yields 8 acetyl-
CoA groups. 1. Fatty acyl-CoA is dehydrogenated producing FADH2 and enoyl-CoA. 2. 
Enoyl-CoA is converted to β-hydroxyacyl-CoA through hydration. 3. β-hydroxyacyl-
CoA loses 2 H+ producing NADH and β-ketoacyl-CoA. 4. Acyl-CoA acetyltransferase 
(thiolase) catalyses the reaction between β-ketoacyl-CoA and a CoA group. As a result, 
the fatty acid carboxy-terminal portion with 2 carbons is cleaved forming an acetyl-CoA 
molecule plus a thioester of fatty acid with 14 carbons (156).  
CPT: carnitine palmitoyltransferase 1; FAD: flavin adenine dinucleotide.  
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1.5.7 Ketone bodies production 
Ketone bodies, i.e. β-hydroxybutyrate, acetone and acetoacetate, are synthesized in the 
liver. β-hydroxybutyrate and acetoacetate can be used as an energy source by extra-
hepatic tissues. The rate of ketone body production is low in metabolic healthy and well-
nourished people. However, in decompensated diabetes or starvation, ketone body 
production is increased due to the accumulation of acetyl-CoA secondary to the depletion 
of TCA cycle intermediates by exaggerate gluconeogenesis. Thus, acetyl-CoA is 
redirected from β-oxidation to ketone body production (Figure 1.9). After hepatic 
synthesis, β-hydroxybutyrate is released into the blood circulation and can be oxidised to 
acetoacetate in other tissues (157) (Figure 1.10).  
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Figure 1.9. Ketone body formation. The linkage of two molecules of acetyl-CoA 
catalysed by a thiolase is the first step in ketone body synthesis. Acetoacetyl is formed 
and condensed to a β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) through the action of 
the enzyme HMG-CoA synthase. HMG-CoA lyase, which is present in the mitochondrial 
matrix, cleaves HMG-CoA molecule generating acetyl-CoA and free acetoacetate. The 
latter is reduced to β-hydroxybutyrate by a β-hydroxybutyrate dehydrogenase in a 
reversible reaction. Acetoacetate can also lose a CO2 molecule and produce acetone, a 
reaction catalysed by an acetoacetate decarboxylase (157).  
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Figure 1.10. Ketone body utilisation as energy. β-hydroxybutyrate produced in the liver 
is released into the blood circulation and oxidised to acetoacetate in other tissues. 
Succinyl-CoA donates a CoA to acetoacetate, which is transformed in acetoacetyl-CoA 
by a β-ketoacyl-CoA transferase. Then, acetoacetyl-CoA is cleaved by a thiolase in 2 
molecules of acetyl-CoA restarting the TCA cycle. 
TCA: tricarboxylic acid.  
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1.6 Normal structure of the placenta 
1.6.1 Macroscopic anatomy of the placenta 
A normal term placenta has a discoid shape that can be symmetrically or eccentrically 
round. It measures between 2 to 4 cm in thickness, around 20 to 22 cm in diameter and 
weighs a mean of 470 g (158).    
The basal plate represents the maternal surface of the placenta, which is attached to the 
uterus during the gestation (Figure 1.11). The parenchyma has a spongy and soft 
consistency. The basal plate is usually maroon or deep red and is divided into 10 to 40 
lobes (cotyledons). The outer surface of the basal plate is occupied by the decidua that is 
the pregnancy endometrium. The decidua that underlies the basal plate, being also the 
implantation site of the embryo in the uterus, is called the decidua basalis. The decidua 
parietalis covers the remainder of the uterine cavity, and the decidua capsularis extends 
around the chorion in the first trimester. After 16 weeks of gestation, the growing fetus 
drives the decidua capsularis in contact with the decidua parietalis. In consequence, both 
deciduae fuse and the uterine cavity disappears (158-160).   
The fetal side of the placenta-the chorionic plate-is covered by the translucent, slightly 
grey and smooth amnion membrane (Figure 1.12). At the edge of the placental disc, the 
chorionic and basal plates converge and form the chorioamniotic membrane, constituted 
by the amnion attached to the smooth chorion or chorion laeve. The umbilical cord inserts 
into the chorionic plate, usually centrally or slightly eccentrically, and contains 2 arteries 
and 1 vein. Rising from the fetus, the umbilical arteries progressively branch and reduce 
their diameter until they form the terminal villi. The role of the terminal villi is to deliver 
fetal blood to the villous trees. The umbilical vein, in turn, is formed from the junction of 
veins of the villous trees and runs underneath the umbilical arteries (Figure 1.12). Each 
cotyledon is supplied by one to four villous trees emerging from the chorionic plate. 
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Cotyledon villous trees are immersed in maternal blood delivered inside the intervillous 
space by spiral arteries. This contact between the villous trees and maternal blood allows 
for the exchange of gases, hormones and nutrients between mother and the fetus. Maternal 
blood in the intervillous space is drained through the utero-placental veins, the openings 
of which are on the floor of the intervillous space (158, 159, 161) (Figure 1.13).  
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Figure 1.11. Photograph of a delivered placenta showing the maternal side. The basal 
plate of the placenta is a maroon/reddish, soft and spongelike structure. It has the 
cotyledons, which are supplied by vessels from the villous trees and represent the fetal 
lobules. The cotyledons cause irregular invaginations in the maternal decidua. The dotted 
line surrounds a cotyledon.   
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Figure 1.12. Photograph of a delivered placenta showing the fetal side. The chorionic 
plate of the placenta is covered by the amnion and chorion. The umbilical cord usually 
centrally or eccentrically inserts into the chorionic plate. Solid arrow: umbilical vein 
branch; dashed arrow: umbilical artery branch.   
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Figure 1.13. Cross section of a term placental. From the uterus, the spiral arteries 
deliver maternal blood into the intervillous space. Blood from the intervillous space, in 
turn, is collected by the utero-placental veins. The umbilical cord, which is covered by 
the chorion and the amnion, has 2 arteries and 1 vein. The umbilical arteries successively 
branch and reduce in diameter up to the terminal villi, where fetal blood is delivered to 
the chorionic villi. Conversely, the umbilical vein is constituted by the union of chorionic 
veins into larger vessels and supply the fetus with blood after exchanges with maternal 
blood. This figure was taken from Burton et al. (162) with kind permission of Elsevier 
Health Sciences.  
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1.6.2 Microscopic anatomy of the placenta  
The basal plate is constituted by decidual stromal cells, immune cells (e.g. macrophages, 
T-lymphocytes and natural killer cells), extravillous trophoblasts, blood clots, 
extracellular matrix and fibrinoid. On the chorionic plate, the fetal membranes possess 
the amnion, which is composed by (i) a single layer of epithelium with a subjacent 
basement membrane attached to an avascular connective tissue layer of amniotic 
mesenchyme; (ii) a layer of extravillous trophoblast; and (iii) the decidua capsularis. In 
the villi, the basement membrane separates the villous trophoblast epithelium from the 
mesenchymal core, which contains fibroblasts, myofibroblasts, endothelial cells, 
erythrocytes, smooth muscle cells and macrophages (158, 160).  
As described, the vessels arising from the chorionic plate progressively branch until they 
supply the capillaries of the villi. A minority of villi contact the basal plate forming 
anchoring villi, in which trophoblastic cell columns are found. The remaining villi 
containing the fetal vessels float within the maternal blood of the intervillous space. These 
free villi are classified as mesenchymal villi, immature intermediate villi, stem villi, 
mature intermediate villi and terminal villi depending on stromal and vessel features, the 
diameter and the time during gestation that they are established. Because mesenchymal 
villi and immature intermediate villi are scarce in the term placenta and stem villi are 
mostly involved in the mechanical support to the villous (160), only mature intermediate 
villi and terminal villi are discussed here.  
From around 20 weeks of gestational age, the placenta starts forming mature intermediate 
villi that are abundant at term. Mature intermediate villi are long and composed by a loose 
stroma with small vessels and capillaries. Terminal villi emerge from mature intermediate 
villi and are at the end of the villous tree with vast participation in the exchanges between 
mother and fetus. Because of this important function, terminal villi show numerous 
capillaries and capillary-derived sinusoids that enlarge the exchange surface. The 
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structure established by the basement membrane, the syncytiotrophoblast and the fetal 
endothelium is called the vasculo-syncytial membrane (Figure 1.14). The exchanges 
between mother blood in the intervillous space and fetal blood in the small vessels of villi 
are optimised by the abundance of capillaries together with the very thin maternal-fetal 
barrier in terminal villi (160, 162).  
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Figure 1.14 Electron microscopy of a placental terminal villous showing the 
maternal-fetal barrier. Terminal villi are at the end of the villous tree and participate in 
the placental exchanges between mother and the fetus. They are composed by capillaries, 
sinusoids, cyto and syncytiotrophoblasts, stroma, mesenchymal cells and the basement 
membrane. The vasculo-syncytial membrane (VSM) is a thin structure formed by the 
basement membrane (BM), the syncytiotrophoblast (SYN TR) and the fetal endothelial 
cell (EC). The exchanges between maternal blood from the intervillous space (IVS) and 
blood from the fetal capillary (FC) occur across the VSM. This figure was taken from 
Carter et al. (163). 
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Among the cells present in terminal villi, cytotrophoblasts and the syncytiotrophoblast 
are the focus of interest in this thesis. In term placenta terminal villi, single 
cytotrophoblasts are found under the syncytiotrophoblast layer and both cyto and 
syncytiotrophoblasts rest on the trophoblast basement membrane. The main function of 
villous cytotrophoblasts, which are mononucleated epithelial cells, is to divide and 
differentiate to fuse into the syncytiotrophoblast. Hence, villous cytotrophoblasts act as a 
pool of immature cells that renew the syncytiotrophoblast. In addition, villous 
cytotrophoblasts can also be converted into extravillous cytotrophoblasts if the contact 
with the syncytiotrophoblast or with the basement membrane is lost. Undifferentiated 
cytotrophoblasts are simple and cuboid cells, with few organelles and a low metabolic 
activity. To fuse with the syncytiotrophoblast, undifferentiated cytotrophoblasts have to 
be transformed into intermediate cytotrophoblasts, which have a very active metabolism 
and possess more organelles, in particular mitochondria, ribosomes and rough 
endoplasmic reticulum. The intermediate cytotrophoblasts are then converted into 
differentiated cytotrophoblasts that have an even higher quantity of organelles, proteins 
and nucleic material. Finally, the differentiated cytotrophoblasts fuse with the 
syncytiotrophoblast becoming part of this large layer (160, 162).  
The syncytiotrophoblast is a multinucleated and uninterrupted layer that covers all villous 
tree surfaces. This layer has an apical microvillous membrane with a brush border bathed 
into maternal blood and a basal membrane in contact with the cytotrophoblasts or the 
basement membrane. In contrast with the cytotrophoblasts, the syncytiotrophoblast layer 
is a completely differentiated cellular structure without mitotic activity. Because the 
syncytiotrophoblast is responsible for many functions (e.g. synthesis of hormones, 
cytokines and adipokines, and the transport and metabolism of nutrients), it displays 
various organelles such as mitochondria, golgi bodies, pinocytotic vesicles, phagosomes, 
lysosomes, and secretory droplets. The syncytiotrophoblast is renewed by the 
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incorporation of cytotrophoblasts, as explained before, whilst the senescent nuclei are 
packed, surrounded by cellular membrane and released into the maternal circulation as 
syncytial knots (159, 162). 
1.7 Placental nutrient transport and metabolism  
The placenta transports and metabolises glucose, fatty acids, and amino acids. Glucose is 
the main source of energy for the placenta and the fetus, and it is readily transported 
across the placenta via facilitated transport (164) mostly dependent on the maternal-fetal 
gradient (165, 166). Lipids cross the placenta with more difficulty than glucose involving 
complex transport processes. In addition to their function as source of energy, they are 
essential for the synthesis of cellular membranes and hormones by the placenta and fetus, 
especially for the fetal nervous system, adipose tissue and feto-placental steroid 
production (33, 166, 167). Amino acids are transported by the placenta to the fetus via 
active and facilitated transport and are utilized for protein synthesis, metabolism into 
other substrates and production of energy (168).  
It is also worthy of note that the fetus is not a passive agent in its intrauterine growth, as 
it seems to regulate the delivery of nutrients by signalling the placenta. For example 
insulin, a potent stimulant of anabolism and cellular growth (169), is produced by the 
fetal pancreas in response to the maternal supply of nutrients, in particular glucose, but 
also fatty acids and amino acids (169). While in early pregnancy, maternal insulin may 
have a role in placental growth from the maternal side of the placenta, fetal insulin, acting 
on the fetal side (endothelial cells) of the placenta, is thought to be more dominant later 
in pregnancy (170). Therefore, both the maternal metabolic milieu and nutrient supply, 
prominently in early pregnancy, and fetal production of metabolic hormones such as 
insulin, insulin growth factors, and leptin later in pregnancy, can affect placental nutrient 
transport and metabolism (171, 172). Thus, in response to the maternal metabolic 
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environment, the fetus can also respond modulating its own growth by regulation of 
placental function and nutrient delivery among other mechanisms (171, 172). In the 
presence of obesity and/or diabetes during the pregnancy, nutrient oversupply can 
stimulate fetal hyperinsulinaemia leading to increased fetal aerobic metabolism, higher 
glucose uptake into fetal tissues and stimulated adipogenesis (169). 
1.7.1 Glucose transport and metabolism 
Both the placenta and the fetus largely consume glucose for energy. Although the fetal 
liver contains most enzymes necessary for gluconeogenesis, this pathway is insignificant 
during intrauterine life (173). Consequently, the fetus relies on placental glucose transfer 
from the maternal circulation across the syncytiotrophoblast and endothelial cells. 
Glucose flux through the placenta is determined by the maternal-to-fetal glucose gradient, 
density and kinetics of glucose carriers, glucose use by the placenta, uterine-placental and 
umbilical-placental blood flow and the thickness of the maternal-fetal barrier (166). Non-
carrier mediated diffusion is responsible for just a small fraction of glucose transport 
across the syncytiotrophoblast microvillous membrane (174, 175). Nevertheless, 
considerable rates of glucose diffusion have been demonstrated in placental perfusion 
studies (165, 176, 177).  
Of the facilitative glucose transporters, GLUT1(146), 3 (178), 4 (179), 9 (143), 10 (180), 
11 (181) and 12 (144) have been detected in human placentas. Among them, the most 
widespread glucose transporter is GLUT1. As previously discussed, GLUT1 is coupled 
with a hexokinase, which is highly active in the placenta (182). The function of GLUT1 
and hexokinase 1 is independent of insulin (183), but GLUT1 expression in the placenta 
can be modulated by insulin and/or hyperglycaemia (184-186). GLUT1 is expressed in 
cytotrophoblasts, stromal cells, vascular smooth muscle, fetal endothelial cells (174), with 
the most dense expression in the syncytiotrophoblasts (146, 187). GLUT1 protein 
expression and transport activity increase in the second trimester of pregnancy (187) 
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probably in response to a much higher fetal glucose requirement associated with fast 
intrauterine growth. Accordingly, term trophoblast homogenates present much higher 
abundance of GLUT1 protein than first trimester trophoblast homogenates (179). In the 
syncytiotrophoblasts, both basal and microvillous membranes show GLUT1 expression. 
In term trophoblasts, GLUT1 is asymmetrically expressed with higher expression in the 
syncytiotrophoblast microvillous membrane than in the basal membrane, leading to 
greater glucose transport rates through the apical membrane (187, 188), although there 
are also descriptions of symmetric glucose transport across the syncytiotrophoblast 
membranes (189). GLUT3 is a high affinity glucose transporter protein that is expressed 
in the extravillous trophoblast, villous cytotrophoblast, endothelial and stromal cells 
(178), and absent in the syncytiotrophoblast (178). In term placentas, endothelial cells 
present the highest expression of GLUT3 (178). GLUT4, which is insulin-responsive, has 
been identified in the syncytiotrophoblast cytosol from early pregnancy placentas (179), 
although not by all authors (190). At term, GLUT4 has a weaker expression (179) and is 
particularly found in villous stromal cells (191). GLUT4 function in pregnancy is not 
completely clear yet, and it may be implicated in insulin-stimulated glucose uptake that 
has been observed in first trimester, but not term, placental villous fragments (179). 
Overall, GLUT3 and GLUT4 are biologically more relevant in early pregnancy than 
GLUT1, whilst GLUT1 and GLUT3 seem to be the most important glucose transporters 
of the maternal-fetal barrier at term, in syncytiotrophoblasts and endothelial cells, 
respectively. However, glucose transport through GLUT1 and GLUT3 has also been 
implicated in placental angiogenesis and implantation processes and in the metabolism of 
decidual leukocytes (190).  
Placental glucose uptake shows a strong positive relation with the available glucose 
supply (176, 192), and appears to be saturable at supra-physiological maternal glucose 
levels (165, 193, 194), which shows the high capacity of the placental glucose transport 
 52
system. This efficient glucose uptake has been demonstrated in multiple studies over the 
past decades. Using microvillous preparations, the Km for 3-O-methylglucose transport 
was 31 ± 13 mM with a Vmax of 7.2 μmol/minute/mg protein (175). Also, the maximal 
placental glucose uptake rate in perfused placentas, assessed over a maternal perfusate 
glucose range from 3 to 53 mM, corrected for simple glucose diffusion, was 1.6 
μmol/minute/g (165). This rate of uptake was measured at maternal perfusate glucose 
concentrations of 20 mM and higher (165).  
Glucose utilisation by placental metabolism (total glucose uptake minus glucose transfer 
to the fetus), as measured in placental perfusion studies, also was shown to correlate with 
the maternal perfusate glucose levels up to 17-22 mM (165). Under normal 
circumstances, about 50% of glucose taken up from the maternal circulation by the 
placenta has been estimated to be transferred to the fetus (165). From the remaining 50% 
of glucose uptake, about 40% has been estimated to be metabolised by the placenta and 
released as lactate, about 20-25% undergoes oxidative metabolism with the other 35-40% 
assumed to be metabolised in other pathways (165, 195). Considering that glycolysis into 
lactate yields about 16 times less ATP than complete glucose oxidation (refer to section 
1.5.1 of this chapter), the low rates of placental glucose oxidation possible necessitates, 
for energy requirements, the high rates of glucose uptake and lactate production. 
However, against this is the finding that both placental glucose oxidation (165) and lactate 
release have not been shown to relate to placental glucose utilisation (196). In placental 
perfusion studies, glucose oxidation and lactate production have been shown to be 
maximal at relatively low maternal glucose perfusate concentrations (165, 176).  
Lactate has also been the main glucose metabolic product in other placental experimental 
models, corresponding to around 70% of glucose metabolism in placental fragments (197) 
and in isolated trophoblasts (148). Nonetheless, in comparison with placental perfusion 
studies, much lower fractions of glucose metabolism into glucose oxidation have been 
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reported in both early pregnancy (2.4%) and term placental fragment cultures (<2%) 
(197), as well as in primary trophoblast cultures from term placenta (1.8-3%) (148).  
Interestingly, total glucose uptake was reduced in placentas from GDM mothers (176) 
and the transplacental glucose flux into the fetal circulation was similar (198) or reduced 
(176) in comparison with placentas from healthy mothers. Also, maternal GDM 
independent of insulin therapy led to a lower placental glucose utilisation than in normal 
controls (198). In addition, early studies found that pyruvate kinase activity, which is 
insulin-responsive, was increased in GDM placentas in comparison with controls (199). 
As neonates born to those GDM mothers were significantly heavier (199), increases in 
pyruvate kinase function could lead to higher fetal supply of pyruvate derived products 
including lactate and fatty acids. Nevertheless, in placental perfusion experiments in 
which the newborns’ weights were matched, the lactate release into maternal and fetal 
circulations was reduced in placentas from GDM pregnancies on diet in comparison with 
normal controls (176). Whether these differences in placental glucose metabolism 
participate in a placental adaptation to prevent fetal excessive growth is undetermined.  
There is less known about glucose utilisation in isolated trophoblasts in response to 
increasing culture glucose concentrations. A previous study from our group showed that 
glycolysis measured by a radioactive tracer method, as described in Chapter 3, did not 
increase with increasing media glucose concentrations above physiological levels (200). 
Indeed, glycolysis rates were near maximal at 4 mM glucose and maximum at media 
glucose concentrations of 8 mM (200). Thus, it is probable that isolated trophoblasts will 
not increase glucose oxidation or lactate synthesis at high glucose media concentrations, 
but this still needs confirmation. 
As discussed in section 1.5.1, glucose 6-phosphate can be oxidised via the pentose 
phosphate pathway, which produces precursors for the synthesis of coenzymes, 
nucleotides, RNA and DNA (ribose 5-phosphate) and NADPH for reducing reactions 
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especially involved in the biosynthesis of fatty acids and cholesterol (149). Hence, the 
shift of glucose to this pathway occurs in organs with intense growth or with high 
biosynthesis demands (149). Ultimately, the NADPH supply also participates in anti-
oxidative processes protecting the cells against excess free oxygen radicals (201). Only a 
few authors have investigated the pentose phosphate pathway in the human placenta. 
Glucose oxidation via the TCA cycle and pentose phosphate pathway, measured through 
the ratio of 14CO2 production from [1-14C]-glucose and [6-14C]-glucose, have suggested 
that oxidation via the TCA cycle is higher than via the pentose phosphate pathway in term 
placental slices, whereas in younger placentas (6-20 weeks) oxidation by the pentose 
phosphate pathway is greater (202). Different proportions of glucose utilisation via 
glycolysis and the TCA cycle or the pentose phosphate pathway were found in another 
research study, but the pentose phosphate pathway also accounted for higher portions of 
glucose utilisation (10%) in early pregnancy (6-10 weeks) compared to term placentas 
(5%) (197). In human trophoblast cultures from term placentas, the oxidative pentose 
phosphate pathway represented less than 1% of the total glucose metabolised (148). 
Furthermore, the activity of this pathway was greater soon after trophoblast isolation than 
in trophoblasts established in culture for one to three days with increasing differentiation 
into syncytiotrophoblasts (148). It is unknown whether glucose partitioning into the 
pentose phosphate glucose pathway increases with increasing glucose supply.  
Although the placenta expresses enzymes implicated in gluconeogenesis (e.g. 
phosphoenolpyruvate carboxykinase, alanine and aspartate aminotransferase) (203), the 
key gluconeogenic enzyme glucose 6-phosphatase (G6Pase) found in the placenta has 
more kinetic similarities with the brain G6Pase isoform than with the hepatic isoform 
(203). Whether the human placenta is capable of gluconeogenesis and the precise function 
of placental G6Pase are unclear. 
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The placenta expresses many enzymes and proteins involved in glycogen turn-over 
including glycogen synthase (204), glycogenin (178), glycogen branching enzyme, 
glycogen debranching enzyme (205) and glycogen phosphorylase (206). Nonetheless, 
placental glycogen metabolism does not seem to be regulated by insulin as observed in 
other tissues such as the liver and skeletal muscle (207). In these latter tissues, insulin 
stimulates glycogen deposition and inhibits glycogen hydrolysis (207). In the placenta, 
glycogen turn-over is mostly controlled by intracellular substrate availability, therefore 
the levels of intracellular glucose and glucose 6-phosphate can modulate the enzymes 
implicated in placental glycogen synthesis and degradation (182, 207). Placental 
glycogen can be stored in fetal endothelial cells, pericytes, cyto- and 
syncytiotrophoblasts, stromal cells, smooth myocytes (208) and in the amnion epithelium 
(207). It is speculated that glucose produced from placental glycogenolysis is mostly used 
by the placenta for its own metabolic needs, although some could be metabolised into 
other products such as lactate or be transferred to the fetus with requirement of glucose 
6-phosphatase (207). In addition, in the presence of maternal hyperglycaemia, excess 
glucose could be buffered by the placenta as a “defensive reaction” against fetal 
glucotoxicity.  
In normal pregnancies, the amount of placental glycogen reduces as the pregnancy 
progresses (207). Glycogen accumulation represented 4.8% and 1.3% of glucose 
metabolism in placental slices from early pregnancy and term placentas, respectively 
(197). Glucose flux into glycogen synthesis measured by 14C incorporation from [1-14C]-
glucose or [6-14C]-glucose corresponded to < 1% of total glucose metabolism in isolated 
human cytotrophoblasts in short-term incubations (148). Also, 14C incorporation into 
glycogen halved in 1-3 days in comparison to freshly isolated trophoblasts, suggesting 
that glycogenesis is higher in more undifferentiated cells (148). 
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Contrary to what occurs in normal pregnancies, glycogen levels increase in term placentas 
affected by diabetes (182), although this finding is not universal and seems to depend on 
diabetes type or therapy (208, 209). Furthermore, gene expression profiles in GDM have 
indicated an increased placental glycogen turn-over, as protein and enzymes implicated 
in both glycogenesis (glycogenin and glycogen branching enzyme) and glycogenolysis 
(glycogen debranching enzyme) were overexpressed in GDM placentas (205).  
Primary human trophoblasts raised glycogen accumulation in cultures in media at 10 mM 
glucose in comparison with 1 mM glucose concentrations assessed by electron 
microscopy (200). However, total glycogen content was unchanged when 
cytotrophoblasts were cultured in glucose concentrations ranging from 5.5 to 28 mM in 
another study (210). Of note, trophoblast glycogen content increased for 2 h after 
replacing the culture media and was 1.5-fold higher from 2 to 5 h following the media 
replacement (210). It would be helpful to know more about the dynamics of this glycogen 
increase post-media refreshment, according to the media glucose concentration and 
whether the cells are from normal or diabetic pregnancies. Moreover, Desoye has 
proposed that fetal hyperinsulinaemia, in response to maternal obesity and/or diabetes, is 
the major factor driving the excess glycogen accumulation in the affected placenta (169). 
This explanation is supported by the lack of relationship between placental insulin 
receptors and serum plasma insulin from mothers with or without diabetes (209), the 
absence of glycogen content increment in cells from the maternal side of the placenta 
(trophoblasts) in the presence of high concentrations of glucose and insulin (210), the 
evidences of a preferential glycogen accumulation in the placental cells in contact with 
fetal blood (endothelial fetal cells and pericytes) as well as the primary location of 
glycogenin and GLUT3 in the endothelial cells at term (178).  
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1.7.1.1 Effects of NEFA on placental glucose metabolism 
Interactions between fatty acid and glucose metabolism have for long been described to 
occur in muscle and adipose tissue and particular reference is often made with respect to 
this interaction to the pathogenesis of insulin resistance in T2DM (211). Glucose and fatty 
acid compete for their oxidation in muscle and the utilisation of one nutrient directly 
inhibits the use of the other even without hormonal action, according to the Randle cycle 
hypothesis (212). Fatty acids can affect glucose metabolism at many points: (i) inhibition 
of glucose transport and hexokinase action; (ii) inhibition of phosphofructokinase-1 (a 
regulatory enzyme of glycolysis-refer to section 1.5.2 of this chapter); and (iii) inhibition 
of pyruvate dehydrogenase, which catalyses the conversion of pyruvate into acetyl-CoA 
to be oxidised in the TCA cycle (212). There are scarce data on the effects of fatty acids 
on human placental glucose metabolism. In placental rat slices, oleate at high dose (0.8 
mM) did not change glucose uptake, oxidation nor lactate release, but it slightly increased 
(by 0.8%) glucose incorporation into glycogen (182). The effects of NEFA on glucose 
metabolism is still not defined in human placenta, notably the effects of different types of 
NEFA such as the saturated NEFAs palmitate and stearate. Thus, the study of NEFA 
effects on glucose metabolism in the placenta, particularly in trophoblast and endothelial 
cell cultures, could help to clarify the pathophysiology of the gestational complications 
that increase more frequently in obesity/diabetes.   
1.7.2 Lipid transport and metabolism  
Maternal TG are the primary lipid source to the fetus, but it must be hydrolyzed by 
placental LPL into NEFA and glycerol to be taken up by the placenta and transferred to 
the fetus (213). LPL protein has been identified in the syncytiotrophoblast and villous 
cytotrophoblasts in early pregnancy and only in smooth muscle cells of vascular vessels 
in term placentas. In addition, LPL mRNA greatly increased at term (214). The placenta 
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also expresses endothelial lipases (EL), which contain a predominant phospholipase 
function with preferably hydrolysis of HDL-C-derived phospholipids, and a minor role 
in TG hydrolysis (215). Comparing with LPL, EL mRNA expression was higher in both 
term and first trimester placentas (214). At term, EL mRNA expression in trophoblasts 
decreased, whereas EL mRNA of whole placenta increased being mostly expressed in 
endothelial cells from fetal vessels (214). This indicates a rearrangement of EL from the 
trophoblast early in pregnancy to the endothelial fetal cells as gestation advances possibly 
to better supply the fetal developmental demands (214).  
The placenta transports NEFA via passive diffusion or through saturable transport 
processes dependent on trophoblast proteins (216, 217). Hence, trophoblasts can take up 
fatty acids using plasma membrane proteins, including fatty acid transport proteins 
(FATPs), fatty acid binding protein plasma membrane (FABPpm), placental membrane 
fatty acid binding protein (p-FABPpm) and fatty acid translocase (FAT/CD36) (216, 
217). Into the cytoplasm, fatty acids bind to FABP which facilitate the use of fatty acids 
for biological functions in the trophoblast intracellular compartment (216, 217). From the 
syncytiotrophoblast basal membrane, the fetal circulation receives NEFA via FAT/CD36 
and FATP or via passive diffusion (217). Fatty acids are then carried by fetal albumin to 
the liver to be metabolised into TG which is transported back into fetal plasma (217). The 
placenta also expresses adipophilin and perilipin (218, 219), proteins implicated in 
intracellular lipid droplet formation and essential for the action of intracellular lipases 
(219, 220).   
Cholesterol is also transferred to the fetus by the placenta and is particularly important 
for steroid hormone synthesis, cellular membranes and as a bile precursor (221). 
Cholesterol and TG containing lipoproteins can be taken up by the trophoblast via specific 
membrane receptors, e.g. scavenger receptor class B (HDL-C); LDL-receptor related 
protein 1 (VLDL-C); lipoprotein-related protein 2 (HDL-C and LDL-C); and ATP-
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binding cassette transporters (efflux of cholesterol through cellular membranes) (222, 
223). Besides, trophoblasts also contain membrane lipoprotein receptors that, once bound 
to LDL-C and VLDL-C, internalize the lipoprotein particles (166). In the cytosol, the 
lipoproteins are carried into endosomes and lysosomes where cholesterol is freed, the TG 
fractions of LDL-C and VLDL-C are hydrolyzed by intracellular lipases, and the placental 
membrane lipoprotein receptors are then recycled (166).  
In addition to lipid transporters and proteins linked to fatty acid storage, the placenta 
contains enzymes for fatty acid oxidation. The expression of enzymes that act in the first, 
third and fourth steps of β-oxidation of fatty acids (see Figure 1.8 in this chapter), i.e. 
acyl-CoA dehydrogenase complex [medium-chain acyl-CoA dehydrogenase (MCAD), 
long-chain acyl-CoA dehydrogenase (LCAD), very-long-chain acyl-CoA dehydrogenase 
(VLCAD)]; β-hydroxyacyl-CoA dehydrogenase complex [short-chain L-3-hydroxyacyl-
CoA dehydrogenase (SCHAD) and long-chain L-3-hydroxyacyl-CoA dehydrogenase 
(LCHAD)], and acyl-CoA acetyltransferase (thiolase) [long-chain 3-ketoacyl-CoA 
thiolase (LKAT)]; respectively, have been described in human placenta (224). In term 
placentas, all cited enzymes were found to be expressed in the syncytiotrophoblast, where 
the expression was the highest, and in cytotrophoblasts. However, no expression was 
detected in chorionic villous vessels nor mesenchymal tissue (224). Moreover, all these 
enzymes were expressed from 12 weeks of pregnancy towards term, but the expression 
and activity of LCHAD, SCHAD and LKAT decreased with pregnancy progression, 
especially after 28 weeks (224). Therefore, there is remarkable evidence that the placenta 
is capable of lipid uptake, transport and metabolism, including fatty acid recycling, 
oxidation and storage.  
The fetus may synthesise some fatty acids (225, 226), but obtains about 50% of its body 
fat from the maternal circulation (166) and it is totally dependent on maternal nutrition 
and placental transfer to acquire essential fatty acids (EFA) [i.e. the polyunsaturated fatty 
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acids (PUFA) α-linoleic (n-3; 18:3) and linoleic (n-6; 18:2) acids] (217). The longer chain 
products of α-linoleic and linoleic acids are crucial for kidney, liver, retina, brain, gonads 
and adrenals development (227), which may be reflected by the placenta preference in 
transferring the n-3 derived docosahexaenoic acid (DHA) to the fetus in comparison with 
palmitic acid, oleic acid and linoleic acid (228), and also by findings of higher proportions 
of long-chain PUFAs in fetal than maternal plasma (226).  
It has been demonstrated that the transport and metabolism of fatty acids can be altered 
in pregnancies affected by obesity and diabetes. Nevertheless, the results are not 
homogeneous, possibly due to differences in study design, type of diabetes assessed 
(GDM, T1DM or T2DM), GDM severity and therapy (diet alone or insulin therapy), the 
occurrence of adverse outcomes such as macrosomia and, in particular, maternal BMI. 
Furthermore, it appears that the combination of GDM and obesity is a major determinant 
of changes in placental lipid metabolism. mRNA expression of adipose TG lipase 
(ATGL) was up-regulated and hormone sensitive lipase (HSL) was down-regulated in 
placentas from women with well-controlled GDM compared with healthy controls 
matched for BMI and gestational age of delivery (218). Even so, there were no differences 
in the protein expression of placental ATGL, HSL, LPL and EL between women with 
and without GDM (218). In addition, IL-6, which is commonly increased in obesity and 
GDM, led to fatty acid accumulation in primary human trophoblast cultures (229). 
Nonetheless, this was not associated with alterations in genes involved in placental fatty 
acid transport (FATP1 and FATP4), adipophilin or LPL activity (229). A study that 
investigated the expression of genes implicated in glucose and lipid metabolism in 
placentas from T1DM and GDM mothers, both with macrosomic neonates, compared to 
those from normal pregnancies, showed that 67% of up-regulated genes were involved in 
lipid metabolism and only 9% of up-regulated genes were related to glucose metabolism 
(205). Genes associated with the synthesis of TG, cholesterol and steroids were, however, 
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preferably overexpressed in placentas of GDM obese mothers with minor or no alterations 
in the placentas of T1DM women (205). This supports the importance of the combination 
of obesity and diabetes in the origin of gestational complications related to placental lipid 
metabolism dysfunction (205).  
Another study that evaluated (i) normal BMI healthy mothers, (ii) obese mothers, and (iii) 
obese mothers with well-controlled T2DM or GDM, showed increased placental villous 
NEFA accumulation and increased expression of FABP4 only in the group with obesity 
and diabetes (230). The obese and GDM group also had higher circulating TG levels in 
both maternal and cord blood and heavier neonates than normal BMI and non-diabetic 
obese mothers (230). Surprisingly though, villous TG quantities were higher in the control 
group than in the obese or obese/diabetic groups (230). In primary trophoblast cultures, 
incubation with 10 nM insulin, 0.8 mM linoleate and 0.4 mM oleate highly induced 
FABP4 expression and led to increased intracellular TG content; whereas siRNA 
knockdown of FABP4 reduced the TG content (230). The authors concluded that up-
regulation of FABP4 in trophoblasts induced by lipid is a key factor in determining the 
accumulation of fatty acids in these cells (230). They also suggested that increased 
concentrations of maternal lipids in the presence of diabetes and obesity drive placental 
fatty acid transport to the fetus through FABP4. As a result, the fetus exhibits higher 
circulating TG with greater fat mass, however without a rise in placental TG content 
(230). 
Furthermore, EL mRNA expression was increased in placentas from obese-GDM women 
in comparison with lean controls, which was not seen in placentas from only obese or 
only GDM women (231). Treatment of normal placental villus primary endothelial cells 
with TNF-α or leptin caused a dose-dependent up-regulation of EL expression from 
normal pregnancies and these effects were further increased when cells were incubated 
with both TNF-α and leptin (231). These results implicate TNF-α and leptin in altering 
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lipid metabolism within the placenta. In this research, as placental EL function is not fully 
understood, the authors have discussed the hypothesis that increased EL activity in 
endothelial cells of the fetus might increase the hydrolysis of phospholipids and TG, 
leading to higher NEFA availability for fetal uptake (231). However, no relationship 
between EL expression and fetal growth assessment was seen in this study and EL activity 
was not measured (231). These data also indicate that the combination of obesity and 
diabetes, which precipitates a more dysfunctional metabolic profile, has a synergistic role 
in the pathogenesis of pregnancy complications, associations that have been demonstrated 
in clinical studies, and that the fetus seems to actively participate in these processes.  
Changes in placental lipid metabolism in cultures appears to be more strongly driven by 
exposure to high levels of lipids than to high glucose concentrations. In primary human 
trophoblast cultures, 0.4 mM oleate induced expression of genes related to cholesterol 
and TG synthesis, an effect that was not observed in the presence of 10 mM glucose 
concentration (205). The combination of 0.4 mM oleate and 10 mM glucose did not 
increase the effect of 0.4 mM oleate alone (205). Moreover, in primary human 
trophoblasts in culture, treatment with 0.25 mM NEFA (palmitate plus oleate) increased 
NEFA esterification into diacylglycerol and TG, adipophilin expression and lipid droplet 
formation (200). Conversely, NEFA treatment decreased fatty acid oxidation and 
lipolysis (200). These results are consonant with an increased lipid storage in trophoblasts 
induced by NEFA (200). Exposure to high compared to low glucose levels (10 vs 1 mM) 
did not impact on lipid pathways, other than down-regulated mRNA adipophilin 
expression (200). In addition, the presence of NEFA, but not high glucose media, 
increased trophoblast syncytialisation indicating that high levels of NEFA may precipitate 
changes in placental structure (200). At variance with these results, human term placental 
explants exposed to higher levels of media glucose (11 mM vs 5 mM) decreased fatty 
acid oxidation, increased NEFA esterification into total lipids and increased placental TG 
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content, demonstrating that glucose can also affect placental lipid metabolism (232). 
These discrepancies may be secondary to methodological differences such as incubation 
conditions and tissue culture of isolated trophoblast cultures in one study (200) and villous 
explants in the other, as the latter included mixed cell population of metabolically active 
cells (e.g. fibroblasts and endothelial cells together with trophoblasts) in a model that 
maintains the histological structure (232).  
Few studies have addressed the roles of altered cholesterol metabolism in the placenta in 
obesity and diabetes, despite the alterations in cholesterol metabolism that happens in 
normal pregnancy (33). Placentas from women with plasma total cholesterol 
concentration > 8 mM late in pregnancy have demonstrated decreased LDL-receptor 
protein expression in relation to women with cholesterol < 7 mM (233). Likewise, LDL-
receptor protein expression was inversely correlated with term maternal plasma LDL 
concentrations (r=-0.53), maternal plasma total cholesterol concentration (r=-0.49), and 
maternal plasma apoB-100 levels (r=-0.44) (233). LDL-receptor expression was also 
associated with maternal pre-pregnancy BMI (233). For women with cholesterol > 8 mM, 
LDL-receptor expression was lower in placentas from women in the highest BMI group 
in comparison with those in the lowest BMI group (233). Interestingly, cord plasma 
cholesterol was the same in neonates born to high and low cholesterol women (233) 
suggesting that these cholesterol transport alterations in the placenta may spare the fetus 
from abnormal maternal circulating lipids. Moreover, high levels of oxysterols may take 
part in the pathogenesis of structural and functional alterations in the placenta since there 
is evidence that these cholesterol oxidation products impair differentiation and 
syncytialisation of term human trophoblasts in vitro (234).     
As mentioned in section 1.3.2 of this chapter, plasma maternal glycerol levels are 
increased during the catabolic phase of pregnancy mainly in the last trimester. However, 
it is unlikely that substantial glycerol transport from the mother to the fetus exists in 
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humans. The intense use of glycerol as a substrate for maternal hepatic and renal 
gluconeogenesis possibly precludes glycerol placental transport (235). Ketone bodies 
cannot be produced by the fetus and are usually at low concentrations in maternal blood, 
but can be increased due to maternal fasting or uncontrolled diabetes (235). The placenta 
is able to metabolise ketone bodies for energy production and to deliver them to the fetus, 
which may also utilise ketone bodies as a nutritional source (236). Ketone bodies are 
transported by the placenta via passive diffusion or, at least in rat, via a carrier-mediated 
transport system (237).  
Data on other factors linking obesity and placental lipid metabolism have been emerging. 
A recent study with term placental explants have demonstrated that hepatocyte growth 
factor (HGF) can reduce CPT-1 activity and fatty acid oxidation, stimulate NEFA 
esterification and de novo fatty acid synthesis with rise in TG content (238). HGF, which 
is a pro-inflammatory cytokine synthesized by the adipose tissue and thereupon 
augmented in obesity, was increased in the amniotic fluid in the second trimester of obese 
gravidas (238).  
1.7.3 Amino acid transport and metabolism 
Contrary to proteins that have a high molecular size and do not cross the placenta (e.g. 
insulin), amino acids are transported through the placenta by active transport or facilitated 
diffusion (239). The amino acid transport across the syncytiotrophoblast microvillous and 
basal membranes is a controlled process, whereas amino acids have free passage through 
the fetal endothelium (240). Amino acid transporters, also sub-classified in isoforms, are 
not evenly distributed in the microvillous and the basal membranes of the 
syncytiotrophoblast. About 20 amino acid transporter types have been identified in the 
human placenta and only the main groups are described here. Systems A, ASC, β, X-AG 
are sodium-dependent transporters, while systems L, T, y+ and y+L are sodium-
independent (240). System A or Na+-coupled neutral amino acid transporters (SNAT) are 
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mostly responsible for the uptake of small neutral non-essential amino acids such as 
glycine and alanine into the trophoblast (241). System A transporters are found in both 
the syncytiotrophoblast microvillous and basal membranes, but are much more active at 
the microvillous membrane (241, 242). System L carries essential amino acids, specially 
branched chain amino acids (e.g. leucine) (241), through the syncytiotrophoblast 
microvillous membrane (241) and the basal membrane (243). In addition, system L 
mediates the transport of the aromatic amino acids tyrosine and tryptophan across the 
microvillous membrane (243). System T transports tyrosine, tryptophan, alanine, 
phenylalanine and leucine through the basal membrane (243, 244), whereas system ASC 
(alanine, serine and cysteine), which is part of a superfamily of non-polar and some 
anionic amino acid transporters, has also been found in the basal (242) and microvillous 
membranes (245). The β-amino acid transport system [e.g. taurine transporter (TauT) ] is 
much more active in the microvillous membrane than in the basal membrane maintaining 
an elevated trophoblast intracellular concentration of taurine (246, 247). Cationic amino 
acids (e.g. arginine) are mainly transported through the microvillous membrane by the 
system y+ and through the basement membrane by the system y+L (248). The anionic 
amino acids (e.g. aspartate and glutamate) are transported by X-AG system, which has been 
described in both the microvillous and basal membrane (249).  
The three main mechanisms of amino acid transport are (i) the uptake from maternal 
circulation with intracellular accumulation in the syncytiotrophoblast (e.g. system 
A)(239); (ii) the exchange of syncytiotrophoblast amino acids with the maternal or fetal 
circulation amino acid pools which results in qualitative but not quantitative changes in 
amino acids (e.g. system ASC and some isoforms of systems L and y+L) (250); and (iii) 
the efflux of amino acid from the syncytiotrophoblast cytosol through the basal membrane 
into the fetal circulation (e.g. some isoforms of systems T and L) (244).  
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An adequate amino acid supply is crucial for a normal fetal growth, and a fetus with 
adequate growth usually has higher circulating amino acid concentrations than the mother 
(251, 252). Amino acids can be converted to other metabolic substrates (e.g. into glucose 
through gluconeogenesis); be oxidised by the fetus and the placenta to produce energy; 
and/or be used as a source of nitrogen and carbon by the fetus (168). The placenta is also 
able to synthesise amino acids, such as alanine, from protein catabolism or pyruvate 
transamination (168). Different amino acids are selectively transported in healthy 
pregnancies and a study has demonstrated that phenylalanine, leucine, methionine, and 
isoleucine cross the placenta faster than tryptophan, lysine, threonine, and histidine (253). 
Moreover, the combination of amino acid types and the amino acid concentrations in 
maternal plasma seems to determine the umbilical cord amino acid uptake, i.e. some 
specific amino acids present in maternal circulation may inhibit the placental transfer of 
amino acids to the fetus (254).  
Disturbances in placental transport and fetal uptake of amino acids have been identified 
in fetal growth restriction (245, 246, 255), a condition in which the fetal-to-maternal 
plasma amino acid ratio is decreased in comparison with pregnancies with normally 
grown fetuses (256). Less studies have investigated the role of placental amino acid 
transport in fetal aberrant growth in pregnancies affected by obesity and/or diabetes, 
nevertheless some evidences suggest that amino acid transport can be altered in these 
conditions. Some amino acids were found to be increased in cord plasma from well-
controlled GDM, but normal in maternal plasma (257), suggesting a selective increase in 
the placental amino acid transport in GDM (257). The activity of the system A and protein 
expression of the SNAT2 isoform were raised in the placental microvillous membranes 
from obese mothers with LGA neonates (258). According to this study, placental amino 
acid transporters may have been stimulated by the activation of insulin and mammalian 
target of rapamycin (mTOR) signalling pathways (258). In addition, the system A activity 
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in the microvillous membrane was increased in T1DM and GDM pregnancies, but leucine 
transport across the microvillous membrane was up-regulated only in GDM pregnancies 
associated with LGA babies (259). Conversely, the activity of system A transporter was 
down-regulated in the microvillous membranes of placentas from GDM/T1DM 
pregnancies with LGA neonates probably due to a reduced number of transporters in 
comparison with healthy pregnancies with appropriate for gestational age babies (260). 
Besides, the activity of placental TauT was lower in women with obesity early in 
pregnancy in comparison with women with normal BMI, even though the TauT protein 
expression was normal (261). As in this study neonates born to obese mothers presented 
normal growth, the authors suggested that this is possibly a post-translational down-
regulation of amino acid transport in response to maternal obesity preventing fetal 
overgrowth (261). It is unknown whether a specific amino acid transporter decrease in 
one system can be overcome by a compensatory rise in a transporter for the same amino 
acid in another system, which could explain the disparities between these studies.  
Leptin has been implicated in modulation of placental amino acid transport. Acute 
exposure to supra-physiological doses of leptin promoted the activity of system A amino 
acid transport in villous explant cultures from healthy mothers via the JAK-STAT 
pathway (262). However, the activity of system A reduced with a more prolonged 
incubation with leptin (262). This may be a placental modulation in response to an 
adipokine that signals maternal adipose tissue and therefore nutritional plenty (262). 
Supporting this hypothesis, system A activity was decreased in placental fragments from 
obese women with normal neonates in comparison with normal BMI mothers (263). Also, 
maternal plasma leptin was negatively correlated to system A activity and the 
syncytiotrophoblast leptin receptor density was reduced in the obese compared to the 
normal BMI mothers (263). Moreover, adiponectin decreased SNAT2 expression (protein 
and mRNA) and system A activity insulin-stimulated in primary human trophoblast cells 
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(264). Adiponectin inhibited insulin action through down-regulation of the insulin 
signalling pathways, as indicated by decreased insulin receptor substrate 1 and protein 
kinase B (AKT/PKB) phosphorylation, and possibly via PPAR-α activation (264), but the 
latter requires further investigation.  
In addition to adipokines, there are evidences that pro-inflammatory cytokines are 
involved in the regulation of placental amino acid transport. In human primary 
trophoblast cultures from term placentas, physiological levels of TNF-α and IL-6 
increased the activity of system A and the protein expression of both SNAT1 and SNAT2 
(265). 
Besides, the fetus may contribute to placental delivery of amino acids. In a mouse model 
of genetic intrauterine growth restriction, the knock-out of the insulin growth factor II 
transcript in the trophoblast firstly led to a reduction in the placental size which was 
followed by fetal growth restriction (266). Initially, placental transport of amino acids 
was increased presumably in an attempt to compensate for the delayed fetal growth (266). 
More studies concomitantly investigating amino acid concentrations in maternal plasma 
and umbilical cord together with amino acid placental transport are needed to elucidate 
the regulation and dynamics of amino acid in obesity and diabetes.  
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1.8 Rationale of this thesis research  
Due to the high prevalence and well-known detrimental consequences of obesity and/or 
diabetes during pregnancy, studies that investigate the pathophysiology of these 
conditions in the feto-placental-maternal unit are invaluable. Previous studies in our 
laboratory have shown the effects of high levels of glucose and NEFA on lipid 
metabolism and morphology in primary human trophoblasts, which are the placental cells 
in contact with maternal blood during pregnancy (200). In continuation of this line of 
research, the current series of experiments were designed to assess the effects of high 
concentrations of NEFA and/or glucose on glucose metabolism pathways in primary 
human trophoblasts in culture in addition to the effects of NEFA on trophoblast 
morphology. Moreover, the studies were conducted in cells at different stages of 
differentiation to investigate whether glucose metabolism diverges in cultures richer in 
cytotrophoblasts or syncytiotrophoblasts. 
1.8.1 Hypotheses 
a. In the presence of higher glucose concentrations, total glucose uptake will be 
increased in human trophoblasts. However, glycolysis and glucose oxidation will 
not be augmented. Excess glucose will be stored as glycogen. 
b. In the presence of NEFA, glucose uptake and metabolism will be inhibited in 
human trophoblasts. 
c. Glucose metabolism will be different between cytotrophoblast and 
syncytiotrophoblast cultures since they present diverse cellular structure.  
d. Chronic exposure to NEFA will change cellular morphology of human 
trophoblasts in primary cultures. 
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1.8.2 Thesis research aims 
a. To investigate the metabolic flux of glucose through major pathways of 
metabolism in primary human trophoblast cultures exposed to increasing glucose 
concentrations. 
b. To assess the acute effects of NEFA on glucose metabolism in human trophoblast 
cultures. 
c. To evaluate glucose metabolism differences in human cytotrophoblast and 
syncytiotrophoblast cultures. 
d. To study the chronic effects of NEFA on human trophoblast culture morphology.  
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2.1 Introduction 
This chapter describes the protocols used for human trophoblast isolation and culture. 
Placental perfusion, explant cultures, trophoblast cell lines and primary cell cultures are 
models to study human placental metabolism. Each method has advantages and 
limitations. Primary trophoblast culture, however, is a commonly used technique to 
address trophoblast metabolism in spite of its artificial in vitro environment and lack of 
modulation by other cells from the placenta. It allows for assessment of trophoblast 
metabolism alone, as other cell types are not present. Primary cultures have the advantage 
over cell lines that the cells are not malignant or transformed and are therefore more 
closely related to the trophoblasts of in vivo human placenta.  
The first 11 trophoblast isolation experiments of this work were performed with a protocol 
established in the laboratory during a previous trophoblast study (200). The results 
however obtained were inconsistent, with variable cell yield and trophoblast purity. In 
addition, the protocol length demanded complex logistics and the cells were usually 
obtained and seeded overnight. Thus, a new method based on protocols from two well 
established trophoblast research centres (234, 267) was developed and tested. The main 
differences between the previous and the new protocol were the villous tissue harvesting 
procedure, the enzymatic digestion, a better control of the experimental variables and the 
logistics. The new protocol produced a higher trophoblast yield and higher trophoblast 
purity. This enhanced the reproducibility of the experiments performed with these 
trophoblasts.  
For this thesis, the first used protocol is named “primary trophoblast isolation-protocol 
1.” The new (current) protocol is described as “primary trophoblast isolation-protocol 2.” 
Only protocol 2 derived trophoblasts are included in the metabolism and morphology 
studies of this thesis.  
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2.2 Study participants 
This study was approved by the Australian Capital Territory (ACT) Health Human 
Research Ethics Committee (HREC) and HREC Calvary Health Care ACT. Informed 
written consent was obtained from all mothers providing the placentas. The participants 
were recruited at TCH and Calvary John James Maternity, between March of 2012 and 
March of 2015. Only the placentas from women undergoing elective caesarean section 
for obstetric indications (e.g. breech), with singleton pregnancies, at term (> 37-41 weeks 
of gestation), without obstetric complications in the current or past pregnancies (e.g. 
GDM, abnormal fetal growth) and without medical diseases (e.g. obesity, diabetes 
mellitus, systemic hypertension, current smoking) were included.  
2.3 Primary human trophoblast isolation–protocol 1 
2.3.1 Preparation of solutions and media 
Refer to Appendix 1-Material, reagents and solutions. 
2.3.2 Tissue harvesting and digestion 
Digestion buffer was prepared using calcium and magnesium free Hank’s Balanced Salt 
Solution (HBSS) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
(refer to Appendix 1) and divided into two Erlenmeyer flasks. The flasks containing the 
digestion buffer were kept at 37ºC. The placentas were collected from the surgical theatre 
and brought to the laboratory within 30 minutes of the newborn delivery. Five cotyledons 
were dissected and finely chopped. The remaining placenta, with cord and membranes, 
was sent to the Department of Anatomical Pathology at TCH for macroscopic and 
histological analysis to confirm normality. The harvested tissue was rinsed with warm 
(37ºC) saline solution to remove blood under sterile conditions. The tissue was evenly 
divided in two parts and placed into the flasks containing the digestion buffer. DNase 1 
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and trypsin were added to each flask. DNase 1 final concentration was 0.13 KU/ml and 
trypsin final concentration was 0.25%. After capping the flasks with aluminum foil, they 
were placed in a water bath (Ratek, Melbourne, VIC, Australia) at 37ºC, with gentle 
shaking for 30 minutes (shaking set=4). After digestion, the flasks were placed under the 
tissue culture hood, tilted to allow undigested tissue pieces to settle down for about 1 
minute. The supernatant was collected into 50 ml Falcon tubes with 3 ml of fetal bovine 
serum (FBS) to inhibit trypsin action. Falcon tubes with supernatant were kept under 
sterile conditions at room temperature. A new volume of digestion buffer, trypsin and 
DNase 1 (refer to Appendix 1) was added to the remaining tissue fragments and incubated 
in the shaking water bath (30 minutes, 37ºC) for the second digestion. The same procedure 
was used to collect the supernatant from the second digestion into 50 ml Falcon tubes 
containing 3 ml of FBS. Then, the digestion buffer, trypsin and DNase 1 were added into 
the flasks and the remaining tissue submitted to a third digestion in the shaking water bath 
(30 minutes, 37ºC). The supernatant was collected as for the previous digestions. The 
supernatants from all digestions were centrifuged (1000 g, 20 minutes, 25ºC) in an 
Allegra X-15R centrifuge (Beckman Coulter, Lane Cove, NSW, Australia). After 
centrifugation, the supernatants were discarded and each cell pellet was resuspended in 5 
ml Connaught Medical Research Laboratories (CMRL) supplemented with 25 mM 
HEPES, Penicillin-Streptomycin-Neomycin (PSN) Antibiotic Mixture (100X) and 10% 
FBS (vol/vol) (complete CMRL medium-refer to Appendix 1). The cell suspensions were 
poured through sterile 100 µm nylon mesh strainers into a single 50 ml Falcon tube to 
separate the undigested tissue. The cell suspension was centrifuged again (1000 g, 10 
minutes, 25ºC) to completely remove trypsin. 
2.3.3 Trophoblast purification 
The supernatant was discarded and the cell pellet was resuspended in 24 ml of calcium 
and magnesium free HBSS with 1% PSN (vol/vol). Aliquots of this cell suspension (4 ml 
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each) were carefully layered onto Percoll density discontinuous gradients (5%-70%) 
prepared in six 50 ml Falcon tubes (refer to Appendix 1). The gradients were centrifuged 
(1200 g, 20 minutes, 25ºC, brake off). Percoll gradient separates villous fragments and 
mesenchymal cells on the top, trophoblasts in the middle (around the 20 ml tube mark) 
and blood cells on the bottom (268). Trophoblasts from all gradients were collected using 
a 5 ml pipette into a new 50 ml Falcon tube. Serum-free CMRL medium at room 
temperature was added and the cell suspension was centrifuged (1000 g, 10 minutes, 
25ºC) to remove the Percoll. This wash procedure was repeated once and the cell pellet 
was then resuspended with 10 ml of complete CMRL medium.  
2.3.4 Cell counting and plating  
Twenty-five µl of cell mix and 25 µl of 0.4% trypan blue was mixed and the viable cell 
number was counted using a haemocytometer.  
Cells were seeded in a density of 1 x 106 live cells per well (12 well culture plates) and in 
a concentration of 1 x 106 cells per ml of complete CMRL medium. Rat tail collagen was 
used to coat microplate wells to increase the trophoblast adhesion (refer to Appendix 1 
for collagen preparation). Collagen coated plates were prepared no more than 15 days 
before cell seeding. Plated cells were kept in a humidified incubator (37ºC, 5% CO2) and 
daily observed under light microscopy.  
2.4 Primary human trophoblast isolation-protocol 2  
2.4.1 Tissue harvesting and digestion 
Each of the placentas were collected into a sterile bucket at room temperature within 30 
minutes of newborn delivery and weighed. For further examination, the placentas were 
placed on a sterile metallic tray. The placentas were measured and examined 
macroscopically for any abnormalities. One section of the umbilical cord, one roll of 
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extra-placental membranes (including the rupture site), two full sections of the placental 
plate (paraumbilical and lateral), a decidual shave and any abnormal areas were placed in 
10% buffered formalin for later microscopic assessment by the staff of the Department of 
Anatomical Pathology at TCH. 
Membranes and the decidua basalis were removed. Blocks of 5 cm x 3 cm x full thickness 
were cut and placed into a bowl full of cold 0.9% sterile saline solution. The blocks were 
then briefly dried on sterile cheese cloth sheets covering a 1,000 ml beaker and then 
transferred to a sterile metallic tray. The villous tissue was scraped leaving vessels and 
connective tissue behind. The scraped tissue was placed in a beaker filled with 250 ml of 
cold sterile saline solution and strained using cheesecloth covering a new beaker. The 
tissue was rinsed thoroughly with sterile cold saline solution to remove blood. The 
strained tissue was placed inside a sterile plastic culture bottle and weighed. Two-hundred 
ml of Dulbecco's Modified Eagle Medium [DMEM-5.5 mM glucose, 3.97 mM L-alanyl-
L-glutamine (GlutaMAX ™), 1mM sodium pyruvate] and 5 ml of HEPES (1 M, pH 7.4) 
were added to the bottle. The tissue was kept at 4°C overnight.  
Next morning, 500 to 750 ml of digestion buffer was prepared mixing HBSS (10X), 
HEPES (250 mM, pH 7.4) and Milli-Q water (refer to Appendix 1 for details of reagents, 
volumes and concentration of solutions). The total volume of digestion buffer to be used 
was determined by the harvested placenta tissue weight, being 500 ml for < 120 g and 
750 ml for > 120g of tissue. Dispase II was added according to the final volume of 
digestion buffer, being 20 ml of dispase II for a total of 500 ml and 30 ml for a total of 
750 ml of digestion buffer. The final dispase II concentration in the digestion buffer was 
2 caseinolytic units/ml. Digestion buffer with dispase II (DBD) was then filtered using a 
0.22 µm filter and kept at 37°C until use. Two ml of the DBD was added to each of two 
bottles of 100 mg DNase 1 (lyophilized powder) and 10 ml of DBD were added to each 
of two bottles of 100 mg trypsin (lyophilized powder). The remaining DBD volume was 
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evenly divided into two or three Erlenmeyer flasks (Pirex, borosilicate, 500 ml capacity, 
graduated, with screw caps, Brisbane, QLD, Australia). The harvested villous tissue, 
which had been kept at 4°C overnight, was strained on 2 unfolded and straight sheets of 
cheesecloth (total of 4 layers) held by 4 sterile clamps covering a 3,000 ml beaker. The 
tissue was then thoroughly rinsed with warm saline solution to completely remove the 
media. The villous tissue was divided into 3 equal parts and placed into the Erlenmeyer 
flasks containing DBD. Five ml of trypsin and 1 ml of DNase 1 were added to each 
Erlenmeyer flask. The flasks were closed with caps, swirled and placed into a 37°C water 
bath with moderate shaking for 30 minutes. The oscillation was set at 6.5 (the water bath 
oscillates–left to right–132 times per minute). The temperature was checked and the flasks 
were swirled every 10 minutes. Seven ml of sterile warm calcium and magnesium free 
phosphate buffered saline (PBS) was added to the remaining trypsin and 2 ml of PBS to 
the remaining DNase 1. After the incubation time, 4 ml of diluted trypsin and 1 ml of 
diluted DNase 1 were added to each Erlenmeyer flask. The final trypsin concentration 
was 3,520 Na–benzoyl–L–arginine ethyl ester (BAEE) units/ml and the final DNase 1 
concentration was 533.3 KU/ml. The flasks were placed into the shaking water bath for 
an additional 15 minutes at 37°C. Two 1,000 ml beakers, which contained 50 ml of FBS 
each, were covered with 2 unfolded cheesecloth sheets held by 2 sterile clamps per 
beaker. The digested tissue was filtered through the 2 cheesecloth “pockets”, which were 
squeezed using sterile gloves to optimise the yield of trophoblasts into the filtrate.  
2.4.2 Trophoblast purification 
The cellular filtrate was transferred to ten to sixteen 50 ml Falcon tubes and centrifuged 
(350 g, 20 minutes, 20°C). After discarding the supernatants, each pellet was resuspended 
in 5 ml of DMEM complete media. The cell suspensions were placed into two 50 ml 
Falcon tubes and centrifuged (350 g, 20 minutes, 20°C) to remove the trypsin. After 
centrifugation, the supernatants were discarded and the pellets from each tube were 
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thoroughly resuspended in 40 ml of erythrocyte lysis buffer (ELB) (refer to Appendix 1). 
Cells were exposed to ELB for approximately 5 minutes at room temperature. Five ml of 
FBS was slowly pipetted into the bottom of each tube to inactivate the ELB and cells 
were then centrifuged (290 g, 7 minutes, 20°C) to completely remove the ELB. The 
supernatants were discarded and 25 ml of complete media was added to each tube for a 
second wash. Cells were thoroughly resuspended as before and centrifuged (290 g, 7 
minutes, 20°C). The supernatants were discarded and 7.5 ml of 5% Percoll were added to 
each of the two Falcon tubes (a total of 15 ml of cells/Percoll). The pellets were 
resuspended using a sterile glass Pasteur pipette, followed by passage twice through an 
18 gauge needle using a 10 ml syringe. The cell suspensions were filtered through a 100 
µm cell strainer into a single new Falcon tube. Five ml aliquots of the cell suspension was 
carefully overlaid onto each of three 35 ml Percoll gradient tubes (prepared within 24 h 
prior to trophoblast isolation) with a 5 ml pipette (refer to Appendix 1 for Percoll 
gradients/layering preparation). The tubes were centrifuged with “slow” acceleration and 
without break (1200 g, 20 minutes, 20°C). Trophoblasts appeared as a thick layer around 
the 25 ml mark on the 50 ml Falcon tube (between the 30 and 35% Percoll concentration 
layers). Trophoblasts (about 5-10 ml per tube) were collected with a sterile glass Pasteur 
pipette pre-rinsed with regular DMEM and placed into two new 50 ml Falcon tubes. Each 
tube containing the cells was topped up to 50 ml with regular DMEM and centrifuged 
(290 g, 7 minutes, 20°C) to wash out the Percoll. The two cell pellets were each 
resuspended in 7.5 ml of 5% Percoll and three aliquots of 5 ml of the cell suspension were 
applied to a second series of Percoll gradients as previously described. After 
centrifugation, trophoblasts were collected and placed into two new 50 ml Falcon tubes. 
The tubes were topped up to 50 ml with regular DMEM and centrifuged (290 g, 7 minutes, 
20°C). The supernatant was removed and the cell pellets were resuspended in complete 
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DMEM (refer to Appendix 1). Cells were pooled into one tube and complete DMEM was 
added to total volume of 10 ml.  
2.4.3 Cell counting 
Twenty µl of the cell suspension was transferred into a 1.5 ml microtube and mixed well 
with 180 µl of 0.4% trypan blue. Ten µl of cell/trypan blue mixture was transferred into 
a haemocytometer. Viable cells (trypan blue excluded) in all 5 big squares (which 
contains 25 smaller squares) were counted twice (each side of the slide). The average 
cells/µl on the haemocytometer obtained was multiplied by trypan blue dilution (x 10), 
by conversion of µl into ml (x 10,000) and by total volume 10 ml (x 10). 
2.4.4 Cell plating 
Cells were plated in a density of 300,000 to 350,000 cells per cm2 and in a concentration 
of 1.4 x 106 cells/ml in complete DMEM. The complete DMEM was refreshed in all wells 
on the following day, and every 24 hours (h) afterwards (except on day 4 of culture when 
the media was not changed). Plate size was selected according to the experiment (refer to 
Chapter 3). Microplates without collagen coating were used in all in vitro experiments 
performed in trophoblasts obtained from protocol 2.  
Epidermal growth factor (EGF) was added to complete media (EGF concentration: 10 
ng/ml) from the cell seeding day, for cultures maintained for more than 3 days. For short-
term cultures, in which the experiments were performed within 36 h of culture, EGF was 
not used. 
2.5 Cytological assessment 
2.5.1 Purity of trophoblast cultures 
Trophoblasts were established in culture for 36 h prior to short-term culture metabolism 
experiments (refer to Chapter 3). At this time point, a sample of cells from 4 to 6 wells 
 80
(12 well plates) was collected to be assessed for purity using immunohistochemistry 
(IHC). Culture media was removed from the wells and the cells were washed in warm 
PBS. Then the cells were covered with 350 µl of warm 0.1% trypsin. Trypsin excess was 
removed and the plate was incubated for 5 minutes (37ºC, 5% CO2). Trypsin was 
inactivated by adding 500 µl of ice cold DMEM containing 10% of FBS (vol/vol) to each 
well. Cells were collected into a single 15 ml tube and then centrifuged (290 g, 7 minutes, 
4ºC). The supernatant was discarded and the cell pellet was resuspended with 250 µl of 
DMEM plus 10% FBS (vol/vol). To prepare a cell clot, 250 µl of human plasma was 
added to the cells with up and down pipetting, followed by the addition of 250 µl of 
thrombin. The cell mixture was incubated at room temperature for 3 minutes to allow clot 
formation. Five ml of 10% buffered formalin was added and left for at least 2 h for cell 
fixation. The cell clot was placed on a filter paper in a cassette and further fixed in 10% 
buffered formalin for 6 h. Then, the cell block was processed into a wax block. The wax 
block was cut in 4 µm thick sections for haematoxylin and eosin staining and in 3 µm 
thickness for IHC staining. The sections were mounted on positively-charged slides and 
IHC was performed on a Ventana Benchmark NexES machine (Roche, Castle Hill, NSW, 
Australia). Cytokeratin antibody (Ab) monoclonal-mouse-clone AE1/AE3 was used to 
stain trophoblasts. Firstly, heat induced epitope retrieval (HIER) with Cell Conditioning 
1 (CC1) buffer (pH 8-8.5) was performed for 36 minutes at 95ºC. Then, cytokeratin Ab 
was added at 1:150 concentration and incubated for 24 minutes. CD68 Ab monoclonal-
mouse-clone KP1 was used to stain macrophages. Antigen retrieval was performed with 
protease 1 for 12 minutes at room temperature. CD68 Ab was added at 1:150 
concentration and incubated for 36 minutes. Vimentin was used as a marker for 
mesenchymal cells, such as fibroblasts. HIER using CC1 pH 8-8.5 was performed for 36 
minutes at 95ºC. Vimentin Ab was added at 1:150 dilution and incubated for 32 minutes. 
ultraView Multimer Ig contained the secondary Ab goat anti-Mouse IgG, goat anti-
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Mouse IgM and goat anti-rabbit IgG. The secondary antibodies were part of the 
“ultraView Universal DAB Detection Kit”. Photomicrographs of IHC slides (40x) were 
taken. Percentage of trophoblasts was calculated based on five random pictures (40x) per 
culture. 
2.5.2 Light microscopy 
Cell cultures were regularly examined under light microscope. Photomicrographs of cell 
cultures (40x) were obtained at specific culture time points (36 h for protocol 1) and (36 
h, 3 d and 5 d for protocol 2). Trophoblast photomicrographs taken on days 3 and 5 of 
culture in the presence or absence of EGF were analysed by 2 independent viewers and 
scored according to Table 2.1.  
 
Table 2.1 
Score for fresh trophoblast culture morphology analysis  
Score Cellular aggregation Syncytia 
1 Single cells None 
2 Loose small cellular groups < 20% cell area 
3 Tight small cellular groups  20-50% cell area 
4 Tight large cellular groups  > 50% cell area 
Photomicrographs of trophoblast cultures in complete DMEM in the presence or absence 
of EGF (10 ng/ml) taken on days 3 and 5 of culture were analysed and scored by two 
independent viewers.  
 
2.6 Results 
Eleven trophoblast isolations were performed with protocol 1 and 48 isolations with 
protocol 2. The mean (± SD) yield was 42.6 ± 36.5 x 106cells for protocol 1 and 266.1 ± 
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141.3 x 106 cells for protocol 2 (Table 2.2). The mean harvested tissue weight was 133 ± 
35 g for protocol 2. Tissue weight was not measured in protocol 1.  
Cells were plated in a density of 1 x 106 cells for protocol 1 on collagen coated 12 well 
plates (Figure 2.1) and 300,000-350,000 cells/cm2 (1.4 x 106 cells for 12 well plates) on 
plin plates for protocol 2 (Figure 2.2). No marked morphology differences between cells 
obtained from protocol 1 and 2 (cultured without EGF) were observed up to 36 h in 
culture (Figures 2.1 and 2.2). However, trophoblasts cultured with EGF showed earlier 
cellular aggregation and higher syncytialisation than cultures without EGF (Figures 2.3 
and 2.4), particularly after 3 days of culture.  
Samples from 4 independent trophoblast isolations were immunostained for cytokeratin 
and CD68 (protocol 1) and 13 samples were stained for cytokeratin, CD68 and vimentin 
markers for protocol 2. Trophoblast purity was only 65% for protocol 1 with macrophages 
contamination (Figure 2.5) and was 98% for protocol 2 (Figure 2.6). The same degree of 
trophoblast purity was observed in cultures maintained in the presence of EGF (Figure 
2.7).   
 
Table 2.2 
Human trophoblast isolations 
  
Summary of trophoblast isolations performed in this research 
 Protocol 1 Protocol 2 
Experiment total number  11 48 
Mean cell number isolated per 
placenta ± SD (range) 
42.6 ± 36.5 x 106  
(0-107.7 x 106) 
266.1 ± 141.3 x 106  
(63.8 x 106-621.5 x 106) 
Trophoblasts 
(range)  
66% 
(52-78%) 
98% 
(96-99%) 
CD68 positive cells 
(range) 
34%  
(21-47%) 
1% 
(0-3%) 
Mesenchymal cells (vimentin positive) 
(range)  
Not performed 1% 
(1-4%) 
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Figure 2.1. Representative photomicrograph from trophoblast primary cultures 
after 36 h in culture (protocol 1derived cells). Cells were cultured in complete DMEM 
without EGF. 
DMEM: Dulbecco's Modified Eagle Medium; EGF: epidermal growth factor.  
 
  
 84
No EGF         Plus EGF 
 
24 h  
   
A          G 
 
36 h 
 
B          H 
 
3 days 
 
C          I 
 
 
 
  
 85
No EGF         Plus EGF 
 
5 days 
 
D          J 
 
6 days 
 
E          K 
 
7 days 
 
F          L 
 
Figure 2.2. Representative photomicrographs from trophoblast primary cultures 
(protocol 2 derived cells) after 24 h, 36 h, 3 days, 5 days and 7 days of the isolation. 
A-F. Trophoblast cultures in complete DMEM without EGF showed large numbers of 
single cells. G-L. Cells cultured in complete DMEM with EGF more commonly promoted 
syncytialisation evident in the longer duration culture time points (I-L). 
DMEM: Dulbecco's Modified Eagle Medium; EGF: epidermal growth factor.  
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Figure 2.3. Complete DMEM supplemented with EGF led to earlier trophoblast 
aggregation than complete DMEM without EGF. Trophoblast culture 
photomicrographs taken on days 3 and 5 of culture in the presence or absence of EGF 
were analysed by 2 independent viewers and scored for cellular aggregation. Cellular 
aggregation (as described in Table 2.1) induced by EGF was evident on day 3 of culture. 
However, cellular aggregation was not significantly different in the presence or absence 
of EGF in older cultures. Chi-square (EGF effect): 3 day cultures, p < 0.0001; 5 day 
cultures, non-significant (ns). A total of 78 pictures (3 days) and 60 pictures (5 days) 
from12 independent trophoblast isolations were analysed. At least 5 photomicrographs 
were randomly taken from each trophoblast isolation. 
DMEM: Dulbecco's Modified Eagle Medium; EGF: epidermal growth factor.  
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Figure 2.4. EGF clearly induced syncytialisation in trophoblast cultures. Trophoblast 
culture photomicrographs taken on days 3 and 5 of culture in the presence or absence of 
EGF were analysed by 2 independent viewers and scored for syncytialisation. Graphs 
represent total number of photomicrographs analysed showing ≤ 50% or > 50% of 
trophoblast areas being syncytialised (as described in Table 2.1). EGF led to 
syncytialisation from the 3rd culture day. The difference was maintained on culture day 
5. 
Fisher's exact test (EGF effect): 3 day cultures, p=0.0002; 5 day cultures, p=0.019. A total 
of 78 pictures (3 days) and 60 pictures (5 days) from 12 independent trophoblast isolations 
were analysed. At least 5 photomicrographs were randomly taken from each trophoblast 
isolation.  
EGF: epidermal growth factor.  
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Figure 2.5. Primary human trophoblast isolation-protocol 1. Representative 
photomicrographs of cell isolates cultured for 36 h. Slides were stained for cytokeratin 
AE1/AE3 (pink-IHC marker for trophoblasts) and CD68 (brown-IHC marker for 
macrophages). It shows trophoblasts mixed with a large number of macrophages. Thin 
arrows are indicative of cytotrophoblasts and thick arrows of CD68 positive cells.  
IHC: immunohistochemistry.  
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Figure 2.6. Primary human trophoblast isolation-protocol 2. Representative 
photomicrographs of cell isolates cultured for 36 h. A. Photomicrograph of cells stained 
for cytokeratin AE1/AE3 (pink-IHC marker for trophoblasts) and CD68 (brown-IHC 
marker for macrophages). B. Photomicrograph of cells stained for vimentin (brown-IHC 
marker for mesenchymal cells). Trophoblasts are stained in blue (vimentin negative). 
Thin arrows are indicative of cytotrophoblasts, dashed arrows of macrophages and thick 
arrows of vimentin positive cells.  
IHC: immunohistochemistry. 
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Figure 2.7. Primary human trophoblast isolation-protocol 2. Representative 
photomicrographs of cell isolates cultured for 10 days with EGF. A. Photomicrograph of 
cells stained for cytokeratin AE1/AE3 (pink-IHC marker for trophoblasts) and CD68 
(brown-IHC marker for macrophages). B. Photomicrograph of cells stained for vimentin 
(brown-IHC marker for mesenchymal cells). Trophoblasts are stained in blue (vimentin 
negative). Thin arrows are indicative of cytotrophoblasts, dashed arrows of macrophages 
and thick arrows of vimentin positive cells.  
EGF: epidermal growth factor; IHC: immunohistochemistry. 
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2.7 Discussion 
Placental function and metabolism can be studied through animal models, human 
placental perfusion, placenta explants culture, cell lines or primary cell cultures. Animal 
models are suitable for placental studies in vivo with the advantage that maternal and fetal 
assessments can be conducted together. This is the only real way to examine placental 
function under very complex in vivo physiological conditions. On the other hand, there 
are usually many confounding factors which are difficult to control. Also, extrapolation 
of results from animals to humans is limited due to differences in placental anatomy and 
physiology between species. Placental cotyledon perfusion is a procedure in which the 
placenta complex structure is maintained. However, functionality of the placental tissue 
is preserved for a few hours only, which restricts this methodology to short-term 
assessment studies (269, 270). Placental explant or cell cultures are more appropriate 
methods for longer term metabolic studies. Trophoblast function and metabolism can be 
studied in term villous explant cultures for up to 10 days if the tissue is carefully assessed 
for structural integrity since the syncytiotrophoblast may detach or undergo fibrinoid 
necrosis (271). Placental explant cultures have the advantage of tissue and cellular 
architecture maintenance, with preservation of cell to cell contact and modulation 
between placental cell types, such as cyto- and syncytiotrophoblasts, endothelial cells, 
mesenchymal stromal cells and immune cells (271). This modulation is particularly 
important when cytotrophoblast proliferative activity has to be analysed since 
cytotrophoblasts, which lose their mitotic activity in vitro, are able to divide even in term 
placentas if in contact with syncytiotrophoblasts (272). Conversely, metabolic studies of 
specific cellular groups cannot be individualised in this co-culture technique. When a 
specific type of cells has to be analysed, isolated cell culture is a suitable method. Cells 
can be obtained from primary cell isolations or from cell lines derived from normal or 
choriocarcinoma cells.  
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Cytotrophoblasts are epithelial cells that fuse during the differentiation process becoming 
a multinucleated syncytial structure named the syncytiotrophoblast. Syncytiotrophoblasts 
are not able to divide (273). In vivo, villous cytotrophoblasts are highly proliferative and 
are a pool for constant rehnewal of the syncytial tissue. Early in pregnancy, during 
blastocyst adhesion, cytotrophoblasts have the ability to fuse together, i.e. 2 
mononucleated cells can fuse their membranes (272). Nevertheless, throughout 
pregnancy, they will only fuse with the syncytiotrophoblast layer, losing their capacity to 
fuse with other cytotrophoblasts (272). In culture, these natural events change. 
Cytotrophoblasts lose their mitotic capacity and are able to fuse with each other (274).   
Cell lines have to be able to multiply and to have an extended lifespan with a stable 
phenotype compatible with the mother cell. Cell lifespan extension may be increased 
through spontaneous immortalization or be induced by transfection. Nonetheless, these 
techniques alter mitosis regulation which may change cellular function and gene 
expression producing cells different from normal cytotrophoblasts (275). 
Finally, cytotrophoblasts, macrophages or endothelial cells can be obtained through 
primary cultures from human placentas. Several human cytotrophoblast isolation 
protocols have been developed. Most of these protocols are variations of 3 mains steps: 
(i) villous tissue harvesting; (ii) enzymatic digestion with trypsin and/or dispase and 
DNase 1; (iii) trophoblast purification with Percoll gradients (276). Cytotrophoblast 
primary cultures are usually time consuming and expensive, but they are particularly 
valuable if the research aims are to investigate trophoblast function and metabolism.  
In this study, the trophoblast isolation-protocol 1 produced an inconsistent cell number 
such that the cell yield from some experiments was not enough to perform the planned 
experiments (Table 2.2). Moreover, many cell isolates were contaminated with immune 
cells, especially macrophages as observed by IHC for cytokeratin (an epithelial marker 
for trophoblasts) and for CD68 (a macrophage marker) (Figure 2.5). Based on the results 
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from these experiments (Table 2.2), a new protocol was introduced following protocols 
described by Nelson et al. (267) and Aye et al. (234) with modifications.  
In the new protocol, the harvesting technique was changed resulting in more volume of 
villous tissue collected; trypsin was substituted by trypsin XII-S, which has a higher 
degree of purity; DNase 1 concentration was increased; and dispase II, which promotes a 
gentle cellular dissociation, was introduced. Percoll gradient number was reduced from 
14 to 7 (Appendix 1) making its preparation faster without compromising the results. The 
cell yield was significantly increased and the average cell number was more consistent 
(Table 2.2). Trophoblast purity was highly enhanced, with almost no other placental cell 
contamination (Figure 2.6). Furthermore, red blood cells were almost totally excluded 
from the fresh trophoblast cultures (Figures 2.2). Erythrocytes were visualised in some 
protocol 1 derived cultures (photomicrographs are not shown). Erythrocytes may interfere 
in glucose metabolism experiments and so should be removed (277).  
Cytotrophoblasts can differentiate and fuse into syncytiotrophoblasts after 3-5 days in 
culture containing serum (274). However, morphology changes were not observed in 
cultures followed for up 7 days in this research. Thus, EGF was added to cells plated for 
long-term culture from the isolation day to induce cytotrophoblast differentiation and 
fusion into syncytiotrophoblasts (274). With EGF addition, marked morphologic 
differences were observed from 3 days of culture (Figure 2.2). 
Cells were plated on collagen coated plates in protocol 1. Interestingly, this procedure 
caused very strong cellular attachment to the microplates, making difficult cell 
detachment by scraping or following trypsin treatment. For that reason, cells were seeded 
in plain culture plates for protocol 2. A good cell attachment was observed after 4 h of 
culture with an improved cellular collection from the wells. Based on these observations, 
collagen coating was eliminated from the established protocol.  
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2.8 Conclusion 
Placental metabolism can be studied by diverse methods. Each method has its own 
applications and limitations and so researchers have to be aware of these particularities 
when analysing results. Primary human trophoblast culture is a reasonable technique to 
address trophoblast metabolism although it is expensive, requires a significant time to 
perform and is an artificial environment without the complex placental tissue architecture 
of placental perfusion or explant cultures.  
Through the work of this thesis, the laboratory established a new high-quality protocol 
with reproducible, elevated yield and highly pure results. Following this step, trophoblast 
metabolism studies were performed as described in Chapter 3.  
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3.1 Methods for assessment of glucose and lipid metabolism in 
primary trophoblast cultures 
3.1.1 Introduction 
This chapter describes the methods by which various pathways of glucose metabolism, 
as well as fatty acid oxidation, were measured in human trophoblasts after their 
establishment in primary culture. Experiments were divided according to trophoblast 
culture age (refer to Chapter 2 for culture details). Experiments performed after 36 h of 
culture in complete DMEM at 5.5 mM glucose, when most cells are cytotrophoblasts, 
were classified as short-term culture studies. The results of these studies are given in 
Chapter 4. Experiments performed after 5 days of culture in complete DMEM at 5.5 mM 
glucose with EGF (final concentration: 10 ng/ml), when many trophoblasts have 
differentiated into syncytiotrophoblasts, were classified as long-term culture studies. The 
results of these studies are presented in Chapter 5. In order to assess the effects of EGF, 
with and without NEFA, on lipid droplet formation, trophoblast TG content, and 
syncytialisation, trophoblasts were cultured in one set of experiments from the isolation 
day, with and without EGF (10 ng/ml), and additionally from day 2 to day 5 in the 
presence and absence of NEFA (0.1 mM, palmitate: oleate ratio; 1:1). The results of these 
experiments are also shown in Chapter 5. 
The metabolism pathways that were assessed in this research are presented in Figure 3.1.  
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Figure 3.1. Metabolism pathways studied in human trophoblasts in primary culture. 
1. Total glucose uptake; 2. Glycogen synthesis; 3. Glycolysis; 4. Lactate production;          
5. Glucose oxidation; 6. Fatty acid oxidation; 7. TG synthesis. 
TG: triacylglycerol.    
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3.1.1.1 Principles of metabolic tracer-tracee methodology  
In the current research, most metabolic fluxes were studied through radioactive tracer-
tracee methodology, as discussed below and in the results of Chapters 4 and 5.  
Isotopes of an element have the same number of protons, but differing numbers of 
neutrons, such that their atomic mass differ (278). These chemical similarities and 
physical differences permit the use of the isotope-labelled molecules, as tracers, to track 
and measure the metabolic reactions of the naturally existing molecules, the tracees (278, 
279). For instance, a naturally existing 12C-D-glucose molecule (a tracee) demonstrates 
the same chemical structure but different physical properties to 13C-labelled D-glucose or 
14C-labelled D-glucose (tracers) (278). Isotopes can be divided into stable (e.g. 1H, 2H, 
12C and 13C) and radioactive (e.g. 3H and 14C) (279). Contrary to stable isotopes, 
radioactive isotopes disintegrate with the emission of sub-atomic particles, such that they 
do not maintain a permanent atomic mass. Although stable isotope-labelled molecules are 
safer and optimal for in vivo human studies because they are not a source of ionizing 
radiation, their use in research has disadvantages. Stable isotope studies need a larger 
tracer mass due to high natural background causing lower sensitivity, and they require 
complex and expensive equipment such as mass spectrometry for measurement. For these 
reasons, the use of stable isotopes results in much higher research costs. Radioactive 
isotope-labelled metabolites are not present in biological systems, and therefore, only 
very small tracer amounts are necessary to map a metabolic reaction (280). Moreover, 
radioactive metabolic tracers are relatively cheaper and can be measured more easily than 
stable tracers. Hence, radioactive isotopes are more attractive for ex-vivo metabolism 
studies (278).  
Radioactive isotopes that release electrons (β radiation), once mixed with scintillation 
cocktail, emit flashes of light. Betacounters contain a photomultiplier tube that can read 
and quantify the absolute radioactive emissions with high sensitivity (278). Thus, 
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radioactive tracers are quantified as disintegrations per minute (DPM) or counts per 
minute (CPM) (280).  
The analysis of metabolism using radioactive isotope labelled metabolic tracers is based 
on the dilution principle, in which a known amount of tracer is added to a biological 
system, such as a cell culture system, diluting a known concentration of tracee. As the 
detection of the fate of the tracer is easier to follow than the tracee, but the metabolism of 
the tracer and tracee are presumed to be identical, the fate of the naturally occurring 
metabolite can be determined. Therefore, following the cellular uptake and accumulation 
of a metabolic tracer within a cell culture system, together with its conversion into other 
substances, which might remain within the cells or be released out of the cells, provides 
a means by which the cellular handling of the corresponding tracee through a metabolic 
pathway of interest can be determined (278, 279). For example, to measure glucose flux 
into glycogen in cell cultures, an isotope-labelled glucose (e.g. [(U)14C]-glucose) is added 
in tracer amounts to the media containing a known concentration of the tracee [(U)12C]-
glucose (such that the dilution of tracee by tracer can be determined) and the system is 
incubated for a determinate period after that the accumulation of the tracer into the 
product glycogen is determined (279). The specific activity (SA) of the media is the 
measure of tracee dilution by tracer, which is the DPM or CPM (due to the presence of 
the tracer) measured per amount of tracee (280) (SA calculation is showed below). Hence, 
if the SA of the glucose in the media is x CPM (glucose tracer) per nmol of glucose 
(tracee), and y CPM accumulates into the glycogen pool per h, the accumulation of 
glucose into glycogen per h will be y/x nmol/h. However, although it is assumed that 
tracers behave exactly in the same way as the natural occurring molecule, it is important 
to be aware of the possibility of the existence of radioactive impurity that may lead to 
fractions of the tracer behaving in different ways (280). In this case, this “impure” tracer 
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portion may be quantified as the result of a chemical reaction without reflecting the truth 
(280).  
3.1.2 Metabolism studies 
3.1.2.1 Preparation of primary trophoblasts for metabolic assessments 
Trophoblasts were established in primary culture (refer to Chapter 2 for trophoblast 
isolation and culture details) in complete DMEM (refer to Appendix 1 for media 
preparation) at a glucose concentration of 5.5 mM and, for long-term experiments only, 
EGF at 10 ng/ml. Cells were seeded in flasks or microplates according to the experiment 
at a density of 300,000 to 350,000 cells per cm2 (Table 3.1). After 36 h or 5 days of 
culture, respectively, short and long-term culture glucose metabolism and fatty acid 
oxidation studies were performed. Metabolism was generally measured in Krebs-Ringer 
Bicarbonate HEPES (KRBH) buffer (Appendix 2) with 0.5% fatty acid free bovine serum 
albumin (BSA-FA free), in the presence or absence of a moderately high concentration 
of a NEFA saturated and monounsaturated mix (0.25 mM, palmitate: oleate ratio; 1:1). 
For NEFA stock preparation, refer to Appendix 2. Briefly, on the experimental day, 
trophoblasts were checked and culture medium was removed. Cells were washed twice 
in warm washing solution (KRBH, 1 mM glucose, 0.1% BSA-FA free). Warm (all warm 
solutions described in this chapter were heated up to 37ºC) incubation solution (KRBH 
with additives, as described for each experimental protocol) was added to plates or flasks, 
which were incubated at 37ºC, 5% CO2 for 2 h. After incubation, cellular metabolism was 
stopped [e.g. by placing microplates on ice or injecting perchloric acid (PCA)] and the 
cells or supernatant were processed according to the specific experiment. All results were 
normalised by protein content (method is described below). Refer to Appendix 2 for 
reagents, suppliers and solution preparation cited in this chapter.  
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Table 3.1  
Cell density seeded according to experiments 
Short-term culture experiments 
Experiment Plastic ware  Cell density 
Total glucose uptake, glycolysis, 
lactate release into the media and 
glycogen synthesis 
12 well plates 1.4 x 106 cells per well 
Total glycogen content 6 well plates 3.5 x 106 cells per well 
Glucose and palmitate oxidation  T25 flasks 7.5 x 106 to 8.75 x 106 cells per flask*  
Long-term culture experiments 
Experiment Plastic ware  Cell density 
Glycolysis  12 well plates 1.4 x 106 cells per well 
Glucose and palmitate oxidation  T25 flasks 7.5 x 106 to 8.75 x 106 cells per flask*  
Oil red O  Chamber slide 2.45 x 105 cells per well 
Total glucose uptake, glycogen 
synthesis and triacylglycerol 
quantification 
6 well plates 3.5 x 106 cells per well 
*The aim was to plate 350,000 cells per cm2. However, if the cell yield from trophoblast 
isolation was not enough, cultures were established in a cell density of 300,000 cells per 
cm2.  
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3.1.2.2 Total glucose uptake 
Labelled 2-deoxyglucose, a glucose analogue, is a suitable tracer to assess total glucose 
uptake in trophoblast cultures because 2-deoxyglucose is a poor Na-dependent glucose 
transport substrate and it is mainly transported by the facilitative GLUT transporters 
(281). In addition, 2-deoxyglucose is phosphorylated by a hexokinase to 2-deoxyglucose 
6-phosphate as would a D-glucose molecule. This phosphorylation maintains the hexose 
gradient, delays the time to achieve an equilibrium and prevents 2-deoxyglycose from 
being further metabolised (282). It is believed that the placenta presents a very low 
glucose 6-phosphatase activity with a negligible 2-deoxyglucose-6-phosphate to 
unphosphorylated 2-deoxyglucose (283). Therefore, total glucose uptake can be 
calculated through the measurement of intracellular labelled 2-deoxyglucose-6-phosphate 
metabolised from labelled 2-deoxyglucose (Figure 3.2). Other glucose tracers are less 
appropriate for glucose uptake studies. For instance, labelled 3-O-methyl glucose is not 
phosphorylated and reaches equilibrium across the cell membrane very quickly, whilst 
labelled D-glucose will be further metabolised through other metabolic pathways (282).   
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Figure 3.2. Glucose uptake and phosphorylation by trophoblasts. As for a D-glucose 
molecule, [(U)14C]-2-deoxyglucose is taken up by trophoblasts through a GLUT. 
However, in contrast to a glucose molecule, which is phosphorylated to glucose-6-
phophate and follows through diverse metabolic fates, a [(U)14C]-2-deoxyglucose 
molecule is inactivated by phosphorylation and trapped inside the cells. It is assumed that 
[(U)14C]-2-deoxyglucose tracer is representative of glucose tracee allowing for total 
glucose uptake calculation, since [(U)14C]-2-deoxyglucose is transported into the cells to 
the same extent as D-glucose, and that both molecules present similar uptake kinetics. In 
addition, intracellular [(U)14C]-2-deoxyglucose 6-phosphate intracellular accumulation is 
considered stable since its hydrolysis is believed to be negligible.   
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For short-term culture studies, trophoblasts were established in culture for 36 h as 
described in Section 3.1.2.1. Culture medium was removed and cells were washed twice 
in 1 ml of warm KRBH, 0.1% BSA-FA free, at 1 mM glucose. Then, 1 ml of warm KRBH 
containing 0.5% BSA-FA free, [(U)14C]-2-deoxyglucose (refer to Table 3.2 for amount) 
and 1, 5, 15, 25 or 35 mM glucose, plus or minus 0.25 mM NEFA, was added to each 
well.  
 
Table 3.2  
[(U)14C]-2-deoxyglucose specific activity for total glucose uptake protocol 
[(U)14C]-2-deoxyglucose 
kBq/ml (µCi/ml) 
Cold glucose 
(mmol/l) 
Cold glucose per 100 
µl of media (nmol) 
CPM in 100 µl 
of media 
SA of the media 
(CPM/nmol glucose) 
3.7 (0.1) 1 100 a a/100 
7.4 (0.2) 5 500 b b/500 
11.1 (0.3) 15 1500 c c/1500 
14.8 (0.4) 25 2500 d d/2500 
14.8 (0.4) 35 3500 d d/3500 
SA: specific activity; CPM: counts per minute. 
 
Trophoblasts were incubated in a humidified incubator at 37ºC, 5% CO2 for 2 h. 
Immediately after incubation, plates were placed on ice to stop metabolism. Trophoblasts 
were washed twice in 500 µl cold PBS to remove unmetabolised [(U)14C]-2-
deoxyglucose. Trophoblasts, which contained intracellular phosphorylated tracer, were 
then scrapped twice in cold 500 µl PBS on ice and collected into scintillation vials. Ten 
ml of scintillation liquid was added to the vials and intracellular accumulation of [(U)14C]-
2-deoxyglucose-6-phosphate was counted in a betacounter (Tri-Carb B3110TR Liquid 
Scintillation Analyzer, Perkin Elmer, Waltham, MA, USA) (Figure 3.3). Negative 
controls (wells without cells) were included in all experiments. Each condition was 
measured in triplicate (3 wells) for samples and blanks in each individual experiment.  
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The same procedures were followed for glucose uptake in long-term cultures, however 
the studies were carried out after 5 days of culture in DMEM 5.5 mM plus EGF (10 
ng/ml), as described in Section 3.1.2.1, and the cells were plated in 6 well plates. Also, 
less conditions were assessed (5 or 25 mM glucose plus or minus 0.25 mM NEFA).  
[(U)14C]-2-deoxyglucose concentrations were selected according to the cold glucose 
concentrations (Table 3.2). For total glucose uptake calculation, the radiation in 100 µl of 
[(U)14C]-2-deoxyglucose media for each glucose concentration was counted in triplicates 
and SA in CPM per nmol was calculated (Table 3.2) (refer to section 3.1.1.1). Total 
glucose uptake was calculated subtracting the background CPM from the sample CPM 
and dividing the result by the SA. Results were normalised by mg of protein and 
expressed as total glucose uptake in nmol/h/mg protein. 
Total glucose uptake (nmol gluc/h/mg protein) =
(cpm samples –  cpm background)/specific activity
mg protein x 2 h (incubation period)
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Figure 3.3. Total glucose uptake by trophoblast-protocol scheme. For short-term 
culture studies, trophoblasts were established in culture for 36 h in complete DMEM at 
5.5 mM glucose in 12 well plates. Cells were washed twice in KRBH, 0.1% BSA-FA free 
and 1 mM glucose. Cells were then incubated in 1 ml of KRBH containing 0.5% BSA-
FA free, [(U)14C]-2-deoxyglucose (amount according to Table 3.2), 1, 5, 15, 25 or 35 mM 
glucose, plus or minus 0.25 mM NEFA. After 2 h incubation (37ºC, 5% CO2), plates were 
placed on ice to stop the metabolism. Cells were washed twice in cold PBS. Trophoblasts 
were scrapped twice in 500 µl cold PBS and collected into scintillation vials. Ten ml of 
scintillation liquid was added to each vial. Intracellular radiation was counted in a 
betacounter and total glucose uptake by trophoblasts was calculated.  
For long-term culture experiments, trophoblasts were established in culture for 5 days in 
complete DMEM at 5.5 mM glucose supplemented with EGF (10 ng/ml) in 6 well plates. 
Incubations were performed in 2 ml KRBH, 0.5% BSA-FA free, [(U)14C]-2-
deoxyglucose (see Table 3.2), 5 or 25 mM glucose, plus or minus 0.25 mM NEFA. All 
other procedures were the same as for short-term culture total glucose uptake 
experiments.  
DMEM: Dulbecco's Modified Eagle Medium; KRBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids; 
PBS: phosphate buffered saline; EGF: epidermal growth factor.  
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3.1.2.3 Glycolysis  
Glucose utilisation rate via glycolysis by trophoblasts was measured with [5-3H]-glucose 
tracer. [5-3H]-glucose loses its 3H into 3H2O at the reaction catalysed by aldolase, in which 
fructose 1,6-bisphosphate is cleaved into glyceraldehyde 3-phosphate and 
dihydroxyacetone-phosphate (refer to Chapter 1 section 1.5.2). If this reaction is not 
complete, 3H2O is produced at the enolase reaction, when 2-phosphoglycerate is 
dehydrated to phosphoenolpyruvate (284). Therefore, glycolysis can be measured by 
determining the amount of 3H2O production (Figure 3.4). In theory, other glucose 
metabolic pathways, such as the pentose phosphate or glycogen synthesis, cannot be 
measured using this method, making [5-3H]-glucose a suitable tracer for glycolysis 
estimation. For short-term culture studies, trophoblasts were cultured for 36 h in complete 
DMEM (5.5 mM glucose) in 12 well plates in a density of 1.4 x 106 cells per well as 
described in Section 3.1.2.1. Trophoblasts were washed twice in 1 ml of warm KRBH, 
0.1% BSA-FA free at 1 mM glucose. Because 3H2O can be formed inside [5-3H]-glucose 
storage bottles due to radiolysis (285), for all experiments [5-3H]-glucose tracer was 
evaporated under nitrogen gas prior to the media preparation so as to avoid 3H2O 
contamination. One ml of KRBH incubation containing 0.5% BSA-FA free, [5-3H]-
glucose (see Table 3.3 for amount) at 1, 5 or 15 mM glucose, plus or minus 0.25 mM 
NEFA, was added to each well. As blank controls, wells with media, but no cells, were 
treated like samples (background). After 2 h incubation in a humidified cell culture 
incubator at 37ºC, 5% CO2, the supernatant with 3H2O from metabolised glucose was 
transferred to 1.5 ml microtubes. Microtubes were then centrifuged (2095 g, 5 minutes, 
4ºC) to precipitate cell debris. Following the centrifugation, 300 µl of the supernatant 
from each tube was transferred to new 1.5 ml microtubes without caps. These tubes were 
carefully placed with tweezers into scintillation vials containing 500 µl of sterile cold 
Milli-Q water at the bottom. Vials were tightly closed and kept at 55ºC for 24 h. 3H2O 
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produced by trophoblasts was recovered through evaporation and equilibrium with the 
cold water in the bottom of each scintillation vial. After incubation, scintillation vials 
were placed at room temperature for 2 h to reduce water drops on vial walls. Microtubes 
with unmetabolised tracer were discarded and 10 ml of scintillation liquid was added to 
each sample, which was counted in a betacounter. Recovered 3H2O counts represent 
metabolised glucose tracer via glycolysis by trophoblasts. Recovery efficiency was 
estimated through evaporation and equilibrium of a known quantity of 3H2O. Thus, 300 
µl of 3H2O (1:160 dilution in Milli-Q water) was equilibrated with 500 µl cold water 
through evaporation under the same conditions as the control blank and experimental 
samples to measure recovery efficiency (Figure 3.4). Equilibrated 3H2O at the bottom of 
the scintillation vial and 300 µl of unequilibrated 3H2O solution were counted in a 
betacounter and the percentage recovery was calculated. Samples, blanks and efficiency 
of 3H2O recovery tubes were measured in triplicates and results for the samples were 
normalised by mg of protein.  
For long-term culture experiments, the same procedures were performed with the 
exception of that trophoblasts were established in complete DMEM at 5.5 mM glucose 
plus EGF (10 ng/ml) for 5 days after the isolation, as described in Section 3.1.2.1, and 
glycolysis was measured at media cold glucose concentrations of 1, 5 and 25 mM.  
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Figure 3.4. Glycolysis-protocol scheme. Trophoblasts were established in culture for 36 
h in complete DMEM at 5.5 mM glucose for short-term culture studies; and for 5 days in 
complete DMEM at 5.5 mM glucose plus EGF (10 ng/ml) for long-term culture studies. 
Cells were washed twice in KRBH, 0.1% BSA-FA free and 1 mM glucose. Trophoblasts 
were then incubated for 2 h (37ºC, 5% CO2) in 1 ml of KRBH containing 0.5% BSA-FA 
free, [5-3H]-glucose (see Table 3.3 for amount), plus or minus 0.25 mM NEFA and 1, 5 
or 15 mM glucose (for short-term culture studies) or 1, 5 or 25 mM glucose (for long-
term culture studies). After incubation, the media was collected and centrifuged. 
Produced tritiated water in the supernatants was recovered into cold water through 
evaporation and equilibration at 55ºC for 24 h. Equilibrated tritiated water was counted 
in a betacounter with 10 ml of scintillation cocktail. Efficiency of 3H2O recovery was 
calculated by measuring the amount of known tritiated water (in triplicate) recovered by 
the equilibration procedure at the same time as the experimental samples and blanks were 
analysed. This method was adapted from Pathmaperuma et al. (200) with modifications. 
DMEM: Dulbecco's Modified Eagle Medium.; KRBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids; 
EGF: epidermal growth factor.  
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The amounts of [5-3H]-glucose used in preparation of the media according to the cold 
glucose concentrations are described in Table 3.3. For the glycolysis rate calculations, the 
radiation in 100 µl of [5-3H]-glucose containing media for each glucose concentration 
was counted in triplicates and SA in CPM per nmol was calculated (Table 3.3). Total 
3H2O produced was calculated subtracting the background CPM from the sample CPM, 
multiplying by 100% divided by percentage of recovery (equilibration efficiency). Since, 
from 1 ml of [5-3H]-glucose media added to each well and metabolised, only 300 µl was 
placed to be equilibrated, total 3H2O produced was corrected multiplying by 1000/300.   
Total H2O production = (cpm sample − cpm blank) ×
1000
300
×
100%
recovery efficiency
 
 
Glucose metabolism via glycolysis(nmol gluc/h/mg protein) =
total H2O   production/specific activity
mg protein x 2 h (incubation period)
 
 
Table 3.3 
[5-3H]-glucose specific activity for glycolysis protocol 
[5-3H]-glucose 
kBq/ml (µCi/ml) 
Cold glucose 
(mmol/l) 
Cold glucose per 100 
µl of media (nmol) 
CPM in 100 µl of 
media 
SA of the media 
(CPM/nmol glucose) 
18.5 (0.5) 1.0 100 a a/100 
37 (1.0) 5.0 500 b b/500 
55.5 (1.5) 15.0 1500 c c/1500 
55.5 (1.5) 25.0 2500 d d/2500 
SA: specific activity; CPM: counts per minute. 
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3.1.2.4 Total lactate release into the media 
At the end of glycolysis, 2 pyruvate molecules are generated per glucose molecule. In 
anaerobic conditions or in tissues such as the placenta, which can produce high levels of 
lactate in spite of adequate oxygen supply (148), pyruvate can be reduced by LDH and 
converted to lactate (refer to Chapter 1 section 1.5.3) (Figure 3.5).  
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Figure 3.5. Pyruvate and lactate production. A. At the end of glycolysis, 2 molecules 
of pyruvate are produced per glucose molecule. B. Pyruvate can be reduced by lactate 
dehydrogenase (LDH) and converted to lactate.  
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Trophoblasts were established in culture for 36 h in complete DMEM (5.5 mM glucose) 
in 12 well plates in a density of 1.4 x 106 cells per well after the isolation, as described in 
Section 3.1.2.1. Cells were washed twice in 1 ml of warm KRBH, 0.1% BSA-FA free and 
1 mM glucose. Trophoblasts were then incubated for 2 h (37ºC, 5% CO2) in 400 µl of 
KRBH containing 0.5% BSA-FA free, 1, 5 or 15 mM glucose, plus or minus 0.25 mM 
NEFA, in triplicate. At the end of the incubation, supernatant was quickly collected, 
centrifuged (2095 g, 5 minutes, 4ºC) to remove cell debris and frozen at -80ºC (Figure 
3.6). An enzymatic colorimetric kit (BioVision, Milpitas, CA, USA) was used to measure 
the total amount of lactate released by trophoblasts. The principle of this method is to 
oxidise the lactate present in the samples and standards by a reaction catalyzed by LDH 
(Figure 3.5). NADH, a co-product of this reaction, interacts with a probe producing a 
colour that can be read. The assay was performed according to the manufacturer 
instructions as follow: “lactate subtract mix” was dissolved in 220 μl of “lactate assay 
buffer”; “lactate enzyme mix” was also resuspended in 220 μl of “lactate assay buffer”. 
For the standard curve preparation, 10 μl of lactate standard was diluted into 990 μl 
“lactate assay buffer” and serial dilutions were then prepared by adding “lactate assay 
buffer” to the diluted lactate standard to produce 0, 2, 4, 6, 8 and 10 nM of lactate. 
“Lactate assay buffer”, “lactate subtract mix” and “lactate enzyme mix” were mixed to 
prepare the “reaction mix” in the proportion 46 μl: 2 μl: 2 μl, respectively. “Reaction mix” 
total volume was determined by the number of samples and standards of each assay. Fifty 
μl of undiluted samples and 50 μl of the standards were added to a 96 well microplates. 
Both samples and standards were added to the wells in duplicates. Fifty μl of the “reaction 
mix” was added to wells loaded with samples and standards and the plate was incubated 
for 30 minutes at room temperature. After colour development, standards and samples 
were placed in a microplate reader at absorbance 450 nm (Fluostar Optima BMG, 
LabTech, Offenburg, Germany). Results were normalised by mg of protein.  
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Figure 3.6. Lactate release into media-protocol scheme. Trophoblasts were established 
in culture for 36 h in DMEM at 5.5 mM glucose. Cells were washed twice in 1 ml KRBH, 
0.1% BSA-FA free at 1 mM glucose. Trophoblasts were then incubated for 2 h (37ºC, 5% 
CO2) in 400 µl of KRBH containing 0.5% BSA-FA free, 1, 5 or 15 mM glucose, plus or 
minus 0.25 mM NEFA. At the end of incubation, the media was collected, centrifuged 
and the supernatant was transferred to new microtubes. Lactate release was quantified 
using an enzymatic colorimetric assay. 
DMEM: Dulbecco's Modified Eagle Medium.; KRBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids.  
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3.1.2.5 Glucose and palmitate oxidation 
Glucose oxidation was measured through 14CO2 production from [(U)14C]-glucose during 
the TCA cycle (Figure 3.7).  
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Figure 3.7. Glucose and palmitate oxidation. Glucose and palmitate carbons are 
changed to the acetyl group of acetyl-CoA, which will enter the mitochondria to be 
oxidised in the tricarboxylic acid cycle. At one turn of this cycle, 2 CO2 molecules are 
produced in oxidative decarboxylation steps.  
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For short-term cultures, trophoblasts were established in culture for 36 h in complete 
DMEM at 5.5 mM glucose, as described in Section 3.1.2.1. On the experimental day, 
media was removed and trophoblasts were washed twice in 2 ml of warm KHBH, 0.1% 
BSA-FA free at 1 mM glucose. Then, 2 ml of incubation solution containing KRBH, 
0.5% BSA-FA free, 1, 5 or 25 mM glucose, [(U)14C]-glucose, plus or minus 0.25 mM 
NEFA was added to assess glucose oxidation (refer to Table 3.4 for [(U)14C]-glucose 
concentration according to cold glucose).  
 
Table 3.4  
[(U)14C]-glucose specific activity for glucose oxidation protocol 
[(U)14C]-glucose 
kBq/ml (µCi/ml) 
Cold glucose 
(mmol/l) 
Cold glucose per 100 µl 
of media (nmol) 
CPM in 100 
µl of media 
SA of the media 
(CPM/nmol glucose) 
3.7 (0.1) 1 100 a a/100 
7.4 (0.2) 5 500 b b/500 
14.8 (0.4) 25 2500 d d/2500 
SA: specific activity; CPM: counts per minute. 
 
After adding incubation solution to cells, the flasks were caped with rubber stoppers to 
avoid gas leakage. Those stoppers were prepared in advance with tubing containing filter 
paper soaked in 5% KOH to trap 14CO2 expelled by the cells (refer to Appendix 2 for all 
preparation details). At the end of the incubation, 200 μl of 40% (vol/vol) PCA was 
injected into the flasks with a syringe (1 ml, Tuberculin syringe, BD, Singapore) and a 
needle (25 gauge, Precision Glide Needle, BD, Singapore) through the cap to acidify the 
medium and liberate the CO2. Flasks with PCA were left overnight at room temperature. 
Next morning, filters were removed from the end of tubing with tweezers and placed into 
scintillation vials. Ten ml of scintillation liquid was added in the vials and left for at least 
12 h to allow CO2 to leach out of the filter. Then, the samples were counted in a 
betacounter. As a direct comparison, palmitate oxidation was performed at the same time 
using a similar method. For palmitate oxidation, 2 ml of a solution containing 5 or 25 mM 
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glucose, 0.1 mM L-carnitine, 0.1 mM palmitate and [(U)14C]-palmitate (final 
concentration: 0.1 μC/ml) was added to each flask (Figure 3.8). Only for palmitate 
oxidation, the incubation solution with PCA and dead cells was collected into 2 ml 
microtubes after the paper filter (with 14CO2) removal. The solution was centrifuged 
(2095 g, 5 minutes, 4ºC) to precipitate the debris. The supernatant containing acid soluble 
fatty acid oxidation intermediates, such as ketone bodies, short-chain fatty acids and TCA 
cycle intermediates (Figure 3.9), was transferred into scintillation vials with scintillation 
liquid and counted in a betacounter. All samples and controls (flasks without cells) were 
performed at least in duplicates (if the trophoblast yield from isolation was enough, 
samples were performed in triplicates).  
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Figure 3.8. Glucose and palmitate oxidation in short-term cultures. For short-term 
culture studies, trophoblasts were established in culture in T25 flasks for 36 h in complete 
DMEM (5.5 mM glucose). Cells were washed twice in 2 ml of KHBH, 0.1% BSA-FA 
free and 1 mM glucose. Then, 2 ml of KRBH, 0.5% BSA-FA free, 1, 5 and 25 mM glucose 
plus or minus 0.25 mM NEFA and [(U)14C]-glucose (for amount refer to table 3.4) were 
added to assess glucose oxidation. For palmitate oxidation, 2 ml of a solution containing 
5 or 25 mM glucose, 0.1 mM L-carnitine, 0.1 mM palmitate and [(U)14C]-palmitate (final 
concentration: 0.1 μC/ml) (for amount refer to table 3.5) were added. After 2 h incubation 
in a humidified incubator at 37ºC and 5% CO2, 200 μl of 40% PCA was injected into the 
flasks and left overnight. Next morning, filters containing 14CO2 were removed and 
transferred to scintillation vials. Ten ml of scintillation cocktail was added and after 12 h, 
samples were read in a betacounter. For palmitate oxidation, after filter removal, the 
solution containing cellular debris, PCA and incubation solution from each sample was 
transferred to 2 ml microtubes and centrifuged. Supernatant was placed in scintillation 
vials. Ten ml of scintillation cocktail were added and acid soluble products were read in 
a betacounter.  
For long-term culture studies, trophoblasts were established in culture in T25 flasks for 5 
days in complete DMEM (5.5 mM glucose) with EGF (10 ng/ml). All procedures were 
performed as for short-term cultures, except that the cells were incubated only at 5 and 
25 mM for glucose oxidation experiments. This method was adapted from (152) with 
modifications.  
DMEM: Dulbecco's Modified Eagle Medium; KHBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids; 
PCA: perchloric acid; EGF: epidermal growth factor.    
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Figure 3.9. Fatty acid oxidation, ketone body production and acid soluble products. 
Fatty acids can be metabolised to acetyl-CoA and skip the TCA cycle especially in 
conditions which deplete oxaloacetate. In this situation, the TCA cycle activity will be 
reduced and acetyl-CoA conversion will be shifted to ketone body production. Ketone 
bodies as well as short-chain fatty acids and metabolites such as citrate can together be 
measured as acid soluble products of fatty acid metabolism.  
TCA: tricarboxylic acid. 
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To calculate glucose and palmitate oxidation, the radiation in 100 µl of [(U)14C]-glucose 
containing media and in 100 µl of [(U)14C]-palmitate containing media was counted in 
triplicates and SA in CPM per nmol for each was calculated (Tables 3.4 and 3.5). 
Oxidation was calculated subtracting the background CPM from the sample CPM and 
dividing the result by SA. Also, soluble acid products were calculated subtracting the 
background CPM from the sample CPM and dividing the result by SA. Results were 
normalised by mg of protein and expressed nmol/h/mg protein. 
 
Glucose oxidation (nmol gluc/h/mg protein) =
(cpm samples –  cpm background)/specific activity
mg protein x 2 h (incubation period)
 
 
Palmitate oxidation (nmol palm/h/mg protein) =
(cpm samples –  cpm background)/specific activity
mg protein x 2 h (incubation period)
 
 
Acid soluble products (nmol palm/h/mg protein) =
(cpm samples –  cpm background)/specific activity
mg protein x 2 h (incubation period)
 
 
Table 3.5  
[(U)14C]-palmitate specific activity for palmitate oxidation protocol. 
[(U)14C]-2-deoxyglucose 
kBq/ml (µCi/ml) 
Cold palmitate 
(mmol/l) 
Cold glucose per 
100 µl of media 
(nmol) 
CPM in 
100 µl of media 
SA of the media 
(CPM/nmol glucose) 
3.7 (0.1) 1 10 A A/10 
SA: specific activity; CPM: counts per minute. 
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3.1.2.6 Glycogen synthesis measured with tracer 
[(U)14C]-glucose tracer was used to measure glucose flux into glycogen. It is assumed 
that a glucose molecule with all carbons labelled is metabolised as a glucose molecule 
(Figure 3.10). The amount of [(U)14C]-glucose tracer stored as glycogen can be assessed 
through precipitation of glycogen.   
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Figure 3.10. Glycogen synthesis with tracer. Glucose can be stored into trophoblasts as 
glycogen. It is assumed that the [(U)14C]-glucose tracer is metabolised into glycogen the 
same way that cold glucose tracee is metabolised. [(U)14C]-glucose tracer is taken up by 
trophoblasts, phosphorylated and then converted to [(U)14C]-glucose-1-phosphate by 
phosphoglucomutase. UDP-glucose pyrophosphatase adds an UDP to [(U)14C]-glucose-
1-phosphate and a [(U)14C]-UDP-glucose molecule is formed. Finally, glycogen synthase 
adds UDP-glucose molecules to elongate the glycogen chain.   
UTP: uridine triphosphate; UDP: uridine diphosphate. 
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For short-term culture experiments, trophoblasts were cultured for 36 h in complete 
DMEM at 5.5 mM glucose in 12 well plates, as described in Section 3.1.2.1. Cells were 
washed twice in 1 ml of warm washing solution. One ml of incubation KRBH solution 
containing [(U)14C]-glucose (for amount see Table 3.6), 0.5% BSA-FA free, at glucose 
concentrations of 1, 5, 15, 25 or 35 mM, in the presence or absence of 0.25 mM NEFA 
was added to the cultured cells. Wells with media, but no cells, were treated like samples 
to measure the background. After 2 h incubation in a humidified incubator 37ºC, 5% CO2, 
microplates were placed on ice to avoid glycogen hydrolysis. Cells were washed twice in 
500 μl cold PBS to remove the background. Trophoblasts were then scraped twice on ice 
in 500 μl cold PBS, collected into 1.5 ml microtubes and centrifuged (335 g, 10 minutes, 
4ºC). After centrifugation, supernatant was discarded and samples were quickly placed 
on dry ice and stored at -80ºC (Figure 3.11).  
 
Table 3.6  
[(U)14C]-glucose specific activity for glycogen protocol 
[(U)14C]-glucose 
kBq/ml (µCi/ml) 
Cold glucose 
(mmol/l) 
Cold glucose per 100 µl 
of media (nmol) 
CPM in 100 
µl of media 
SA of the media 
(CPM/nmol glucose) 
3.7 (0.1) 1 100 a a/100 
7.4 (0.2) 5 500 b b/500 
11.1 (0.3) 15 1500 c c/1500 
14.8 (0.4) 25 2500 d d/2500 
14.8 (0.4) 35 3500 d d/3500 
SA: specific activity; CPM: counts per minute. 
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Figure 3.11. Glucose flux into glycogen-protocol scheme. For short-term culture 
studies, trophoblasts were established in culture for 36 h in complete DMEM at 5.5 mM 
glucose in 12 well plates. Cells were washed twice in KRBH, 0.1% BSA-FA free and 1 
mM glucose. Cells were then incubated in 1 ml of KRBH containing 0.5% BSA-FA free, 
[(U)14C]-glucose (see Table 3.6 for amount), at 1, 5, 15, 25 or 35 mM cold glucose 
concentrations, plus or minus 0.25 mM NEFA. After 2 h incubation (37ºC, 5% CO2), 
plates were placed on ice to stop the metabolism. Cells were washed twice in cold PBS. 
Trophoblasts were then scrapped twice in ice 500 µl cold PBS, collected into 1.5 ml 
microtubes and centrifuged. After centrifugation, the supernatants were discarded and 
samples were quickly placed on dry ice and stored at -80ºC into microtubes. Later, 
glycogen was precipitated (see text for procedure description). Samples were diluted in 
water and collected into scintillation vials. Scintillation liquid was added to the samples 
and radiation was counted in a betacounter.  
For long-term culture experiments, trophoblasts were established in culture for 5 days in 
complete DMEM at 5.5 mM glucose supplemented with EGF (10 ng/ml) in 6 well plates, 
as described in Section 3.1.2.1. Incubations were performed in 2 ml KRBH containing 
0.5% BSA-FA free, [(U)14C]-glucose (refer to Table 3.6) at 5 or 25 mM cold glucose, 
plus or minus 0.25 mM NEFA. All other procedures were done as for short-term culture 
experiment. 
DMEM: Dulbecco's Modified Eagle Medium.; KRBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids; 
EGF: epidermal growth factor.   
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Later, 30 μl of 30% KOH (Appendix 2) was added to the pellets, which were heated at 
70ºC for 30 minutes until the pellets were digested. Fifteen μl of 6% Na2SO4 was added 
to the samples and thoroughly mixed with up and down pipetting plus vortexing for 
glycogen digestion. To make a final methanol concentration of 70%, 105 μl of 100% 
methanol was added to each of the samples, which were placed overnight at -20ºC to 
allow glycogen precipitation. On the next day, samples were centrifuged (1000 g, 30 sec, 
4ºC) and supernatants were discarded. Pellets were then washed twice by adding 1 ml of 
100% methanol, vortexing, centrifuging (1000 g, 30 seconds, 4ºC) and discarding the 
supernatant. After pellet washing, tubes were placed on a heating block at 50ºC to 
completely evaporate methanol. When dry, pellets were resuspended in 400 μl of Milli-
Q water and collected into scintillation vials. Ten ml of scintillation cocktail was added 
to each vial and the samples were counted in a betacounter.  
For long-term culture experiments, trophoblasts were cultured for 5 days from the 
isolation in complete DMEM (5.5 mM glucose) with EGF (10 ng/ml) in 6 well plates. All 
procedures were the same as for the short-term cultures, except that the cells were 
incubated in 5 or 25 mM glucose and all the reagent volumes were adjusted according to 
the well size. Well size was changed because the signal obtained from glucose flux into 
glycogen experiments in long-term trophoblasts cultured in 12 well plates (1.4 x 106 cells 
per well) was low. Thus, cells were plated in 6 well plates (3.5 x 106 cells per well) to 
enable higher readings. The glycogen precipitation method was adapted from Walaas et 
al. (286) with modifications.  
For glycogen calculation, the radiation in 100 µl of [(U)14C]-glucose media for each 
glucose concentration was counted in triplicates and SA in CPM per nmol was calculated 
(Table 3.6). Glycogenesis was calculated subtracting the background CPM from the 
sample CPM and dividing the result by SA. Results were normalised by mg of protein 
and expressed as nmol glucose incorporated into glycogen/h/mg protein. 
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Glycogen (nmol glucose incorporated/h/mg protein) =
(cpm samples –  cpm background)/specific activity
mg protein x 2 h (incubation period)
 
 
3.1.2.7 Total glycogen content  
In parallel to glycogen synthesis with tracer, total glycogen content was measured in 
experiments performed without [U14C]-glucose tracer. Trophoblasts were cultured for 36 
h in complete DMEM at 5.5 mM glucose. To deplete glycogen immediately prior to the 
experiment, however, cells were pre-incubated for 2 h in complete DMEM at 1 mM 
glucose concentration (Appendix 2). After the pre-incubation, trophoblasts were washed 
twice in 2 ml of warm washing solution and 2 ml of incubation solution containing 
glucose at 1, 5, 15, 25 and 35 mM glucose concentration in the presence or absence of 
NEFA mix was added to the cells. After 2 h incubation (37ºC, 5%, CO2), plates were 
placed on ice and cells were washed twice in 2 ml of cold PBS. Trophoblasts were then 
scraped twice on ice in 1 ml cold PBS, collected into 2 ml microtubes and centrifuged 
(335 g, 10 minutes, 4ºC). After centrifugation, supernatant was discarded and samples 
were placed on dry ice and stored at -80ºC. Later, glycogen precipitation was performed 
as for the glycogen synthesis with tracer method. Following methanol evaporation on a 
heating block, the pellets were resuspended in 50 μl amyloglucosidase (2 mg/ml) solution 
(Appendix 2) and placed into a water bath at 40ºC for 90 minutes to hydrolyze glycogen 
to glucose. Glucose was then measured using an enzymatic colorimetric kit (Appendix 
2). Glycogen was also measured from samples cultured in complete DMEM at 5.5 mM 
glucose concentration to determine the “basal glycogen”. Glycogen from bovine liver was 
used as a control (Appendix 2). Figure 3.12 shows the scheme for assessment of 
trophoblast glycogen content according to incubation conditions.   
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Figure 3.12. Total glycogen content-protocol scheme. Trophoblasts were established 
in culture for 36 h in complete DMEM at 5.5 mM glucose in 6 well plates. Cells were 
washed twice in KRBH, 0.1% BSA-FA free and 1 mM glucose, pre-incubated for 2 h in 
400 μl KRBH, 0.1% BSA-FA free and 1 mM glucose. After removal of the pre-incubation 
media, cells were incubated for 2 h (37ºC, 5% CO2) in 400 μl of KRBH, 0.5% BSA-FA 
free, at 1, 5, 15, 25 and 35 mM glucose concentrations plus or minus 0.25 mM NEFA. 
The plates were then placed on ice to stop the metabolism and cells were washed twice 
in cold PBS. Trophoblasts were then scrapped twice in 500 µl of ice cold PBS, collected 
into 1.5 ml microtubes and centrifuged. Following centrifugation, supernatant was 
discarded and samples were quickly placed on dry ice and stored at -80ºC. Later, glycogen 
was precipitated (see text for procedure description). After glycogen precipitation, pellets 
were resuspended in amyloglucosidase (2 mg/ml) solution and incubated into a water bath 
at 40ºC for 90 minutes to hydrolyze glycogen into glucose. Glucose was then measured 
using an enzymatic colorimetric kit. Glycogen basal was defined as glycogen from 
samples cultured in complete DMEM at 5.5 mM glucose concentration without 
incubations in KRBH. Refer to Appendix 2 for reagents and solutions.  
DMEM: Dulbecco's Modified Eagle Medium.; KRBH: Krebs-Ringer Bicarbonate 
HEPES; BSA: bovine serum albumin; FA: fatty acid; NEFA: non-esterified fatty acids.   
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3.1.3 Trophoblast protein content 
Trophoblast protein content was used to normalise the results to take in account any 
variation in cell number per well or flask in each experiment. At the same time point as 
for the metabolism studies, the cells were washed twice in cold PBS and scraped twice 
on ice (in 500 µl of PBS for 12 well plates and in 1 ml of PBS for 6 well plates). For cells 
seeded on T25 flasks, cells were extracted by trypsinisation (method is described in 
section 2.5.1 of Chapter 2). Cell mix was collected from wells and centrifuged (335 g, 
4°C, 10 minutes). Supernatant was discarded and pellets were frozen after the addition of 
100 µl of protein lysis buffer (Appendix 2) per 1.4 x 106 seeded cells. On the protein assay 
day, the samples were sonicated 10 times (Sonicator Omni-Ruptor 250, Omni 
International, Kennesaw, GA, USA) on ice and 10 µl of samples and standards were 
placed on a 96 well plate in duplicate. BSA was used as the standard. Two-hundred µl of 
the bicinchoninic acid (BCA) method colour solution (Pierce BCA protein kit) was added 
to the samples and standards and incubated at 37°C for 30 minutes. Following colour 
development, microplates were read in a microplate reader at an absorbance 540 nm.   
3.2 Cellular morphology and triacylglycerol quantification in long-
term cultures 
3.2.1 Oil red O staining  
Trophoblasts were seeded in chamber slides (245 x103 trophoblasts per chamber) in 200 
µl of complete DMEM at 5.5 mM glucose in the presence or absence of EGF (10 ng/ml) 
and kept for 5 days (see Appendix 1 for reagents and material suppliers). From day 2 to 
day 5 of culture, trophoblasts were grown in 400 µl of complete DMEM (5.5 mM glucose; 
± 10 ng/ml EGF) in the presence or absence of NEFA mix (0.1 mM, palmitate: oleate 
ratio; 1:1) according to Figure 3.13.  
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Figure 3.13. Trophoblast culture in chamber slides for assessment of cell 
morphology and lipid droplet accumulation. Trophoblast were cultured in complete 
DMEM at 5.5 mM glucose in the presence or absence of EGF (10 ng/ml) from the 
isolation day. From day 2 to day 5 of culture, NEFA mix (0.1 mM, palmitate: oleate ratio; 
1:1) was added to 2 chambers in which cells had been maintained in the presence of 
complete DMEM supplemented with EGF and to 2 chambers in which cells were grown 
in complete DMEM without EGF. On day 5 of culture, slides were stained for Oil red O 
and counterstained for haematoxylin. 
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On day 5 of culture, cells were stained with Oil Red O, a neutral lipid droplets stain that 
is specific for TG and cholesteryl esters, in particular cholesteryl oleate (287), and 
counterstained with haematoxylin. For the staining, culture media was removed and 
trophoblasts were gently washed twice with 300 µl of PBS for 2 minutes each wash. PBS 
was removed and 300 µl of 10% buffered formalin was added to each well, and the slides 
were incubated at room temperature for 10 minutes. Formalin was removed and 300 µl 
of fresh 10% buffered formalin was then added to the wells and left for 30 minutes for 
fixation. Formalin was removed and the chamber framing was detached from the slide 
using the lever from the chamber slide kit. Slides were gently washed by dipping 10 times 
into a 50 ml Falcon tube filled with distillated water (ddH2O). This washing (10 dips) was 
repeated once again into a new 50 ml Falcon tube with fresh ddH2O. Cells were then 
gently rinsed by dipping the slide in 60% isopropanol for 1 minute at room temperature. 
Trophoblasts were stained with freshly prepared Oil Red O working solution (refer to 
Appendix 2 for preparation of solutions) for 15 minutes at room temperature. The staining 
was performed in a slide tray using a transfer pipette to cover the sections with Oil Red 
O, making sure the slide tray was covered to prevent evaporation of the isopropanol. After 
incubation, slides were again washed by dipping 10 times in ddH2O. On the staining day, 
Harris haematoxylin was diluted in ddH2O (1:2) and filtered with a 0.22 µm filter. Nuclei 
were then stained by dipping the slides in 50 % Harris haematoxylin 4 times. Slides were 
gently washed in ddH2O and dipped in warm tap water 5 times to intensify the colour 
blue of haematoxylin. Finally, slides were gently washed 3 times with ddH2O for 2 
minutes each. Chamber slides were cover slipped using PermaFluor aqueous mounting 
media (Appendix 2) and coverslip edges were sealed off with nail polish. Slides stained 
for Oil red O were analysed by 2 independent viewers and scored according to Table 3.6. 
Lipid droplets were classified according to whether the globules size were small or large 
and scored according to the percentage of cells containing them in each slide. In addition, 
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percentages of cell area forming cellular aggregation and syncytia were also analysed 
(Table 3.6).  
 
Table 3.6  
Score for morphology of trophoblasts Oil red O stained 
Morphology analysis Score 
Percentage of cells with large lipid 
droplets  
<10% 10-25% 25-50% 50-80% >80% 
Percentage of cells with small lipid 
droplets 
<20% 20-80% >80% 
  
Percentage of cell area forming 
cellular aggregation 
< 10% 10-25% 25-50% 50-80% > 80% 
Percentage of cell area forming 
syncytia 
<5% 5-10% 10-25% >25% 
 
 
3.2.2 Triacylglycerol quantification 
Primary human trophoblast cultures were established in 6 well plates in a density of 3.5 
x 106 cells over 2 days post isolation in complete DMEM (5.5 mM glucose) with or 
without EGF (10 ng/ml). For a further 3 days, trophoblasts were also cultured in complete 
DMEM (5.5 mM glucose; with and without EGF) in the presence or absence of NEFA 
(0.1 mM, palmitate: oleate ratio; 1:1). At the same time point as for Oil Red O staining, 
culture media was removed and cells were detached using trypsinisation (method is given 
in Chapter 2, section 2.5.1). Cells from 2 wells (a total of 7 x 106 trophoblasts per sample) 
were collected in 1.5 ml microtubes and centrifuged (290 g, 7 minutes, 4ºC). Supernatants 
were discarded and the pellets were resuspended in 1 ml of cold PBS. Cell suspensions 
were mixed well and 100 µl was taken from each sample and stored in 1.5 ml microtubes 
for later protein measurement. Samples for TG extraction were centrifuged again (290 g, 
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7 minutes, 4ºC). Supernatants were discarded and 25 µl of 0.5 M alcoholic KOH was 
added to each pellet to promote lipid saponification. Samples were sonicated on ice for 
10 times. Cell homogenates were incubated in a water bath at 70˚C for 20 minutes. 
Following incubation, samples were placed at room temperature for 10 minutes to cool 
down. Then, 50 µl of 0.15 M MgSO4 was added to each microtube to precipitate insoluble 
debris. Negative controls without cells were prepared mixing 25 µl of 0.5 M KOH and 
50 µl of 0.15 M MgSO4 to measure the background. All microtubes were vortexed well 
and centrifuged (5,250 g, 5 minutes, 4˚C) to precipitate insoluble substances. Supernatant 
was transferred into a new set of microtubes and pellet was discarded. Samples were then 
measured with an enzymatic colorimetric kit (Appendix 2). The principle of this method 
is to measure the glycerol concentration following TG hydrolysis by a LPL enzyme. The 
glycerol is phosphorylated to glycerol 3-phosphate by glycerol kinase. Glycerol 3-
phosphate is converted to dihydroxyacetone phosphate and hydrogen peroxide by the 
enzyme glycerol phosphate oxidase. Hydrogen peroxide, N-Ethyl-N-(3-sulfopropyl)-m-
anisidine (ESPA) and 4-aminoantipyrine (4-AAP) are converted to quinoneimine dye and 
water in a redox-coupled reaction catalysed by a peroxidase. The dye produces a colour 
in which the absorbance is directly correlated with the glycerol concentration in the 
sample (Figure 3.14). The assay was performed following the manufacturer’s 
instructions: free glycerol reagent was reconstituted in 40 ml of Milli-Q water and TG 
reagent was dissolved in 10 ml of Milli-Q water. Glycerol was used as a standard. Ten µl 
of samples, standards (0.5, 1, 2, 4, 6, 8 and 10 µl glycerol standard and completed volume 
with water up to 10 µl final volume) and negative controls were added to 96 well plates. 
A hundred and sixty µl of free glycerol reagent solution was distributed to the wells. 
Plates were gently shaken and incubated at room temperature for 15 minutes. Then, 40 µl 
of TG reagent solution was added to the wells. Plates were carefully mixed and incubated 
for 15 minutes at room temperature. Absorbance was read in a microplate reader at 540 
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nm. Results were normalised by trophoblast protein content. TG extraction method was 
adapted from Salmon et al. (288) with modifications. 
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Figure 3.14. TG determination assay principle. TG is hydrolysed by LPL to release 
glycerol, which is phosphorylated to glycerol 3-phosphate by glycerol kinase. Glycerol 
3-phosphate is converted to dihydroxyacetone phosphate and hydrogen peroxide by the 
enzyme glycerol phosphate oxidase. Hydrogen peroxide, N-Ethyl-N-(3-sulfopropyl)-m-
anisidine (ESPA) and 4-aminoantipyrine (4-AAP) are converted to quinoneimine dye and 
water in a redox-coupled reaction catalysed by a peroxidase. The dye produces a colour 
in which the absorbance is directly correlated with the glycerol concentration in the 
sample.  
LPL: lipoprotein lipase; TG: triacylglycerol.  
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3.3 Statistical analysis 
The statistical analyses in this thesis were performed using the software GraphPad Prism 
6 (GraphPad Software, Inc., La Jolla, CA, USA). Variable distribution (normality) was 
tested with the Shapiro-Wilk test and the Kolmogorov-Smirnov test. Results were given 
as means ± standard error of the mean (SEM) in graphic descriptions or SD for normally 
distributed data in which the description of dispersion from the mean was appropriate. 
Student t test was used to compare means of 2 groups of continuous variables that were 
normally distributed and the Mann-Whitney test was used for non-parametric 
comparisons. ANOVA with Bonferroni’s post-hoc testing was used for comparisons 
between the mean of more than 2 continuous variables. Chi-square and Fisher's exact test 
were used to compare categorical data. Statistical significance was considered for a p 
value of < 0.05. 
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Chapter 4 
 
 
Results for glucose metabolism studies in 
short-term trophoblast cultures 
4. Results for glucose metabolism studies in short-term 
trophoblast cultures 
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4.1 Introduction 
Previous research has shown that glucose metabolism by glycolysis in trophoblasts is near 
maximal at the glucose concentration of 4 mM (200). Human placental perfusion studies, 
however, suggest that glucose utilisation of placenta is not maximal until the perfusate 
glucose concentration reaches about 17 mM (165, 176). The purpose of the following 
metabolism experiments in short-term cultures was to evaluate trophoblast glucose uptake 
and metabolism in more detail to elucidate the reasons for the discrepancy between the 
previous placental glucose utilisation and trophoblast glycolysis findings. In addition, 
because of interest in the effects of elevated lipids on placental function, the experiments 
were also designed to determine the effects of fatty acids on glucose uptake and 
metabolism. Pathways of glucose uptake, glycolysis, lactate production, glucose 
oxidation and glycogen synthesis were assessed in trophoblasts established in culture for 
36 h (Figure 4.1). The experiments were performed over 2 h at diverse glucose 
concentrations in the presence or absence of NEFA (0.25 mM, palmitate: oleate ratio; 
1:1). Palmitate oxidation and acid soluble products from palmitate were also measured to 
allow comparison between rates of glucose and fatty acid oxidation. 
A combination of radio-labelled metabolic tracer methods and metabolite assay methods 
were used, as described in Chapter 3. All tracer methods were performed taking into 
account the SA of the tracers within the incubation media. Total glucose uptake in 
trophoblasts was assessed by measuring intracellular 14C labelled 2-deoxyglucose 6-
phosphate accumulation. Glycolysis was analysed through 3H labelled water production 
from [5-3H]-glucose, whilst lactate release into the media was measured using an 
enzymatic metabolite colorimetric assay. Glucose and palmitate oxidation were assessed 
through the production of 14C labelled CO2 from [(U)14C]-glucose and [(U)14C]-palmitate, 
respectively. Glucose flux into glycogen synthesis was quantified using a [(U)14C]-
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glucose tracer and the total intracellular glycogen content was measured with an 
enzymatic colorimetric method.  
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Figure 4.1. Experimental design scheme for metabolism studies in short-term 
primary human trophoblast cultures. Human placental villous tissue was harvested 
(day -1) and trophoblasts were isolated and seeded on the following day (day 0). Human 
trophoblasts were established in complete DMEM at 5.5 mM glucose (refer to Chapter 2 
for culture details and Appendix 1 for media preparation). Short-term trophoblast culture 
metabolism experiments were performed 36 h post isolation, when most cells were 
cytotrophoblasts.  
DMEM: Dulbecco's Modified Eagle Medium. 
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4.2 Total glucose uptake 
In primary human trophoblast cultures established over 36 h post isolation, the rate of 
glucose uptake as measured by the 14C labelled 2-deoxyglucose 6-phosphate method 
during 2 h incubations, as described in Chapter 3, increased through all cold glucose 
concentrations from 1 to 15 mM without reaching plateau. There were no differences in 
the presence or absence of NEFA. Total glucose uptake, as assessed by this method, was 
strongly correlated with the medium glucose concentration [r2=0.71, p < 0.0001 (no 
NEFA); r2=0.88, p < 0.0001 (plus NEFA)] (Figure 4.2). After this preliminary result, the 
total glucose uptake protocol was revised. Cold glucose concentrations of 25 to 35 mM 
were then added to the experiment in an attempt to determine the level at which total 
glucose uptake reaches a maximum and plateau. Using the same tracer method, the rates 
of total glucose uptake increased through all media glucose concentrations from 1 to 35 
mM without reaching plateau in the absence of NEFA in the media. For trophoblasts 
incubated with NEFA, the relationship between increasing glucose concentration and 
glucose uptake was not different from that observed in the absence of NEFA. The strong 
linear correlations between total glucose uptake rates and cold glucose concentrations 
were maintained [r2=0.82, p < 0.0001 (no NEFA); r2=0.64, p < 0.0001 (plus NEFA)] 
(Figure 4.3).  
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Figure 4.2. Total glucose uptake by trophoblasts in short-term cultures 
progressively increased with increasing glucose availability without effect of NEFA. 
Total glucose uptake in trophoblasts established in culture for 36 h, as measured by the 
14C labelled 2-deoxyglucose 6-phosphate method during 2 h incubations as described in 
Chapter 3, increased through all cold glucose concentrations from 1 to 15 mM. Total 
glucose uptake was similar in the presence or absence of 0.25 mM NEFA. 
Two-way ANOVA: NEFA effect ns; glucose effect p < 0.0001; NEFA-glucose 
interaction ns. Data are means ± SEM of 8 independent experiments in which each point 
was the average of triplicate wells. 
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Figure 4.3. Total glucose uptake by trophoblasts in short-term cultures 
progressively increased with media glucose concentrations up to 35 mM without 
evidence of plateau. Total glucose uptake in trophoblasts established in culture for 36 h, 
as measured by the 14C labelled 2-deoxyglucose 6-phosphate method during 2 h 
incubations as previously described (Chapter 3), increased through all cold glucose 
concentrations from 1 to 35 mM. Total glucose uptake was similar in the presence or 
absence of 0.25 mM NEFA.  
Two-way ANOVA: NEFA effect ns; glucose effect p < 0.0001; NEFA-glucose 
interaction ns. Data are means ± SEM of 5 independent experiments in which each point 
was the average of triplicate wells. 
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4.3 Glycolysis 
The rate of glucose utilisation via glycolysis by primary human trophoblasts cultures 
established over 36 h post isolation was measured by the [5-3H]-glucose tracer method, 
as described in Chapter 3. Glycolysis rate was almost maximum at the lowest cold glucose 
concentration of 1 mM glucose in the media. There was a minimal increase in the rate of 
glycolysis with rising cold glucose concentrations from 1 to 15 mM, statistically 
significant only in the presence of NEFA (57.1 % increase). However, the rates of 
glycolysis at the different glucose concentrations overall were not statistically different 
according to the absence or presence of NEFA (Figure 4.4). 
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Figure 4.4. Glucose utilisation via the glycolysis pathway in short-term human 
trophoblast cultures was maximal at low media glucose concentrations without 
effect of NEFA. Glycolysis rate over 2 h incubations, as estimated by the [5-3H]-glucose 
tracer method (refer to Chapter 3), showed a limited increase with increasing media 
glucose concentrations from 1 to 15 mM in trophoblasts established in culture for 36 h. 
Glycolysis rates were similar in the presence or absence of 0.25 mM NEFA. 
Two-way ANOVA: NEFA effect ns; glucose effect p=0.002; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: 1 mM glucose vs 5 mM glucose (plus NEFA) p=0.044; 1 
mM glucose vs 15 mM glucose (plus NEFA) p=0.018. Data are means ± SEM of 8 
independent experiments in which each point was the average of triplicate wells. 
 
 
 146
4.4 Total lactate release into the media 
Lactate released into the media by human trophoblasts established in cultures over 36 h 
after isolation was measured by an enzymatic colorimetric assay as described in Chapter 
3. Lactate release was maximum at the media glucose concentration of 5 mM. The lactate 
release rate was similar in the absence or presence of NEFA. Lactate release increased by 
22.5% (in the absence of NEFA) and by 20.8 % (in the presence of NEFA) when glucose 
concentration in the media rose from 1 to 15 mM (Figure 4.5).  
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Figure 4.5. Lactate release into the media in short-term primary human trophoblast 
cultures plateaued at the media glucose concentration of 5 mM without NEFA effect. 
Lactate release in primary human trophoblasts established in culture over 36 h post 
isolation, as measured by the enzymatic colorimetric assay described in Chapter 3, 
reached the maximum concentration at 5 mM glucose in the media. Lactate release was 
similar in the presence or absence of 0.25 mM NEFA.  
Two-way ANOVA: NEFA effect ns; glucose effect p=0.012; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: 1 mM glucose vs 5 mM glucose (no NEFA) p=0.009; 1 mM 
glucose vs 15 mM glucose (no NEFA) p=0.003; 1 mM glucose vs 5 mM glucose (plus 
NEFA) p=0.011; 1 mM glucose vs 15 mM glucose (plus NEFA) p=0.004. Data are means 
± SEM of 4 independent experiments in which each point was the average of triplicate 
wells. 
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4.5 Glucose oxidation 
Glucose oxidation in primary human trophoblasts established in culture over 36 h after 
isolation was assessed through [(U)14C]-glucose metabolism into 14C labelled CO2 as 
described in Chapter 3. Glucose oxidation was significantly higher in the absence of 
NEFA at the lowest glucose concentration in the media (1 mM) than in the presence of 
NEFA, and there was a non-significant trend for it to be lower in the presence of NEFA 
at glucose concentrations of 5 and 25 mM. With rising glucose concentrations in the 
media, trophoblast glucose oxidation increased in both the absence and presence of 
NEFA, with the majority of this increase occurring for media glucose concentration rises 
from 1 to 5 mM. (Figure 4.6). 
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Figure 4.6. Glucose oxidation in short-term trophoblast cultures was near maximum 
at a cold glucose concentration of 5 mM in the media. Overall, NEFA did not affect 
this metabolic pathway. Glucose oxidation in human trophoblasts established in culture 
over 36 h after isolation was measured by the [(U)14C]-glucose tracer metabolism method 
in which 14C labelled CO2 is captured and quantified (refer to Chapter 3). Glucose 
oxidation was almost maximum at the media glucose concentration of 5 mM. The 
presence of NEFA significantly reduced glucose oxidation rate only at 1 mM cold glucose 
concentration.  
Two-way ANOVA: NEFA effect p=0.025; glucose effect p=0.003; NEFA-glucose 
interaction ns. Bonferroni post-hoc test: *1 mM glucose (no NEFA) vs 1 mM glucose 
(plus NEFA) p=0.025; 1 mM glucose vs 5 mM glucose (no NEFA) ns; 1 mM glucose vs 
25 mM glucose (no NEFA) p=0.018; 5 mM glucose vs 25 mM glucose (no NEFA) ns; 1 
mM glucose vs 5 mM glucose (plus NEFA) p=0.017; 1 mM glucose vs 25 mM glucose 
(plus NEFA) p=0.0009; 5 mM glucose vs 25 mM glucose (plus NEFA) ns.  
Data are means ± SEM of 6 independent experiments in which each point was the average 
of duplicate or triplicate T25 flasks. 
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4.6 Palmitate oxidation and acid soluble product formation 
In primary human trophoblasts established in culture over 36 h after isolation, the rate of 
palmitate oxidation was measured during 2 h incubations by the [(U)14C]-palmitate tracer 
method in which 14C labelled CO2, as well as 14C labelled acid soluble products, are 
captured and quantified (refer to Chapter 3). Palmitate oxidation showed a trend towards 
reduction with the increase in the media glucose concentration from 5 to 25 mM (Figure 
4.7). The levels of acid soluble products accumulation from palmitate oxidation, as 
described in Chapter 3, were similar at media glucose concentrations of 5 and 25 mM. 
(Figure 4.8).  
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Figure 4.7. Palmitate oxidation in short-term trophoblast cultures showed a trend 
towards reduction in the presence of a high level of glucose in the media. Palmitate 
oxidation in human trophoblasts established in culture over 36 h after isolation and 
measured by [(U)14C]-palmitate tracer metabolism into 14C labelled CO2 (described in 
Chapter 3) presented a downward trend at 25 mM glucose concentration in the media. 
Data are means ± SEM of 6 independent experiments in which each value was the average 
of duplicate or triplicate T25 flasks. 
 
 152
 
 
Figure 4.8. Acid soluble product generation during palmitate oxidation in short-
term human trophoblast cultures were similar at lower and higher glucose levels in 
the media. Palmitate oxidation into acid soluble products in human trophoblasts 
established in culture over 36 h after isolation, as measured by [(U)14C]-palmitate tracer 
metabolism into 14C acid soluble products according to the method described in Chapter 
3, exhibited similar values at 5 and 25 mM glucose concentrations in the media. Data are 
means ± SEM of 4 independent experiments in which each value was the average of 
duplicate or triplicate T25 flasks. 
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4.7 Glycogen synthesis measured with tracer 
The acute glucose flux into glycogen in human trophoblasts established in culture over 
36 h post isolation was quantified using the [(U)14C]-glucose tracer method, as explained 
before (Chapter 3). Glycogen synthesis increase was linearly correlated with all media 
glucose concentrations from 1 to 35 mM [r2=0.70, p < 0.0001 (no NEFA); r2=0.75, p < 
0.0001 (plus NEFA)]. Trophoblast cultures in the presence of 0.25 mM NEFA showed 
significantly higher glycogen synthesis as quantified by this tracer method (Figure 4.9).  
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Figure 4.9. The acute glucose flux into glycogen synthesis in short-term primary 
human trophoblast cultures increased with rising cold glucose concentrations in the 
media. Glycogen synthesis was further increased in the presence of NEFA. The acute 
glucose flux into glycogen in human trophoblasts established in culture over 36 h after 
isolation, as quantified with [(U)14C]-glucose tracer method described in Chapter 3, 
progressively increased through all glucose concentrations in the media from 1 to 35 mM. 
Glycogen synthesis was significantly higher in the presence of 0.25 mM NEFA.  
Two-way ANOVA: NEFA effect p=0.006; glucose effect p < 0.0001; NEFA-glucose 
interaction p < 0.0001. Bonferroni post-hoc test: *15 mM glucose (no NEFA) vs 15 mM 
glucose (plus NEFA) p=0.006; **25 mM glucose (no NEFA) vs 25 mM glucose (plus 
NEFA) p=0.003; ***35 mM glucose (no NEFA) vs 35 mM glucose (plus NEFA) p < 
0.0001. Data are means ± SEM of 7 independent experiments in which each point was 
the average of triplicate wells. 
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4.8 Total glycogen content 
Total intracellular glycogen content in human trophoblasts established in culture over 36 
h post isolation was measured using an enzymatic colorimetric assay as described in 
Chapter 3. Total glycogen content quantified in trophoblasts grown for 36 h in complete 
media at 5.5 mM glucose concentration without further incubation was considered the 
“basal” glycogen concentration. Total glycogen content measured after acute incubations 
(2 h pre-incubation in complete DMEM at 1 mM glucose followed by 2 h incubation in 
KRBH, 0.5% BSA-FA free, at glucose concentrations of 1, 5, 15, 25 and 35 mM in 
presence or absence of NEFA), as described in Chapter 3, showed a minimal increase in 
glycogen content with increasing media glucose according to ANOVA (Figure 4.10). 
However, with post-hoc testing, total glycogen content quantified after incubations was 
not different from basal glycogen content and was similar in the presence or absence of 
NEFA. The glycogen content (nmol glucose equivalent as glycogen ± SD) after 2 h 
incubation at the indicated glucose concentration in the absence and presence of NEFA 
was, respectively, 225.67 (± 59.61) and 235.37 (± 66.78) nmol/mg protein at 1 mM 
glucose, 253.11 (± 41.70) and 257.14 (± 52.63) nmol/mg protein at 15 mM glucose, and 
244.61 (± 51.39) and 278.09 (± 79.00) nmol/mg protein at 35 mM glucose. This is 
comparable to the basal glycogen content of 215.88 (± 30.90) nmol/mg protein.  
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Figure 4.10. Total glycogen content in short-term human trophoblast cultures 
increased minimally with rising media glucose concentration and was not affected 
by the presence of NEFA. Total glycogen content in trophoblasts established in culture 
over 36 h post isolation was measured by the enzymatic colorimetric assay described in 
Chapter 3. Basal levels of total glycogen content were measured in trophoblasts grown in 
complete media at 5.5 mM glucose without further incubation. For other measurements, 
total glycogen content in the trophoblasts was measured following a further 2 h incubation 
in KRBH media containing from 1 to 35 mM glucose in the absence or presence of 0.25 
mM NEFA. Total glycogen content increased minimally with increasing glucose 
concentrations in the media and was not affected by the presence of NEFA. Basal 
glycogen content was also similar to total glycogen content quantified after acute 
incubations in KRBH.  
Two-way ANOVA: NEFA effect ns; glucose effect p=0.019; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: ns. Data are means ± SEM of 4 independent experiments in 
which each point was the average of triplicate wells. 
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4.9 Discussion 
The main aim of this research was to determine the fate of glucose flux in primary human 
trophoblasts exposed to increasing media glucose concentrations since studies have 
shown that total glucose uptake into placental tissue can increase as glucose supply 
concentrations rise to levels above 15 mM (165, 176), whereas glycolysis rates become 
maximal at much lower glucose supply concentrations of about 5 mM (200). This may 
be a consequence of placental glucose storage (total glucose utilisation minus lactate 
production from glucose and glucose oxidation) drastically rising at maternal glucose 
concentrations of  ≥ 10 mM (165). In addition, the effects of 0.25 mM NEFA (palmitate 
and oleate) on glucose metabolism pathways, which have been extensively investigated 
in other tissues, were studied in primary human trophoblast cultures.  
Results from this research showed that human trophoblasts, established in culture over 36 
h post isolation and assessed using the labelled 2-deoxyglucose method over a 2 h period, 
were able to take up an increasing amount of glucose according to the glucose availability 
without evidence of saturation. Total glucose uptake presented a strong linear correlation 
with the media glucose concentration from 1 to 35 mM in both the presence and absence 
of NEFA. Glycolysis assessed by [5-3H]-glucose metabolism, lactate release in the media 
quantified with an enzymatic colorimetric assay and glucose oxidation studied through 
[(U)-14C]-glucose metabolism all reached a plateau at the relatively low media glucose 
concentration of 5 mM. Overall, NEFA did not affect these glucose metabolism pathways 
(total glucose uptake, glycolysis, lactate release into the media and glucose oxidation). 
Similarly to total glucose uptake, glucose flux into glycogen assessed by [(U)-14C]-
glucose accumulation as labelled glycogen linearly increased according to available 
glucose in the media. Moreover, glucose flux into glycogen was further enhanced in the 
presence of NEFA. On the other hand, total glycogen content quantified by an enzymatic 
colorimetric assay showed only a minimal trend to rise over a 2 h period according to the 
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glucose concentration in the media, with no demonstrable effect of the presence compared 
to the absence of NEFA. Palmitate oxidation, measured through [(U)-14C]-palmitate 
metabolism, showed a trend of reduction at the supra-physiological media glucose 
concentration of 25 mM; whereas acid soluble product formation assessed in the same 
experiments was not affected by glucose.   
4.9.1 Effects of increasing media glucose concentration on glucose 
metabolism pathways in primary human trophoblast cultures 
4.9.1.1 Glucose uptake 
Total glucose uptake rates in human trophoblasts obtained in this research are in 
accordance with previous publications which have shown that total glucose uptake in 
placental perfusion studies and experiments with trophoblast cultures is directly 
correlated with available glucose without saturation (176, 184, 192) or with saturation at 
supra-physiological glucose levels (165, 193, 194). Glucose is the main nutritional energy 
source to the fetus. The first step in the glucose flux from mother to the fetus is glucose 
uptake by trophoblasts which occurs mainly through GLUT1. Previous results have 
shown that GLUT1 is down-regulated when trophoblasts are cultured at high glucose 
concentrations for 24-96 h (184), but in the current experiments trophoblasts were 
cultured in the different glucose concentrations for 2 h only, which is not likely to be long 
enough to alter GLUT1 levels. Hahn et al. demonstrated that  trophoblasts harvested from 
term placenta chronically exposed to high glucose concentration (25 mM glucose for ≥ 
24 h) exhibited a decrease in GLUT1 mRNA by 50 % and a reduction in GLUT1 protein 
by 16 % in comparison with trophoblasts cultured at 5 mM (184). Glucose uptake by the 
experimental trophoblasts measured through the 3-O-[14C]-methyl-D-glucose method 
was reduced by 25%, however only in circumstances when the cold glucose 
concentrations during measurements were increased to ≥ 20 mM (184). This effect was 
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caused by a reduction by 50% in the Vmax for glucose uptake rather than a change in the 
Km for glucose transport which was very high at 73 mM (184). As the Vmax is determined 
by the number of transporters, the decrease in transport in response to sustained 
hyperglycaemia is consistent with a reduction in GLUT1 expression. Moreover, another 
study with primary human trophoblasts in co-culture with acellular amniotic membrane 
reported a half-saturation for trans-trophoblast D-glucose transport at 44 mM glucose 
(194). Studies with perfused cotyledons have also supported the hypothesis that the main 
determining factor for glucose uptake in the placenta is the substrate gradient and not 
GLUT1 concentration or activity. Glucose uptake increased linearly in two studies 
(r2=0.74) (192) and (r2=0.65) (176) with available glucose concentration up to 20-25 mM 
without suggestion of transport saturation. In agreement, maximum placental glucose 
uptake reported by Day et al. (192) was much higher than the predicted (theoretical) 
GLUT1 saturation, suggesting again that other factors regulate glucose uptake beyond 
GLUT1 transport. GLUT3, a high affinity glucose transporter expressed in 
cytotrophoblasts from term placentas (178), could maintain the glucose flux, even when 
GLUT1 is down-regulated. Thus, the placenta and trophoblast cells in culture, as 
investigated in this research, seem to have a high capacity for glucose uptake which is 
mostly determined by the available glucose concentration.  
4.9.1.2 Glycolysis 
Anaerobic glycolysis has been described as the main glucose utilisation pathway in the 
placenta (207). The placenta, however, seems to have a very limited ability to increase 
aerobic or anaerobic glycolysis rates in higher than physiological glucose concentrations. 
In the experiments of this thesis, glycolysis rates in primary human trophoblasts at 1 mM 
and 5 mM media glucose concentration were 83.3% and 95.6% of the maximum rates, 
respectively. These results coincide with previous data that showed that glycolysis rates 
were 90% of maximal at 4 mM glucose and maximum at 8 mM glucose in the culture 
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media (200). It is possible that the trophoblast’s limited ability to increase glycolysis is 
due to a low activity of enzymes involved in glycolysis. With the exception of hexokinase 
and pyruvate kinase, liver enzymes are many times more active than placental enzymes 
(207). Thus, it is likely that excess glucose is not metabolised via glycolysis by human 
trophoblasts when the glucose supply to the cells is high. In accordance with minimal 
increases in glycolysis at elevated glucose concentrations in the media, lactate production 
in the current experiments did not increase for media glucose concentrations above 5 mM. 
This finding is similar to the results from past placental perfusion studies which report no 
increase in lactate production when maternal glucose is above 5.5 mM (165), or when the 
glucose supply was increased from 4 to 24 mM (176). Furthermore, in the latter study, 
there was no correlation between lactate production and maternal glucose (176). In the 
current work, the lactate production at 5 mM glucose represented about 69% of total 
glucose uptake, since 1 mol of glucose yields 2 mol of lactate. This proportion was similar 
to what was observed in another study with isolated trophoblasts from term placenta, in 
which 70% of glucose utilisation was converted to lactate (148). Our results also 
coincided with the lactate production rate of 68.7% of total glucose utilisation in placental 
slices (197), and to the fraction reported in placental perfusion studies. In these studies, 
lactate production per molecule of glucose was 69% of placental glucose utilisation at 5.6 
mM maternal glucose concentration (165) and around 78% at 4 mM (176). Also, 
consistent with the results of this thesis, as glucose availability increased above 5 mM, 
the percentage of glucose uptake (trophoblast cultures of the current study) or percentage 
of glucose utilisation (placental perfusion studies), contributing to lactate production 
became less. For example, in the current study, at glucose concentrations in the media of 
15 mM, only 37.5% of the glucose taken up by the isolated trophoblasts contributed to 
lactate production. In the placental perfusion studies, at the maternal glucose perfusate 
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concentrations of 16.9 mM (165) and 16 mM (176), respectively, 17% and about 45% of 
the glucose utilised by the placenta could be accounted for lactate production.  
Of note, lactate production exceeded total glucose uptake at the media glucose 
concentration of 1 mM in this thesis, which is unlikely since the predominant source for 
lactate synthesis would have been glucose. Unknown, is the amount of glycogen 
breakdown that could have contributed to lactate production. Lactate production from 
amino acids was implausible because the only amino acid source in the incubating media 
in this research was BSA, which was used to bind and solubilise NEFA. It would have 
been inaccessible to metabolism. In addition, the absolute glycolysis rates were higher 
than the absolute total glucose uptake rates at media glucose concentrations of 1 and 5 
mM. Furthermore, this measure was of glycolysis from the media glucose, as the 
glycogen stored within trophoblasts would have been unlabelled. Therefore, due to the 
lack of correlation between the percentage of glycolysis, lactate release and total glucose 
uptake, it is possible that total glucose uptake absolute rates obtained by 2-deoxyglucose 
method in this work were underestimated and/or the glycolysis absolute rates assessed by 
[5-3H]-glucose were overestimated even though the trend according to media glucose 
seems to be reliable (see discussion below).  
4.9.1.3 Glucose and palmitate oxidation  
In the current studies, glucose oxidation as determined by the production of 14CO2 from 
[(U)14C]-glucose showed a plateau at 5 mM media glucose concentration, as for 
glycolysis. In accordance to these results, oxygen utilisation was shown to be limited in 
perfused placentas studies, without increments for maternal glucose rises from 3 to 53 
mM (165). Also, studies in sheep have demonstrated that acute or chronic maternal 
hyperglycaemia increased utero-placental total glucose uptake, but did not alter the utero-
placental oxygen consumption (289).  
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In order to directly compare the rates of trophoblast glucose and palmitate oxidation, both 
were performed at the same time within trophoblasts from the same placentas. The results 
of the current study showed a non-significant reduction of palmitate oxidation by 33% at 
the higher media glucose concentration (25 mM vs 5 mM). Previous experiments 
performed in human trophoblast cultures, conversely, did not show this trend, with 
palmitate oxidation rates unchanged across a range of media glucose concentrations from 
0.5 to18 mM (200). On the other hand, the results of this thesis are similar to those of 
Visiedo et al. study with placental explants in which palmitate oxidation measured using 
the [9, 10 (n)-3H]-palmitate metabolism method was significantly reduced by 20% in 
cultures exposed to high glucose levels (11 mM glucose vs 5 mM) incubated for 18 h 
(232). According to the latter study, the mechanism of palmitate oxidation inhibition by 
glucose was similar to that observed in other tissues, where high glucose concentrations 
induce increases in malonyl-CoA levels, which in turn inhibit CPT-1 activity and the 
long-chain NEFA transport into the mitochondria for oxidation (232). Incubation at 11 
mM media glucose reduced the phosphorylation levels of acetyl-CoA carboxylase, the 
enzyme that converts acetyl-CoA into malonyl-CoA, by 25% and inhibited CPT-1 
activity by 70%. (232). In this thesis research, however, glycolysis did not increase when 
cells were exposed to glucose concentrations higher than 5 mM during 2 h incubations. 
Thereupon, the assumption that malonyl-CoA was involved in palmitate oxidation 
reduction in this research cannot be made and other intermediates of glucose metabolism 
may play a role. Also, the results of Visiedo el al. study showed about 3-fold higher 
palmitate oxidation rates (at 5 mM glucose and 0.1 mM palmitate) (232) than the current 
research, which may be owing to methodological differences. Villous explants maintain 
placental tissue architecture and contain other cell types (i.e. endothelial cells, fibroblasts, 
macrophages) in addition to trophoblasts, which could increase fatty acid oxidation rates. 
Moreover, in the previous study (232), the incubations were performed for longer time 
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(18 h) than the current research and palmitate oxidation was assessed by [9, 10 (n)-3H]-
palmitate method, which may also lead to differences. Nevertheless, a study with 
cytotrophoblast cultures from term placentas (224) showed that palmitate oxidation 
performed with [9, 10 (n)-3H]-palmitate method at 5.5 mM glucose had very similar rates 
to those found in this thesis (1.8 nmol palmitate/h/mg protein (224) vs 1.6 nmol 
palmitate/h/mg protein in this thesis).  
Although fatty acids have been considered a minor nutritional source for placental 
metabolism (207), trophoblasts utilised a considerable amount of palmitate for energy 
production in this research. Since the oxidation of a 16-carbon palmitate molecule yields 
108 ATP and a 6-carbon glucose only 32 ATP, trophoblasts are obtaining about 47% of 
oxidative energy from palmitate and 53% from glucose at 5 mM media glucose 
concentration; and about 30% of oxidative energy from palmitate and 70% from glucose 
at 25 mM media glucose concentration according to the current study. Hence, this 
suggests that fatty acid metabolism is an important energy source for the placenta. Indeed, 
the placenta expresses a range of enzymes that participate in fatty acid oxidation (290, 
291) particularly within syncytio- and cytotrophoblasts. Some of these enzymes such as 
CPT-2 and VLCAD have even exhibited higher activity in the placenta than the liver 
(290). The finding of this research that fatty acids are a valuable nutritional source to 
trophoblasts would fit well with the known increased availability of NEFA in the maternal 
circulation from the second trimester of pregnancy, directly from adipose tissue lipolysis, 
but also from the increased circulating TG supply that can be hydrolysed by placental 
lipases (EL and LPL). A capacity for the placenta to be able to use NEFA for energy also 
makes sense owing to the many energy dependent processes the placenta is implicated. 
The placenta has to grow and develop rapidly. It is also responsible for the active transport 
of many substances to and from the fetus and it is very actively involved in the production 
and secretion of hormones, cytokines and adipokines, all of which demand high energy.   
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The rate of acid soluble product (ketone bodies, short-chain fatty acids and TCA cycle 
intermediates) production in trophoblast cultures did not change in the presence of the 5 
mM compared to 25 mM glucose media concentration in this research. Of particular 
interest, however, is the finding that the acid soluble product accumulation from palmitate 
carbons was 2.5 times higher than CO2 at 5 mM glucose, and 4.2 times higher at 25 mM. 
Unknown, is the percentage of ketone bodies in the acid soluble products compared to 
other metabolites such as acetate. Interesting, neonatal as opposed to adult pig 
hepatocytes are less able to produce ketone bodies and produce considerable quantities 
of acetate (292). Ketone bodies are synthesized from acetyl-CoA which does not enter 
the TCA cycle for further oxidation to CO2. Thus, it may be that acetyl-CoA is being 
redirected to ketone bodies formation in the trophoblasts (refer to Chapter 1 for all 
reactions). These results suggest that trophoblast capacity to completely oxidise long-
chain fatty acids is limited and that in the presence of fatty acids, the cells can shift NEFA 
from TCA cycle to acid soluble products which could be ketone bodies or other 
molecules. Of note, the expression of enzymes implicated in ketone body production by 
the placenta has been minimally investigated. On the other hand, it has been reported that 
the placenta contains enzymes implicated in ketone body metabolism such as β-
hydroxybutyrate dehydrogenase, succinyl-CoA transferase and acetoacetyl-CoA thiolase 
(293). Furthermore, placental oxidation of β-hydroxybutyrate to CO2, at least in rats, 
seems to be higher than oxidation in fetal brain or liver (294). Considering the substantial 
production of acid soluble products from human trophoblasts in this study, further 
investigation of fatty acid oxidation to products other than CO2 are potentially very 
important.  
4.9.1.4 Glycogen  
Data from this research have shown that the human trophoblast can synthesize glycogen 
and the flux into this pathway is directly correlated with the available glucose in the media 
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in the absence of insulin. Recent research confirmed that cytotrophoblasts contain high 
levels of glycogen throughout pregnancy and that they express glycogen synthase and 
phosphorylase enzymes, which catalyse glycogen synthesis and breakdown, respectively 
(295). Also, it has been reported that term placenta trophoblasts express glycogenin, a 
protein essential to initiate glycogen synthesis (178). Besides, the results of this thesis are 
in agreement with earlier studies that have shown that the main regulating factor for 
placental glycogen formation is the available glucose levels and that placental glycogen 
is not highly regulated by insulin. In rats, placental glycogen was higher in diabetic 
mothers and was related to glucose and glucose 6-phosphate availability (296). Also, 
glycogen storage was independent of insulin regulation (297). In accordance to the 
findings of this study, abundant intracellular glycogen lakes were observed through 
transmission electron microscopy in primary human trophoblasts cultured for 24 h at 10 
mM glucose concentration in the absence of insulin, whilst, no glycogen lakes were found 
when cells were cultured at 1 mM glucose for the same period (200). These results show 
that trophoblasts can store glucose as glycogen solely stimulated by high glucose 
concentration in the media (200). Indeed, there is evidence that glycogen synthase can be 
indirectly activated by high glucose levels as well as by glucose 6-phosphate (296). In 
addition, glucose can inhibit glycogen phosphorylase, thus contributing to glycogen 
storage by inhibiting glycogen breakdown (296). 
In perfused placentas, placental glucose storage increased from 0-70% when maternal 
glucose levels rose from 4 to 53 mM (165). Although placental glycogen was not 
measured in that study, this dramatic glucose retention by the placenta suggests that 
glycogenesis may have increased (165). Another research study demonstrated that 
glycogen measured in placentas from T1DM mothers was increased and associated with 
a higher maternal-to-fetal glucose ratio in comparison with healthy mothers (209). 
Conversely, placental glycogen in women with GDM on insulin was not higher than that 
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of the control group, despite a maternal-to-fetal glucose ratio 40% higher than the control 
groups (209).  
In the current research, total glycogen content measured with an enzymatic colorimetric 
assay increased minimally with rising media glucose concentration and this was not 
affected by the presence of NEFA. The difference between methods is that the metabolic 
tracer method only assesses newly formed glycogen less the newly formed glycogen that 
is catabolised within the 2 h incubation; whereas, the total glycogen content method takes 
into account the glycogen present at baseline and the total glycogen breakdown in the 2 
h period. This total glycogen content results of this thesis are similar to the study of 
Schmon et al.(210), in which primary human trophoblasts cultured for 1 to 4 days after 
isolation did not change total glycogen content at 5.5, 17 or 28 mM glucose concentration, 
regardless of the presence of insulin (210). Interestingly, in this study glycogen content 
significantly increased for 2 h after changing the media. Also, the cells presented 50% 
higher glycogen content from 2 to 5 h after fresh media was added compared to that at 
the time of the change (210). Unknown from the study of Schmon et al. is the change in 
glycogen of the trophoblasts that may have been seen if the cells were incubated in 
glucose concentrations lower than 5.5 mM, as glycogen lakes observed using electron 
microscopy in another study were clearly reduced with incubation at 1 mM glucose (200). 
Comparing glycogen content (expressed as µg of glycogen/mg protein) measured in 
isolated trophoblasts cultured at 5 mM glucose in our study (45.7 ± 11.5) was lower than 
that from Hahn et al. (87.4 ± 16.4 µg/mg protein) (178), but higher than the results 
reported by Schmon et al. (17.7 ± 3.2 µg/mg protein) (210).  
The discrepancies between acute glucose flux into glycogen and total glycogen content 
in response to increasing media glucose concentration add weight to the controversies 
about placental glycogen metabolism. Considering that total glycogen did not increase in 
trophoblast cultures at high glucose concentrations and was not responsive to insulin 
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(210), together with the finding that the greatest glycogen deposition in term placentas 
from mothers with well-controlled overt diabetes was found in fetal capillaries 
(endothelial cells and pericytes) (208), some authors have argued that placental cells other 
than trophoblasts are more responsible for glycogen accumulation in diabetic placentas. 
Moreover, factors other than maternal insulin and glucose may be responsible for 
glycogen accumulation in the placenta, including the possibility of fetal insulin (210). 
The report that the highest expression of glycogenin is in endothelial cells from term 
placentas supports this hypothesis (178). Nevertheless, experiments in rats with fetal 
insulin deficiency induced through intra-fetal streptozotocin administration refute this 
hypothesis. Placental glycogen was higher in diabetic pregnant rats than pregnant healthy 
rats independently of fetal hypoinsulinaemia or intra-fetal insulin administration (297). 
The activities of glycogen synthase, glycogen phosphorylase and the glycogen 
distribution in the placenta were also unchanged by induction of hypoinsulinaemic fetuses 
from both diabetic and control dams (297). However, fetal hypoinsulinaemia reduced 
fetal weight, hepatic size and glycogen content, which were restored by intra-fetal 
administration (297). Therefore, further studies are required to clarify the regulation of 
glycogen synthesis in the placenta.   
4.9.2 NEFA effects on glucose metabolism pathways in primary human 
trophoblast cultures 
Interactions between fatty acid and glucose metabolism have long been described in 
muscle and adipose tissue with particular regard to insulin resistance in T2DM (211). 
According to the Randle cycle hypothesis, glucose and fatty acid compete for their 
oxidation in muscle and the utilisation of one nutrient directly inhibits the use of the other. 
Fatty acids can affect glucose metabolism by decreasing glucose transport and hexokinase 
function, supressing phosphofructokinase-1 (a regulatory enzyme of glycolysis-refer to 
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Chapter 1) activity, and inhibiting pyruvate dehydrogenase, which catalyses the 
conversion of pyruvate into acetyl-CoA to be oxidised in the TCA cycle (212).  
In this research, however, NEFA did not affect most glucose metabolism pathways. The 
absence of effects on glucose metabolism in trophoblasts observed in this thesis may be 
due to many factors: (i) NEFA concentration used during experiments (0.25 mM) could 
be too low to affect trophoblast metabolism, as is discussed in more details below; (ii) 
cells were exposed to NEFA for too short a period (2 h incubations) to observe NEFA 
effects, as longer exposure may be required to change gene and protein expression to 
affect glucose metabolism; (iii) it may be a consequence of the marked differences 
between glucose metabolism in trophoblasts and other cell types in which glucose 
metabolism has been shown to be affected by NEFA (e.g. myocytes and pancreatic β 
cells) such as the lack of insulin responsivity in trophoblasts and their abundant 
expression of GLUT1 and 3 (both insulin non-responsive), but not GLUT4 (191); (iv) it 
could be a consequence of the specific NEFA mixture used in this research, with the 
possibility that the palmitate and oleate mix used here may have quite different effects on 
glucose metabolism compared to a much more physiological NEFA mix; (v) the absence 
of L-carnitine during glucose metabolism experiments, as this could limit NEFA transport 
and oxidation into the mitochondria not allowing the catabolism of NEFA into oxidation 
products that could be important in mediating the effects of NEFA on glucose metabolism 
pathways, notably on glucose oxidation.  
Palmitate and oleate were the selected NEFA in the current research because they are the 
commonest circulating NEFA (298) and the concentration of 0.25 mM was chosen 
because it represents a high physiological NEFA level in which toxicity would not be 
expected. The incubations were performed in 2 h to observe the acute effects on glucose 
metabolism since the placenta alters its metabolism almost immediately in response to 
changes in glucose supply (299).  
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Most literature regarding lipid effects on glucose transport and metabolism is based on 
glucose and NEFA interactions in insulin sensitive tissues such as skeletal muscle and 
adipocytes. The results emphasise the effects of saturated fatty acids in causing insulin 
resistance and mono and/or PUFAs having “protective” roles. To understand how 
different fatty acid types and doses, as well as the period of incubation in the presence of 
NEFA, may affect glucose metabolism in trophoblasts, studies performed in other tissues, 
in particular muscle, but also liver and adipose tissue, are discussed here.  
In the current studies glucose uptake was not affected in the presence of 0.25 mM NEFA. 
Nonetheless, there are descriptions in other tissues of increase, decrease or maintenance 
of glucose uptake in the presence of oleate depending on its dose and insulin addition. 
Most studies only found significant palmitate effects on glucose uptake when it was at 
high concentration, for more than 4 h incubations or after insulin stimulation. A dose and 
time-response curve in rat muscle showed that exposure to palmitoleate, a 
monounsaturated (n - 7) fatty acid, increased total glucose uptake measured through 2-
deoxyglucose uptake from concentrations ≥ 0.25 mM with the maximum effect at 0.75 
mM (300). This effect on total glucose uptake was observed only from 4 h of incubation 
with the maximum effect of 2.4-fold increase in total glucose uptake having been 
observed after 16 h (300). Incubations with oleate at 0.75 mM for 16 h also increased 
glucose uptake, however, exposure to palmitate at the same dose and duration neither 
affected glucose uptake alone or the rise promoted by palmitoleate (300). Nevertheless, 
pre-incubation with palmitate 0.75 mM inhibited total glucose uptake stimulated by 
insulin (300). Basal glucose uptake induced by palmitatoleate was not due to increased 
protein synthesis, but due to recruitment of GLUT1 and GLUT4 to the plasma membrane. 
Moreover, dissimilar to insulin action, which is fast and occurs in minutes, palmitoleate 
had a slow and sustained response (300). It is possible, therefore, that trophoblasts may 
have affected total glucose uptake and metabolism if exposed to NEFA at higher 
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concentrations or for longer time, even though trophoblast cells are not highly responsive 
to insulin as are muscle cells. Pre-incubation of human muscle cells with 0.6 mM oleate 
for 24 h had neither an effect on basal nor an effect on insulin-stimulated glucose uptake 
(301). On the other hand, incubations for 24 h with 0.6 mM eicosapentaenoic acid (EPA), 
a polyunsaturated (n-3) fatty acid, increased basal glucose uptake by 2.4-fold, which was 
further increased by insulin (301). In addition to a glucose uptake increment, the exposure 
to 0.6 mM EPA for 24 h led to an increase in GLUT1 mRNA expression of 2.5-fold, but 
no increase in GLUT4 mRNA (301). Thus, as EPA is an important dietary fatty acid 
during pregnancy, especially to the fetus nervous system tissue (302), it would be 
interesting to include this NEFA when addressing trophoblast metabolism. A study with 
3T3-L1 adipocytes, a cell line, demonstrated that basal and insulin-stimulated glucose 
uptake rates were not affected after 4 h incubation with a high dose of palmitate (0.8 mM) 
(303). Moreover, a study with rat muscle strips reported that basal and insulin-mediated 
glucose uptake and phosphorylation (measured by the labelled 2-deoxyglucose method) 
was significantly reduced in cultures exposed to 2 mM palmitate only in incubations 
longer than 4 h (304). Conversely, insulin-mediated glucose uptake was not affected by 
a lower palmitate concentration (1 mM) in muscle strips incubated for the same duration 
(304). Interestingly, muscle strips also had reduced insulin-stimulated glucose uptake 
following 4 h incubation with 1 mM of oleate, but only at a high insulin concentrations 
(304).  
Unlike previous published research in other organs and tissues, we did not find a 
significant effect of NEFA on glycolysis and lactate production in human trophoblast 
cultures. In renal proximal tubular cell cultures, palmitate (at 0.4 mM concentration for 
24 h incubation) reduced both glycolysis and lactate release by 38% only when L-
carnitine was added (305). On the other hand, palmitate at the same concentration for 96 
h induced a significant decrease in glycolysis and lactate even without L-carnitine (305). 
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The decrease in glycolysis occurred in parallel with a similar reduction in total glucose 
uptake at both basolateral and apical cellular surfaces at 24 h, and the reduction at 96 h 
(without L-carnitine) was accompanied by a decrease in glucose uptake only from the 
basolateral surface (305). Hence, it is possible in the previous results in renal tubules that 
the shorter term (24 h) reduction in glycolysis and lactate production was due to a decline 
in the availability of glucose substrate in the presence of palmitate and L-carnitine; whilst, 
after 96 h other changes, such as inhibition of the expression of glycolytic enzymes, may 
have contributed to a reduction in the glycolysis rate (305). In rat hepatocytes incubated 
at 15 mM glucose concentration with insulin to mimic the post-prandial liver 
environment, exposure to palmitate or oleate (at 50 and 150 μM for at least 24 h) neither 
altered glycolysis measured by tritiated water production from [6-3H]-glucose nor the 
accumulation of lactate and pyruvate (306). As discussed previously, products of lipid 
oxidation can affect glycolysis through inhibition of phosphofructokinase and pyruvate 
dehydrogenase. In accordance with our data, in rat placental slices glucose metabolism, 
including measures of total glucose uptake, as well as lactate and CO2 formation, were 
not changed when incubated in the presence of 0.8 mM oleate for 1 h (207). In contrast, 
glycogen synthesis was increased by 0.8% (207). Also, the addition of citrate to placental 
cultures, a strong inhibitor of phosphofructokinase in muscle, did not inhibit total glucose 
uptake, lactate formation, glycogen synthesis or glucose oxidation (207). 
Glucose oxidation can be inhibited in the presence of fatty acids, as has been shown in 
muscles (307). In the presence of lipids, fatty acid oxidation is promoted which leads to 
pyruvate dehydrogenase suppression in the mitochondria and, consequently, reduction of 
glucose oxidation (307). In the present research, however, glucose oxidation was affected 
by NEFA only at low glucose concentrations. Otherwise, NEFA had minimal effect on 
glucose oxidation, most likely owing to the reasons discussed above.   
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In the current study, NEFA increased the glucose flux into glycogen. In vivo, conditions 
such as prolonged physical exercise or poorly controlled diabetes can increase circulating 
NEFA and ketone bodies. NEFA concentrations are also increased after meals rich in fat 
(212). Consequently, glucose is not utilised for oxidation in these conditions and, at least 
in the heart, can be shifted to glycogenesis (212). Thus, it is possible that the first glucose 
metabolic pathways affected by NEFA in trophoblasts relate to glycogen storage 
(glycogenesis and possibly glycogenolysis), as the net rate of glycogen synthesis in the 
current studies, within 2 h incubations, was greater in the presence of fatty acids. Perhaps 
other pathways would be affected if the cells were incubated at the same NEFA 
concentration for longer periods. There are descriptions of both inhibition or stimulation 
of glycogen synthesis in the presence of NEFA in other tissues. In rat skeletal muscle 
cells, palmitoleate induced glucose flux into glycogen (300). This stimulation of glycogen 
influx, however, was less potent than that caused by insulin and did not seem to occur 
through the same classic molecular mechanism activated by insulin, i.e. phosphorylation 
of glycogen synthase kinase 3 and dephosphorylation of glycogen synthase (300). 
Conversely, in rat muscle palmitate decreased insulin-stimulated glycogen synthesis by 
51%, with near maximum effect after 2 h at a 2 mM concentration or after 4 h at a 1 mM 
concentration (304). Interestingly, palmitate affected glycogen synthesis before inhibiting 
basal or insulin-stimulated glucose uptake (304). Oleate (at 1 mM concentration for 4 h) 
also decreased glycogen synthesis but only when cultures were in the presence of ≥ 300 
μIU insulin/ml (304). Similarly, oleate (at 0.6 mM for 24 h) did not affect glycogen 
synthesis in human skeletal muscle cell cultures in the presence or absence of 100 nM 
insulin (17 μIU/ml) (301).  
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4.10 Limitations in the methods for the assessment of glucose 
metabolism  
The main limitation in the interpretation of the results of this thesis chapter are the 
discrepancies between the absolute values of glucose metabolism in the various pathways 
using the different methods. This was particularly evident when comparing total glucose 
uptake with glycolysis rates. At the 1 mM media glucose concentration, glycolysis was 
between 2.7 (plus NEFA) and 3.7-fold (no NEFA) higher than total glucose uptake; at 5 
mM media glucose concentration glycolysis was 1.6-fold higher than total glucose 
uptake; and at 15 mM total glucose uptake was between 1.2 (no NEFA) and 1.4-fold (plus 
NEFA) higher than glycolysis rates. It is clear therefore that the glycolysis rate was 
disproportionally high perhaps not reflecting the real absolute fractions of glucose 
partitioning into this pathway. Hence, results from different pathways assessed in this 
research cannot be directly compared in terms of absolute results and limitations of 
tracer/tracee methodology used in this research have to be considered.   
At least in rats, 2-deoxyglucose is transferred across the placenta to the same extent as D-
glucose (308). In this thesis research with isolated trophoblasts in culture, it is assumed 
that only phosphorylated 2-deoxyglucose remains intracellularly after media removal and 
cellular washes. It is possible that the total glucose uptake curve could be underestimated 
if trophoblasts are unable to phosphorylate all the 2-deoxyglucose taken up into the 
intracellular space or the phosphorylated 2-deoxyglucose is dephosphorylated at a 
significant rate depending on the presence of glucose 6-phosphatase or other less specific 
phosphatases. This could explain why the absolute values of the total glucose uptake 
curve are lower compared to some of the other pathways studied. The method used in this 
research does not discriminate between the accumulation of free and phosphorylated 
[(U)14C]-2-deoxyglucose; thus the separation and purification of these compounds by 
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chromatography would be valuable. In isolated rat lungs perfused for 20 minutes, 
[(U)14C]-2-deoxyglucose uptake was followed by accumulation not only of 
phosphorylated [(U)14C]-2-deoxyglucose, but also of unphosphorylated [(U)14C]-2-
deoxyglucose, which was significantly higher than that of phosphorylated [(U)14C]-2-
deoxyglucose. (309). Unphosphorylated [(U)14C]-2-deoxyglucose presented a kinetic 
curve similar to the total [(U)14C]-2-deoxyglucose uptake curve (calculated as the sum of 
intracellular phosphorylated and unphosphorylated [(U)14C]-2-deoxyglucose) (309). In 
that research, intracellular accumulation of unphosphorylated [(U)14C]-2-deoxyglucose 
The authors of that paper (309) argued that in rat lungs [(U)14C]-2-deoxyglucose 
intracellular transport may be higher than its phosphorylation owing to inhibition of 
hexokinase activity by a decrease in ATP levels in the tissue or by a [(U)14C]-2-
deoxyglucose 6-phosphate negative feed-back (309). Alternatively, the presence of 
enzymes with non-specific phosphatase activity in the lungs allows for the conversion of 
[(U)14C]-2-deoxyglucose 6-phosphate into free [(U)14C]-2-deoxyglucose (309). Total 
glucose uptake estimation by the [(U)14C]-2-deoxyglucose method has been extensively 
studied in the brain. A study with rats showed that the rate of total glucose uptake in the 
brain using [(U)14C]-2-deoxyglucose measures the rate of the hexokinase reaction, but 
not total glucose utilisation (310). In the brain, the rate constant for labelled 2-
deoxyglucose phosphorylation was about 10%/minute, whereas the rate constant for 
dephosphorylation was about 3%/minute (310). In addition, the kinetics of D-glucose and 
2-deoxyglucose were dissimilar (e.g. 2-deoxyglucose transport is 40% faster than D-
glucose) and phosphorylation rates of each molecule can vary at extreme glucose 
conditions in the brain (310). Under low blood glucose arterial levels, transport through 
the blood-brain barrier would be optimised and higher than 2-deoxyglucose 
phosphorylation (310). In the presence of hyperglycaemia, glucose or 2-deoxyglucose 
proportional uptake would be limited by the blood-brain barrier to a greater extent than 
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hexose phosphorylation (311). Furthermore, glucose and 2-deoxyglucose metabolism 
was not found to be the same in different regions of the brain (312). Nonetheless, it may 
not be appropriate to extrapolate data derived from research in the brain, an organ highly 
complex, to much simpler cells such as cytotrophoblasts. Another hypothesis to explain 
the underestimation of glucose uptake measured in the current study at lower media 
glucose concentrations is that 2-deoxyglucose 6-phosphate may be dephosphorylated by 
phosphatases in the trophoblasts. The liver and kidney contain high concentrations of the 
endoplasmic reticulum glucose 6-phosphatase catalytic subunit-1 (G6PC1), which 
promotes glucose 6-phosphate hydrolysis for glucose production from the 
gluconeogenesis and glycogenolysis pathways (313). The placenta does not express 
G6PC1, but it expresses another glucose 6-phosphatase isoform (G6PC3), which is 
particularly found in the human brain, skeletal muscle and heart (313). G6PC3 showed a 
higher predilection for 2-deoxyglucose 6-phosphate as a substrate compared to glucose 
6-phosphate (313). There are no data on specific G6PC3 expression and activity in human 
trophoblasts, since most literature has reported results from the whole placenta and not 
individual cellular groups. Thus, if there is G6PC3 expression in isolated human 
trophoblasts, the results from total glucose uptake measured in this research may be 
underestimated owing to 2-deoxyglucose 6-phosphate dephosphorylation by intracellular 
phosphatases. In addition, it is not known if the rate of dephosphorylation of 2-
deoxyglucose 6-phosphate (if present) is homogenous through all glucose concentrations 
in all placental cellular groups.   
In theory, the glycolysis tracer method used in the current research is based on 3H losses 
from [5-3H]-glucose into 3H2O mainly at the reaction catalysed by aldolase (284). In this 
reaction, fructose 1, 6-bisphosphate is cleaved into glyceraldehyde 3-phosphate and 
dihydroxyacetone-phosphate (refer to Chapter 1). If this reaction is not complete, 3H2O 
is produced at the enolase reaction, when 2-phosphoglycerate is dehydrated to 
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phosphoenolpyruvate (284). Nevertheless, results from a study which compared the 
glycolytic flux based on 3H2O synthesis from [5-3H]-glucose metabolism with net 
glycolytic flux (net release of pyruvate plus lactate) and efflux of 14C pyruvate plus 14C 
lactate from 14C labelled glucose in rat heart showed that the glycolysis rate based on the 
3H2O release from [5-3H]-glucose method was 260% higher than the other methods (314). 
In this study, the authors suggested that the non-oxidative branch of the pentose phosphate 
pathway was the major source of 3H2O via the reaction catalysed by the enzyme 
transaldolase (314), which is similar to the reaction catalysed by aldolase.  
Another hypothesis to explain the overestimation of glycolysis rates measured by the [5-
3H]-glucose method is that a futile cycling between hexose and triose phosphate was 
present. However, this would depend on fructose 1,6-bisphosphatase activity, which was 
found to be very low in the human placenta (315).  
Other potential limitations of the experiments of this chapter relate to possible osmotic 
pressure effects on cells incubated at the higher glucose concentrations, as these effects 
were not directly studied. It could be assessed using L-glucose, since the hexose transport 
system in the placenta, mainly via GLUT 1, is stereospecific for D-glucose and the rate 
of L-glucose transport in trophoblasts is only about 10% of the transport of D-glucose 
(184). However, cellular damage due to increased osmotic pressure in the media is 
unlikely to have occurred since, in some laboratories, trophoblasts are grown in regular 
DMEM that contains 25 mM glucose. In addition, no major cellular changes were 
observed during 2 h incubations at the media glucose concentration of 35 mM.  
Finally, the results of this chapter all had high variability from placenta to placenta as is 
reflected in the standard error and standard deviations. This was especially true for 
glycolysis and lactate production. Although all trophoblast isolations were performed by 
the same researcher and the donor mothers were carefully selected under strict criteria, 
biological variations among primary cultures are common and may have occurred.   
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4.11 Conclusions 
In conclusion, during acute exposure to high glucose media, human trophoblast take up 
increasing amounts of glucose that is not channelled to glycolytic and oxidative pathways. 
Conversely, glucose flux is diverted to non-oxidative metabolic pathways i.e. glycogen 
synthesis and perhaps the non-oxidative pentose phosphate pathway. In addition, glucose 
metabolism in human trophoblasts does not seem highly sensitive to NEFA action as 
demonstrated in other tissues.   
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Chapter 5 
 
 
Results for metabolism and morphology 
studies in long-term primary trophoblast 
cultures 
5. Results for metabolism and morphology studies in 
long-term primary human trophoblast   
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5.1 Metabolism studies 
5.1.1 Introduction 
The results of metabolism studies in primary human trophoblast short-term cultures were 
presented in Chapter 4. Since at this cellular differentiation stage (36 h) most cells were 
cytotrophoblasts, a new set of experiments were performed in primary human 
trophoblasts on day 5 of culture with complete DMEM supplemented with EGF (10 
ng/ml) to induce syncytialisation (Figure 5.1). The rationale of these studies was to 
observe possible differences regarding glucose metabolism in a group of more 
differentiated cells with greater syncytialisation. Hence, key glucose and palmitate 
metabolism experiments were selected to be performed at physiological (5 mM) and high 
(25 mM) glucose concentrations in the presence or absence of NEFA (0.25 mM, 
palmitate: oleate ratio; 1:1). Only for glycolysis assessment, experiments at 1 mM media 
glucose concentration were also included to enable the analysis of a rate curve.   
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Figure 5.1. Experimental design scheme for metabolism studies in long-term 
primary human trophoblast cultures. Human placental villous tissue was harvested 
(day -1) and trophoblasts were isolated and seeded on the following day (day 0). Human 
trophoblast were established in culture over 5 days post isolation in complete DMEM 
(refer to Chapter 2 and Appendix 1 for culture details) at 5.5 mM glucose concentration 
supplemented with EGF (10 ng/ml) to induce syncytialisation. Long-term culture 
metabolism experiments were performed on day 5 after isolation when many cells are 
aggregated and fused into syncytiotrophoblasts, as was demonstrated in the results of 
Chapter 2.  
DMEM: Dulbecco's Modified Eagle Medium; EGF: epidermal growth factor.  
Day -1
DMEM plus EGF 
Placenta 
Harvesting
Trophoblast 
isolation 
Day 0
+ EGF
Day 1 Day 2
+ EGF
Day 5
+ EGF
Day 4 Day 3 
+ EGF + EGF
Metabolism 
Experiments
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5.1.2 Results 
5.1.2.1 Total glucose uptake 
In primary human trophoblasts cultures established over 5 days post isolation in complete 
DMEM supplemented with EGF, the rate of glucose uptake as measured by the 14C 
labelled 2-deoxyglucose 6-phosphate method during 2 h incubations, as previously 
described (Chapter 3), significantly increased with an increase in the media glucose 
concentration from 5 to 25 mM. Total glucose uptake in long-term trophoblast cultures 
was further increased in the presence of NEFA (Figure 5.2). The linear correlation 
between total glucose uptake and available glucose in the media was moderate in the 
absence of NEFA (r2=0.58, p=0.027) and strong in the presence of NEFA (r2=0.80, 
p=0.003). 
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Figure 5.2. Total glucose uptake by trophoblasts in long-term cultures increased 
with rising media glucose concentration and was higher in the presence of NEFA. 
Total glucose uptake in trophoblasts established in culture in the presence of EGF (10 
ng/ml) over 5 days, as measured by the 14C labelled 2-deoxyglucose 6-phosphate method 
during 2 h incubations (refer to Chapter 3), increased with an increase of the media cold 
glucose concentration from 5 to 25 mM. Total glucose uptake was further increased at 
the media glucose concentration of 25 mM glucose in the presence of 0.25 mM NEFA. 
Two-way ANOVA: NEFA effect p=0.049; glucose effect p=0.013, NEFA-glucose 
interaction p=0.038. Bonferroni post-hoc test: *25 mM glucose (no NEFA) vs 25 mM 
glucose (plus NEFA) p=0.022. Data are means ± SEM of 4 independent experiments in 
which each point was the average of triplicate wells. 
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5.1.2.2 Glycolysis  
The rate of glucose utilisation via glycolysis by primary human trophoblasts cultures 
established over 5 days post isolation in the presence of EGF was measured by the [5-
3H]-glucose tracer method as described in Chapter 3. The glycolysis rate showed an 
increase with increasing media glucose concentrations according to the glucose main 
effect using ANOVA (Figure 5.3). However, with post-hoc testing, a significant increase 
in glycolysis rate was only demonstrated when the media glucose concentration was 
increased from 1 to 25 mM in the presence of NEFA. NEFA did not affect glycolysis in 
these experiments (Figure 5.3). 
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Figure 5.3. Glucose utilisation via the glycolysis pathway in long-term human 
trophoblast cultures increased with increasing glucose concentrations in the media. 
Glycolysis rate over 2 h was measured in trophoblasts cultured for 5 days in the presence 
of EGF using the [5-3H]-glucose tracer method previously described (Chapter 3). 
Glycolysis rates were higher at increased glucose concentrations in the media, as assessed 
by the glucose main effect using ANOVA. However, in post-hoc assessment, a significant 
effect was only found for an increase in the media glucose concentration from 1 to 25 
mM in the presence of NEFA. Overall, NEFA did not affect this metabolic pathway.  
Two-way ANOVA: NEFA effect ns; glucose effect p=0.006; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: 1 mM vs 25 mM (plus NEFA) p < 0.05. Data are means ± 
SEM of 3 independent experiments in which each point was the average of triplicate 
wells. 
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5.1.2.3 Glucose oxidation  
The glucose oxidation rate in primary human trophoblasts established in culture over 5 
days after isolation in the presence of EGF was assessed through [(U)14C]-glucose 
metabolism into 14C labelled CO2 as mentioned in Chapter 3. The glucose oxidation rate, 
in response to a rise in the media glucose concentration from 5 to 25 mM, increased 
according to the glucose main effect. However, in post-hoc testing this glucose effect was 
only significant for the increase found in the presence of NEFA (by 218.5%) (Figure 5.4).  
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Figure 5.4. Glucose oxidation rate in long-term human trophoblast cultures 
increased at the higher glucose concentration in the media. Glucose oxidation rates in 
human trophoblasts established in culture with EGF (10 ng/ml) over 5 days after isolation 
were measured by [(U)14C]-glucose tracer metabolism into 14C labelled CO2 method as 
explained in Chapter 3. Glucose oxidation significantly increased with a rise in the media 
glucose from 5 to 25 mM as assessed by the main glucose effect using ANOVA. 
However, in post-hoc assessment, a significant effect was only found for an increase in 
the media glucose concentration from 5 to 25 mM in the presence of NEFA. Overall, 
NEFA did not affect this metabolism pathway.   
Two-way ANOVA: NEFA effect ns; glucose effect p=0.007; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: 5 mM glucose vs 25 mM glucose (plus NEFA) p=0.006. 
Data are means ± SEM of 6 independent experiments in which each value was the average 
of duplicate or triplicate T25 flasks. 
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5.1.2.4 Palmitate oxidation and acid soluble product formation 
In primary human trophoblasts established in culture in the presence of EGF over 5 days 
post isolation, the rate of palmitate oxidation as measured during 2 h incubations by the 
[(U)14C]-palmitate tracer metabolism into 14C labelled CO2 method (Chapter 3) showed a 
trend towards reduction with an increment of the cold glucose concentration in the media 
from 5 to 25 mM (Figure 5.5). The levels of acid soluble products from palmitate 
oxidation, as assessed by the method explained in Chapter 3, were similar in the presence 
of glucose concentrations in the media of 5 and 25 mM (Figure 5.6).   
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Figure 5.5. Palmitate oxidation in long-term human trophoblast cultures showed a 
trend towards reduction in the presence of the higher level of glucose in the media. 
Palmitate oxidation in human trophoblasts established in culture with EGF (10 ng/ml) 
over 5 days post isolation and measured by [(U)14C]-palmitate tracer metabolism into 14C 
labelled CO2 method (described in Chapter 3) presented a downward trend at 25 mM 
glucose concentration in the media. Data are means ± SEM of 6 independent experiments 
in which each value was the average of duplicate or triplicate T25 flasks. 
 
 
 
 
 
 189
 
 
Figure 5.6. Acid soluble product synthesis during palmitate oxidation in long-term 
human trophoblast cultures were similar at low and high glucose concentrations in 
the media. Palmitate oxidation into acid soluble products in human trophoblasts 
established in culture with EGF over 5 days post isolation, as measured by [(U)14C]-
palmitate tracer metabolism into 14C labelled acid soluble products method described in 
Chapter 3, showed similar values at 5 or 25 mM glucose concentrations in the media. 
Data are means ± SEM of 7 independent experiments in which each value was the average 
of duplicate or triplicate T25 flasks. 
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5.1.2.5 Glycogen synthesis with tracer 
The flux of glucose into glycogen in primary human trophoblasts cultures established 
over 5 days post isolation in the presence of EGF, as measured by the [(U)14C]-glucose 
tracer method previously explained in Chapter 3, increased by 142.4% in the absence of 
NEFA and by 252.3% in the presence of NEFA with an increment in the glucose 
concentration of the media from 5 to 25 mM. Although this increase in the glycogen 
synthesis rate was significant according to main glucose effect using ANOVA, it was not 
significant using Bonferroni post-hoc testing for the effects of glucose in the absence or 
presence of NEFA. Glucose flux into glycogen was not affected by the presence of 0.25 
mM NEFA (Figure 5.7). 
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Figure 5.7. The acute glucose flux into glycogen synthesis in long-term primary 
human trophoblast cultures increased with an increase in the media glucose 
concentration. The presence of NEFA did not affect this metabolic pathway. The 
acute glucose flux into glycogen was measured in human trophoblasts established in 
culture supplemented with EGF over 5 days post isolation using the [(U)14C]-glucose 
tracer method, as previously described (Chapter 3). Glycogen synthesis rates in the 
trophoblasts were significantly higher with incubation at 25 mM compared to 5 mM 
glucose according to the main glucose effect using ANOVA. However, with Bonferroni 
post-hoc testing, the effects of glucose, either in the presence or absence of NEFA, to 
increase glycogen synthesis was not significant. NEFA had no effects on glycogen 
synthesis rates.  
Two-way ANOVA: NEFA effect ns; glucose effect p=0.017; NEFA-glucose interaction 
ns. Bonferroni post-hoc test: ns. Data are means ± SEM of 4 independent experiments in 
which each point was the average of triplicate wells. 
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5.2 Cellular morphology and triacylglycerol quantification in long-
term primary human trophoblast cultures 
5.2.1 Introduction 
Primary human trophoblasts were established in culture in complete DMEM (at 5.5 mM 
glucose concentration) in the presence or absence of EGF (10 ng/ml) for 48 h after 
isolation. The media was change on day 2 to complete DMEM in the presence or absence 
of EGF and in the presence or absence of NEFA (0.1 mM, palmitate: oleate ratio; 1:1). 
For reagents and media preparation refer to Appendix 1. On the 5th day of culture, 
trophoblasts were stained for Oil red O to observe EGF and/or NEFA effects on 
trophoblast morphological characteristics such as lipid droplet formation, cellular 
aggregation and syncytialisation (Figure 5.8). In addition, trophoblast intracellular TG 
content was quantified.  
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Figure 5.8. Experimental design scheme for morphology studies and TG 
quantification in long-term primary human trophoblast cultures. Human placental 
villous tissue was harvested (day -1) and trophoblasts were isolated and seeded on the 
following day (day 0). Trophoblasts were established in culture over 48 h in complete 
DMEM (at 5.5 mM glucose concentration) in the presence or absence of EGF (10 ng/ml). 
From this time point (day 2), trophoblasts were cultured in complete DMEM (at 5.5 mM 
glucose) in the presence or absence of NEFA (0.1 mM, palmitate: oleate ratio; 1:1) and 
in the presence or absence of EGF (10 ng/ml). On the 5th culture day, trophoblasts were 
stained for Oil red O and TG content was measured.  
DMEM: Dulbecco's Modified Eagle Medium. EGF: epidermal growth factor; TG: 
triacylglycerol. 
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5.2.2 Results 
5.2.2.1 Oil red O staining 
Primary human trophoblast cultures were established in chamber slides over 48 h post 
isolation in complete DMEM (5.5 mM glucose) with or without EGF (10 ng/ml). From 
day 2 to 5 of culture, trophoblasts were grown in complete DMEM (5.5 mM glucose) in 
the presence or absence of EGF) and in the presence or absence of 0.1 mM NEFA. 
Trophoblasts were then stained for Oil red O according to the method described in 
Chapter 3. Slides stained for Oil red O were analysed by 2 independent viewers and 
scored according to Table 3.6 (refer to Chapter 3). Large and small lipid droplets 
formation was not significantly different in the conditions analysed (± EGF ± NEFA) 
(Figures 5.9 and 5.10). Cellular aggregation and syncytialisation increased in the presence 
of EGF in comparison with cultures in the absence of EGF. In cultures in the absence of 
EGF, the addition of NEFA did not change cellular aggregation, but resulted in a trend 
towards syncytialisation. In the presence of EGF, NEFA caused a trend towards cellular 
aggregation, but did not affect syncytialisation (Figure 5.11).   
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A               B 
    
C               D 
 
Figure 5.9. Representative photomicrographs of long-term primary human 
trophoblasts cultured in the presence or absence of EGF and in the presence or 
absence of NEFA stained for Oil red O. Primary human trophoblasts were cultured in 
chamber slides in complete DMEM (at 5.5 mM glucose concentration) with or without 
EGF (10 ng/ml) over 48 h post isolation (refer to Chapter 3). From day 2 to 5 of culture, 
trophoblasts were grown in the presence or absence NEFA (0.1 mM) and in the presence 
or absence of EGF. On day 5, slides were stained for Oil red O (red-staining for lipid 
droplets) and counterstained with haematoxylin (blue-staining for nuclei). A. 
Photomicrography of trophoblast culture in the absence of EGF and NEFA. B. 
Photomicrography of trophoblast culture in the absence of EGF and in the presence of 
NEFA. C. Photomicrography of trophoblast culture in the presence of EGF and in the 
absence of NEFA. D. Photomicrography of trophoblast culture in the presence of EGF 
and NEFA. Lipid droplet accumulation (small and large globules) was observed in all 
conditions (A-D).
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Figure 5.10. Lipid droplet formation was similar in long-term primary human trophoblast cultures stained for Oil red O in the 
presence or absence of NEFA and was not affected by EGF. Primary human trophoblast cultures were established in chamber slides over 
48 h post isolation in complete DMEM (5.5 mM glucose) with or without EGF (10 ng/ml). From day 2 to 5 of culture, trophoblasts were 
cultured in complete DMEM (5.5 mM glucose) with or without 10 ng/ml of EGF in the presence or absence of 0.1 mM NEFA. On day 5 of 
culture, trophoblasts were stained for Oil red O according to the method described in Chapter 3. Slides stained for Oil red O were analysed by 
2 independent viewers and scored for lipid droplet formation as described in Chapter 3 (Table 3.6). Lipid droplets were divided into small and 
large size. The accumulation of lipid droplets was similar for all 4 conditions studied for both small and large lipid droplets.  
Data are the absolute number of photomicrographs scored in each category of 4 independent experiments in duplicates.  
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Figure 5.11. Long-term primary human trophoblast cultures stained for Oil red O showed increased syncytialisation in the presence 
of EGF, with less evident effects of NEFA. Primary human trophoblasts were cultured in chamber slides in complete DMEM (at 5.5 mM 
glucose concentration) with or without EGF (10 ng/ml) over 2 days post isolation. From day 2 to 5 of culture, trophoblasts were grown in the 
presence or absence NEFA (0.1 mM), and in the presence or absence of EGF. On day 5, slides were stained for Oil red O. A. EGF increased 
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cellular aggregation. B. In the absence of EGF, NEFA had no effect on cellular aggregation. C. In the presence of EGF, NEFA showed a trend 
towards increasing cellular aggregation. D. EGF induced syncytialisation. E. In the absence of EGF, NEFA showed a trend towards an increase 
of syncytialisation. F. In the presence of EGF, NEFA did not affect syncytialisation.   
A. Chi-square for cellular aggregation (EGF effect) p=0.0002. B. Fisher's exact test for syncytia (EGF effect) p=0.0003. Data are the absolute 
number of photomicrographs scored in each category of 4 independent experiments in which at least 2 chambers with the same condition were 
scored.  
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5.2.2.2 Triacylglycerol quantification 
Primary human trophoblast cultures were established in 6 well plates over 48 h post 
isolation in complete DMEM (5.5 mM glucose) in the presence or absence of EGF (10 
ng/ml). For a further 3 days, trophoblasts were cultured in complete DMEM (5.5 mM 
glucose) with or without EGF in the presence or absence of NEFA (0.1 mM, palmitate: 
oleate ratio; 1:1). Trophoblasts were then collected and TG content of cells was analysed 
through an enzymatic colorimetric method as described in Chapter 3 to quantitatively 
assess the piece of information about lipid droplet formation obtained with Oil red O. TG 
content as measured by this method was similar in all conditions (Figure 5.12). 
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Figure 5.12. TG content was similar in long-term primary human trophoblasts in 
the presence or absence of EGF and in the presence or absence of NEFA. Primary 
human trophoblast cultures were established over 48 h post isolation in complete DMEM 
(5.5 mM glucose) with or without EGF (10 ng/ml). For a further 3 days, trophoblasts were 
cultured in complete DMEM (at 5.5 mM glucose) with or without EGF in the presence 
or absence of 0.1 mM NEFA. TG content of cells was quantified using the enzymatic 
colorimetric method as described in Chapter 3. There were no differences in the TG 
content between the conditions. Data are means ± SEM of 4 independent experiments in 
which each value was the average of triplicate wells.   
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5.3 Discussion 
The main aim of the experiments performed in these longer-term primary human 
trophoblast cultures (5 days from the isolation day) was to investigate the glucose 
metabolism pathways following syncytialisation induced by EGF. The pathways analysed 
were similar to those of the short-term experiments (Chapter 4). In the majority of 
experiments, glucose metabolism was assessed at media glucose concentrations of 5 and 
25 mM in 2 h incubations (except for glycolysis experiments in which 1 mM glucose 
concentration was also included). In addition, and as was performed in the short-term 
culture experiments, the acute effects of 0.25 mM NEFA (palmitate and oleate) on 
glucose metabolism was also studied.  
Human trophoblasts established in culture over 5 days post isolation had higher glucose 
uptake rates at media glucose concentrations of 25 mM compared to 5 mM using the 
labelled 2-deoxyglucose metabolism method. Unexpectedly, total glucose uptake was 
significantly increased in the presence of NEFA. Glycolysis rates, assessed by [5-3H]-
glucose metabolism method, showed an increase with rising media glucose 
concentrations, but this was significant in post-hoc testing only for an increase in the 
media glucose concentration from 1 to 25 mM in the presence of NEFA. Similarly, 
glucose oxidation studied by the [(U)-14C]-glucose metabolism method increased with an 
increment in the media glucose concentration from 5 to 25 mM, which again in post-hoc 
testing was only significant in the presence of NEFA. Palmitate oxidation measured by 
the [(U)-14C]-palmitate metabolism method demonstrated a trend of reduction at 25 mM 
media glucose concentration, whilst acid soluble product formation assessed in the same 
experiments was not affected by glucose. Glucose flux into glycogen, measured by [(U)-
14C]-glucose accumulation as labelled glycogen method, increased with changes in the 
media glucose concentration from 5 to 25 mM according to ANOVA. However, non-
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significant increases were seen for a glucose effect in the presence or absence of NEFA, 
when analysed with Bonferroni post-hoc testing. Of note, a limitation in post-hoc testing 
was the number of experiments. Overall, in the presence of high available glucose levels 
trophoblasts in long-term cultures showed increased total glucose uptake, glycolysis, 
glucose oxidation and glycogen synthesis. Moreover, NEFA did not affect most glucose 
pathways, only increasing total glucose uptake.  
5.3.1 The effects of increasing the media glucose concentration on glucose 
metabolism pathways in primary human trophoblasts in long compared to 
short-term cultures 
As for the short-term trophoblast cultures, the long-term cultures showed increased total 
glucose uptake when in the presence of greater media glucose concentrations. However, 
NEFA stimulated glucose uptake in long-term cultures and did not affect this pathway in 
short-term cultures. The reasons and mechanism by which NEFA stimulated glucose 
uptake in cultures richer in syncytiotrophoblasts are unclear. Making a parallel with the 
effects of palmitoleate on glucose uptake in rat muscle (300), as discussed in Chapter 4, 
oleate might lead to GLUT1 recruitment to the plasma membrane in syncytiotrophoblasts 
but not in cytotrophoblasts due to inherent differences between trophoblasts with distinct 
levels of differentiation.  
Glycolysis rates in long-term trophoblast cultures showed an increase with increasing 
media glucose concentrations only significant in the presence of NEFA. This pattern was 
similar to that observed in short-term trophoblast cultures, in which the glycolysis rate 
was near maximum at 1 mM media glucose with a minimal rise with increments of the 
media glucose concentration above 1 mM to 15 mM, also only statistically significant in 
the presence of NEFA. Nonetheless, the percentage of increase of glycolysis rates from 
the lowest to the highest media glucose concentrations were higher for long-term 
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trophoblast cultures [83.8-113.9% (long-term cultures) vs 29.4-57.1% (short-term 
cultures)].  
In the absence of NEFA, the glucose oxidation rate in long-term trophoblast cultures 
showed a non-significant increase of 48.4% when measured at the media glucose 
concentration of 25 compared to 5 mM. In the presence of NEFA, glucose oxidation by 
the more differentiated trophoblasts showed the same trend as for glycolysis, with a 
significant increase of 190.5%. Comparing the long-term to the short-term cultures, 
changes in the rates of glucose oxidation with increases in the media glucose 
concentrations from 5 to 25 mM glucose were between 1.4 and 2.1-fold higher. These 
dissimilarities between long and short-term cultures suggest that syncytiotrophoblasts and 
cytotrophoblasts may have different capabilities to metabolise glucose through glycolysis 
and oxidation. This may have implications in situations of chronic maternal 
hyperglycaemia as occurs in diabetic pregnancy. 
Rates of palmitate oxidation to CO2 in both the short and long-term trophoblast culture 
experiments trended down by about 30-33% at media glucose concentrations of 25 mM 
compared to 5 mM. However, unlike glucose oxidation, palmitate oxidation rates were 
about 2.7-fold lower in the long-term compared to the short-term trophoblast cultures. 
Palmitate metabolism into acid soluble products also was lower in the long compared to 
short-term culture experiments. These results suggest that glucose inhibits palmitate 
oxidation in a similar way in both long and short-term cultures, but lipids are utilised less 
for energy production in syncytiotrophoblasts compared to cytotrophoblasts. The only 
published study comparing the expression of enzymes involved in fatty acid oxidation in 
different placental cell types using immunostaining of placental sections suggested an 
increased quantity of MCAD, LCAD, VLCAD, SCHAD, LCHAD and LKAT in 
syncytiotrophoblasts compared to cytotrophoblasts (224). These results are at variance 
with our findings suggesting greater fatty acid oxidation capacity in cytotrophoblasts. 
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Considering that the activity of LCHAD, SCHAD, and LKAT in cultures of freshly 
isolated trophoblast from term placentas were 2 to 3 times higher than those in fresh 
placental tissue from term pregnancies (224), it is possible that increased fatty acid 
oxidation in cytotrophoblasts in culture may be a consequence of the isolation and culture 
process. Clearly though, the placenta has all the enzymes necessary for fatty acid 
oxidation and this pathway almost certainly contributes to the overall energy provisions 
for this tissue. 
Glucose flux into glycogen rates in long-term trophoblast cultures at 5 mM media glucose 
concentration were between 1.9 (in the absence of NEFA) and 3-fold (in the presence of 
NEFA) lower than in short-term cultures. At 25 mM media glucose, these rates in long-
term cultures were between 2.9 (in the absence of NEFA) and 3.6-fold (in the presence 
of NEFA) lower than in short-term cultures. These results suggest that there are major 
differences in glycogen synthesis capacity between cytotrophoblasts and 
syncytiotrophoblasts. Consistent with the results of the current thesis, glycogen content 
was about 3 times higher in cytotrophoblasts after 24 h of culture than in 
syncytiotrophoblasts after 96 h of culture in a previously reported study (316). The 
glycogen content of cytotrophoblasts peaked after 24 h of culture followed by intense 
glycogen hydrolysis without new glycogenesis prior to differentiation into 
syncytiotrophoblasts at 48 h (316). Based on the observations of their time course 
research, the authors of this paper suggested that glycogen hydrolysis is linked to 
syncytialisation. In addition, a recent study has shown that cytotrophoblasts present high 
levels of glycogen throughout pregnancy (from 6 weeks to term), in contrast with 
syncytiotrophoblasts, in which strong staining was not observed at any stage of pregnancy 
(295). Both these previous studies support the findings of the current research that 
glycogen synthesis is greater in cytotrophoblasts compared to syncytiotrophoblasts.  
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Overall, the results of our work indicate that cytotrophoblasts and sycytiotrophoblasts 
have important differences concerning glucose and lipid metabolism and how the cells 
deal with excess glucose supply. When exposed to high glucose media, 
syncytiotrophoblasts seem to utilise excess glucose for glycolysis and glucose oxidation, 
whereas cytotrophoblasts tend to divert excess glucose to glycogen synthesis. 
Furthermore, this research suggested that NEFA utilisation is less intense in 
syncytiotrophoblasts compared to cytotrophoblasts. Although not many works have 
investigated glucose and lipid metabolism in cytotrophoblast and syncytiotrophoblast 
cultures, there is other evidence that these cell groups metabolise nutrients in different 
ways. Moe et al. have suggested that the pentose phosphate pathway activity declines 
when cytotrophoblasts differentiate into syncytiotrophoblasts (148). Besides, changes in 
glucose metabolism seem to be necessary for the cellular fusion process. Bax et al. 
demonstrated that anaerobic glycolysis and glycogen hydrolysis suddenly increase while 
syncytia are being formed, with return to lower levels afterwards (316). Furthermore, 
impairment of BeWo cell line syncytialisation and differentiation induced by hypoxia 
were associated with up-regulation of glycolytic proteins (i.e. enolase and maleate 
dehydrogenase) together with up or down-regulation of proteins related to cytoskeletal 
formation, protein structure and degradation, signal transduction, oxidative stress 
regulation and cell mobility (317).  
Also, there are hints in placental diseases, such as pre-eclampsia, that alterations in 
glucose metabolism may relate to the degree of syncytialisation, placental maturity and 
syncytial knots formation. For instance, the activity of phosphofructokinase was reduced 
by 32% in placentas from intrauterine growth restricted pregnancies (including mothers 
with pre-eclampsia, essential hypertension, diabetes and no medical conditions) (318). 
On the other hand, the expression of enzymes involved in glycolysis and the TCA cycle 
were upregulated in placentas from pregnancies with idiopathic intrauterine growth 
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restriction (319). Even though the placental pathological findings and maternal smoking 
status were not reported in this research (319), smoking is considered an important cause 
of intrauterine growth restriction (320) and has been associated with defective mitosis 
and differentiation of cytotrophoblasts (321). In addition to alterations related to 
intrauterine growth restriction, glycogen content was 10 times higher in villous 
syncytiotrophoblast microvesicles prepared from placentas affected by pre-eclampsia 
compared to placentas from age matched controls (322). Along with this rise in glycogen 
content, syncytiotrophoblast microvesicles from pre-eclampsia placentas had a 16 times 
higher glycogen synthase activity and a 3 times higher glycogen phosphorylase activity 
compared to control placentas (322). Interestingly, the same alterations were observed in 
syncytiotrophoblast microvesicles prepared from hydatidiform moles (322). Thus, the 
authors statement that glycogen accumulation is a sign of cellular immaturity (322) may 
be true in the case of pre-eclampsia, a disease marked by altered villous cytotrophoblast 
differentiation (323) leading to a dysfunctional syncytiotrophoblast layer.  
Besides the metabolism studies, trophoblasts in long-term cultures were submitted to 
prolonged incubations (from day 2 to day 5 after the isolation) in the presence or absence 
of EGF and in the presence or absence of physiological levels of NEFA (0.1 mM) to 
investigate effects of both EGF and NEFA on lipid droplet formation and trophoblast 
morphology including syncytialisation. Unexpectedly, analysis of lipid droplet formation 
in cultures stained by Oil red O, a method which detects TG and cholesteryl esters (287), 
did not demonstrate differences between the various culture conditions. This suggests that 
trophoblasts in the presence of 0.1 mM NEFA did not increase TG synthesis, contrary to 
what was expected, and that lipid droplet formation was not influenced by 
syncytialisation. As Oil red O analysis only allows a qualitative analysis, total TG content 
of the cells were also performed and confirmed the results. One speculation is that the 
FBS batch used contained a significant source of NEFA. However, NEFA concentrations 
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in the FBS were tested using a NEFA colorimetric assay (described in Appendix 2) and 
were below the level of the method detection in all FBS batches. Earlier studies have 
shown increases in TG synthesis in trophoblasts and placenta explants exposed to fatty 
acids. Pathmaperuma et al. found an increase in TG synthesis in trophoblasts cultured for 
24 h following increasing the media palmitate concentrations from 0.1 to 0.4 mM (200). 
Nevertheless, no control without palmitate was included, and the basal palmitate 
concentration was 0.1 mM (200), such that it is not possible to compare those findings 
with these of the current thesis. Scifres et al. demonstrated that primary human 
trophoblasts incubated for 24 h with 0.8 mM linoleic plus 0.4 mM oleate increased TG 
esterification by about 4 times in comparison with trophoblasts incubated with vehicle 
control (230). The concentrations of the NEFA mixes used in these previous studies were 
2 (200) to 12-fold (230) greater than the concentration used in this thesis research, 
suggesting that the NEFA concentration may need to be at high physiological or supra-
physiological levels to elicit effects on human trophoblasts even in prolonged incubations 
as performed in this thesis. Another difference between the studies is the duration of 
exposure to FBS with and without NEFA, which was much longer in the current study. It 
is possible that a steady state of lipid droplets is reached in both situations at the end, 
whilst, the rate of lipid droplet formation could have been different between the culture 
conditions. 
On top of TG synthesis, morphology alterations were also analysed. In the absence of 
EGF, NEFA did not affect cellular aggregation of trophoblasts but it did lead to at least a 
trend for increased syncytialisation. Conversely, exposure to NEFA in the presence of 
EGF showed a trend of increasing cellular clumping without differences in 
syncytialisation. Previous findings have shown that incubations in the presence of 0.25 
mM palmitate plus oleate for 48 h induced cellular aggregation and syncytialisation (200). 
Hence, it is possible that more robust results would be observed in this research if higher 
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NEFA concentrations were used. Notably, results of primary trophoblasts cultured with 
other lipid classes, e.g. oxysterols, have demonstrated opposite results with reductions in 
syncytialisation (234). Therefore, despite the results of this thesis on effects of NEFA on 
lipid accumulation in trophoblasts, it is highly likely that various lipid species do have an 
important role on trophoblast structure and function.   
5.4 Limitations 
The major limitation of these experiments is that, with exception of some glucose and 
palmitate oxidation experiments, long and short-term cultures did not contain 
trophoblasts isolated from the same placenta, which preclude a direct comparison of 
results owing to possible biological variation between the placentas. The ideal would be 
that all metabolism experiments could be performed in short and long-term cultures with 
trophoblasts from the same placenta.    
Besides, syncytialisation was only analysed by cells stained in Oil red O, which is not an 
optimal stain for this purpose. E-cadherin immunofluorescence was performed in many 
experiments assessing cultures incubated from day 2 to day 5 post isolation under 
different conditions. Unfortunately, the quality of membrane staining was unsatisfactory 
for appropriate analysis. For this reason, these experiments have been excluded.    
5.5 Conclusions  
Data from this study suggest that glucose and lipid metabolism are different in human 
primary trophoblasts cultured for 36 h, when most are cytotrophoblasts, compared to 5 
days, when most are syncytiotrophoblasts. This is particularly so when media glucose 
levels are elevated. Following longer-term culture with the induction of syncytialisation, 
glycolysis rates were generally higher, particularly at higher media glucose 
concentrations; whereas, fatty acid oxidation, acid soluble product formation and glucose 
flux into glycogen were generally lower. Glucose oxidation rates were similar in the 
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trophoblasts of the short and long-term cultures. Thus, synctiotrophoblasts may have a 
greater capacity to metabolise higher levels of glucose for energy production with less 
capacity for glycogen synthesis than cytotrophoblasts. In general, NEFA did not have a 
major effect on glucose metabolism pathways in either the short or long-term trophoblast 
cultures. However, the palmitate oxidation rate was generally lower in the longer-term 
cultured cells, suggesting that syncytiotrophoblasts may rely more on glucose for energy 
than lipid. Clearly though, lipid is a source of energy substrate for both cytotrophoblasts 
and syncytiotrophoblasts. In these experiments, there was a non-significant trend for 
palmitate oxidation to CO2 to be reduced by high glucose concentrations, but palmitate 
metabolism into acid soluble products was not reduced by glucose. Of particular interest 
is the finding of relatively high amounts of palmitate being metabolised into acid soluble 
products compared to CO2, such that this pathway is of significance in trophoblasts and 
warrants further investigation. These conclusions need to be considered within the context 
of the limitations of the studies, as described above, with confirmation in future studies 
in which a time course of assessment of trophoblast metabolism through the process of 
differentiation from cytotrophoblasts to syncytiotrophoblasts is undertaken. 
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Summary of results and final conclusions 
6. Summary of results and final conclusions  
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6.1 Summary of results  
In order to understand the pathophysiology of elevated nutrient levels on placental 
function and adverse pregnancy outcomes in mothers with obesity and/or diabetes, it is 
important first to comprehend the normal physiology of placental nutrient metabolism. 
The primary aim of this thesis was to investigate the effects of high glucose and NEFA 
on the various pathways of glucose metabolism in primary human trophoblast cultures.   
• Chapter 2 demonstrated the establishment of a modified and optimised human 
trophoblast isolation protocol which was based on literature review and protocols 
from other laboratories. The harvesting technique, enzymatic digestion and 
culture conditions were the elements of the method that were most changed in the 
updated protocol. This protocol greatly increased the cell yield and trophoblast 
purity with almost no contamination with other placental cell groups. Minimal 
morphological alterations were observed in trophoblasts established in complete 
media with 10% FBS within 2 to 5 days post isolation. Significant syncytialisation 
was then noticed from the 3rd day after isolation with EGF supplementation.   
• Chapter 4 showed the results of metabolism experiments in human primary 
trophoblast short-term cultures in which the majority of cells were 
cytotrophoblasts.  
Total glucose uptake studies showed a high capacity of substrate transport without 
evidence of plateau at increasing glucose concentrations in the media from 1 to 
35 mM. There was a strong correlation between the glucose uptake rate and 
glucose levels in the media. Glycolysis, lactate release into the supernatant and 
glucose oxidation were, however, limited with a maximal rate at a media glucose 
concentration of 1-5 mM. Glucose flux into glycogen (newly formed glycogen) 
was linearly increased with rising glucose levels, whereas total glycogen content 
(glycogen previously stored plus newly synthesised glycogen minus glycogen 
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hydrolysis) had a minimal increase. There was a trend for palmitate oxidation to 
CO2 to be partially inhibited in the presence of high glucose levels. Conversely, 
the production of acid soluble products from palmitate metabolism was the same 
at physiological (5 mM) or high (25 mM) glucose concentrations. The acid soluble 
product accumulation from palmitate carbons was 2.5 times higher than CO2 at 5 
mM glucose, and 4.2 times higher at 25 mM. NEFA did not affect total glucose 
uptake, glycolysis, lactate release, glucose oxidation, nor total glycogen content. 
Glycogen synthesis, however, was further increased in the presence of NEFA.  
• Chapter 5 showed the key glucose metabolism pathway and fatty acid oxidation 
experiments performed in human trophoblasts cultured for 5 days in the presence 
of EGF in which many of the cells had differentiated into syncytiotrophoblasts. 
Overall, the activity of the pathways of glucose metabolism in these more 
differentiated trophoblasts were similar to the cytotrophoblast experiments of 
Chapter 4; nevertheless, not without some differences. The trophoblasts from the 
long-term cultures appeared to be able to increase glycolysis rates and glucose 
oxidation to some extent with increases in media glucose concentrations greater 
than 5 mM. This was not at all evident in the short-term cultured cells. Associated 
with this, there were lower overall rates of glycogen synthesis and fatty acid 
oxidation in the long-term cultured trophoblasts. In the results of this chapter, it 
was also shown that EGF significantly increased cellular aggregation and 
syncytialisation, but not lipid droplet formation as assessed by Oil red O staining. 
Using the same staining technique, NEFA (0.1 mM) also showed a trend towards 
increasing syncytialisation, but this was not evident in the presence of EGF. 
Interestingly, NEFA in these long-term experiments did not obviously increase 
lipid droplet formation. Lipid accumulation in cells was also assessed through the 
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measurement of cellular TG content, which was not different between the 
conditions (± EGF ± NEFA).  
6.2 Discussion 
Our results show that trophoblasts utilise mostly glucose for energy supply, which is well-
established in previous literature, and that fatty acids are also substantially utilised for 
oxidative processes. In addition, the results indicate that syncytiotrophoblasts may be able 
to better utilise glucose at higher glucose concentrations than cytotrophoblasts as 
demonstrated by glycolysis and glucose oxidation rates. This is a new finding that still 
needs confirmation due to limitations in the current study as discussed below. Moreover, 
at elevated glucose concentrations, cytotrophoblasts have a high capacity for glycogen 
storage which is less evident in syncytiotrophoblasts. This result is supported by studies 
that have demonstrated reductions in glycogen throughout the syncytialisation process 
(316) and higher glycogen content in cytotrophoblasts in all stages of pregnancy (295). 
The finding of little change in total glycogen content over 2 h at different glucose 
concentrations seemed to be at variance with the glycogen synthesis rate results, but was 
in agreement with a previous study (210). This most probably reflects differences in what 
the two methods were measuring, i.e. the newly formed glycogen assessed with a 
radioactive tracer and the net total cellular glycogen content quantified using an 
enzymatic colorimetric assay.  
Comparing the rates of the different glucose pathways, it was evident that glycolysis was 
significantly higher than the combination of lactate production and glucose oxidation to 
CO2 by the TCA cycle. Interestingly, there is evidence that [5-3H]-glucose metabolised 
by the pentose phosphate pathway in the heart can result in release of tritiated water and 
overestimation of glycolysis rates (314). The pentose phosphate pathway was not 
investigated in this thesis, but if it is active in the placenta, this could provide an 
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explanation for the glycolysis rates. The pentose phosphate pathway was previously 
assessed to be a minor pathway in human placental trophoblasts, but with substantial 
capacity (148). It only accounted for about 0.6% and 0.2% of the glucose metabolized by 
cells freshly isolated and cultured for 3 days, respectively (148). However, not evaluated 
were the effects of elevated glucose supply on this pathway in trophoblasts (148) The 
relevance of increased activity in fresh trophoblasts, as compared to trophoblasts 
following 3 days of culture is unknown, but it could be indicative of greater activity of 
this pathway in cytotrophoblasts compared to syncytiotrophoblasts. 
The pentose phosphate pathway is of particular importance in cell proliferation and 
growth, as it is important for RNA and DNA synthesis as well as the provision of NADPH 
to the cell. Thus, if this pathway is more active when the supply of glucose is high, as 
occurs in diabetic pregnancy, it would support increased placental growth. In diabetes, 
especially without diagnosis or treatment, placental weights are very often increased with 
greater parenchymal volume due to a larger trophoblast layer as well as 
hypervascularisation of placental villi, among other pathological alterations (324). An 
increased placental size is also observed in obesity (325).  
Increased oxidative stress has been reported in human diabetic placentas (326), but this 
is still controversial in placentas from obese mothers (327). In pregnant women with 
diabetes oxidative stress is promoted due to the combination of increased generation of 
reactive oxygen species and reduced antioxidant defences (328, 329). Vascular NADPH 
oxidase, which is expressed in human placental endothelial cells and syncytiotrophoblasts 
and is a source of reactive oxygen species (330), is activated in conditions of high 
oxidative stress, as occurs with hyperglycaemia and/or conditions causing high levels of 
pro-inflammatory cytokines (331). If increased glucose level results in enhanced pentose 
phosphate pathway activity, this would be able to replenish NADPH which would be 
depleted by high activity of this oxidase enzyme. Thereof, hyperglycaemia, via the 
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pentose phosphate pathway could support NADPH oxidase activity and reactive oxygen 
species production in the placenta.  
Previous work showed that high glucose levels minimally affect trophoblast lipid 
metabolism causing decreased trophoblast lipid droplet formation without influencing 
fatty acid oxidation, lipolysis or fatty acid esterification (200). Here the results show that 
NEFA has little effect on glucose metabolism other than a mild effect of stimulating 
glycogen synthesis in cytotrophoblasts and total glucose uptake in syncytiotrophoblasts. 
Hence, high glucose and NEFA concentrations do not seem to act in synergy in human 
trophoblasts, at least in the assessed metabolic pathways in the current and previous 
studies (200), a finding that is dissimilar to what is observed in other human tissues.  
The considerable NEFA oxidation, incomplete to acid soluble products and complete to 
CO2, by trophoblasts found in this thesis is corroborated by preceding studies which have 
demonstrated the expression of a wide range of enzymes implicated in fatty acid oxidation 
in human trophoblasts (224, 290, 291). By comparing estimates of ATP production from 
glucose metabolism (combination of anaerobic and aerobic glycolysis) with that from 
lipid metabolism (combination of fatty acid oxidation to acid soluble products and CO2) 
(Table 6.1), it is clear that NEFA metabolism has the potential to provide a significant 
proportion of the energy requirements of trophoblasts. From estimates of these current 
experiments, the proportion of ATP produced from fatty acids compared to glucose in 
syncytiotrophoblasts (19 % at 5 mM glucose) was less than for cytotrophoblasts (37% at 
5 mM glucose) (Table 6.1.). Nonetheless, it contradicts the demonstration of higher 
expression of enzymes for lipid oxidation in syncytiotrophoblasts (224). Thus, further 
studies of this new finding from this thesis are necessary to elucidate these differences.  
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Table 6.1 
Estimated ATP production for glucose and palmitate metabolism in short and long-
term primary human trophoblast cultures1 
 ATP production (nmol/h/mg protein) at 5 mM media 
glucose concentration2 
Short-term cultures Long-term cultures 
ATP from glucose 
ATP from anaerobic glycolysis3  
ATP from glucose metabolism to CO2  
Total ATP from glucose metabolism 
 
321 
197 
518 
 
369 
139 
508 
ATP from NEFA 
ATP from FA β-oxidation to ASP 
ATP from FA oxidation to CO2 
Total ATP from FA metabolism 
 
135 
175 
310 
 
79 
37 
116 
Percentage ATP  
From glucose 
From NEFA 
 
63% 
37% 
 
81% 
19% 
1Calculations from glycolysis, glucose oxidation, fatty acid oxidation to CO2 and acid 
soluble products (ASP) at 5 mM glucose in the presence of NEFA from short-term 
(Chapter 4) and long-term (Chapter 5) culture experiments. 
2ATP calculation is based on the following (149): 
Anaerobic glycolysis: 1 glucose molecule into pyruvate produces 2 ATP 
Glucose metabolism to CO2: 1 glucose molecule into CO2 produces 32 ATP 
Fatty acid (FA) β-oxidation to ASP2 (assuming the production of acetoacetate from 
palmitate): produces 33 ATP  
FA oxidation to CO2: 1 palmitate molecule into CO2 produces108 ATP 
3Anaerobic metabolism of glucose was calculated as the total glycolysis rate minus the 
rate of glucose oxidation to CO2. 
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Regardless the trophoblast culture age, palmitate oxidation in this research showed a 
downward trend in the presence of higher glucose concentration (5 vs 25 mM), which is 
in accordance with a previous study (232), but not with an earlier research performed by 
our group (200). This may be caused by methodological differences (e.g. the use of 
different tracers). The finding of no effect of glucose on fatty acid oxidation in isolated 
trophoblasts measured by [9, 10 (n)-3H]-palmitic acid (200) may be reflected by a lack of 
suppression of acid soluble product synthesis in the presence of high glucose levels as 
demonstrated in the current work. This is because the [9, 10 (n)-3H]-palmitic acid method 
cannot differentiate between metabolism to acid soluble products and CO2. 
The most novel finding of this thesis was that of the substantial accumulation of acid 
soluble products from NEFA by the trophoblasts, indicative of this being a significant 
metabolic pathway in placenta. To the best of our knowledge, no similar result has been 
published such that this warrants further investigation. A study with mitochondria isolated 
from murine muscle analysing the metabolomic profile in different palmitate 
concentrations showed that complete palmitate oxidation increased the levels of TCA 
intermediates (alpha-ketoglutaric acid, citric acid and malate), myristic acid (C14:0), 
octadecanol, inosine, β-hydroxybutyrate, lipid species (putrescine and 1-hexadecanol) 
and phthalic acid; whereas incomplete palmitate oxidation (acid soluble product 
synthesis) raised the concentrations of malate, eleidic acid, arachidonic acid, β-
hydroxybutyrate, inosine, lactic and glycosylic acids (332). In this previous study, the 
incorporation of labelled palmitate carbons were about 2 to 4-fold higher in acid soluble 
products than in CO2 (332), consistent with the findings of this thesis research in 
trophoblasts. Another finding of the murine muscle study was that, with increasing 
palmitate concentrations in the media, a linear increase in metabolism to acid soluble 
products was evident, while complete palmitate oxidation to CO2 plateaued (332). 
Metabolomic analysis has been done in maternal biofluids, cord plasma (333) and in 
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human placentas mostly with focus on preeclampia (334), congenital malformations 
(335), small for gestational age, hypoxaemia among other complications (336). Studies 
of isolated cells or placental explants under diverse lipid or glucose concentrations are 
missing. Key to the future research is careful analysis of the nature of the acid soluble 
products (e.g. ketone bodies, short chain fatty acids or TCA cycle intermediates) produced 
by NEFA catabolism in trophoblasts.  
Placental products of incomplete fatty acid oxidation such as ketone bodies could be 
utilised by the fetus, mother or the placenta itself. Hydroxybutyrate dehydrogenase 
activity, acetoacetyl-CoA thiolase and 3-oxoacid-CoA transferase activity, which are 
implicated in ketone bodies catabolism, have all been detected in early and term human 
placentas (337, 338). On top of that, it has been demonstrated that the mitochondria of 
human placenta can utilise acetoacetate at a rate of 0.8-1 nmol/min/mg protein (338). At 
least in rats, the placenta and fetal tissues such as the liver and brain, as well as the whole 
carcass, can oxidase β-hydroxybutyrate to CO2 (236, 294). However, if ketone bodies do 
form a substantial proportion of the acid soluble products produced by trophoblasts, the 
fact that they were not oxidised to CO2 is against ketone bodies oxidation being a 
substantial metabolic pathway of cytotrophoblasts and syncytiotrophoblasts. It is 
unknown to what extent acid soluble products can be utilised by other cells of the 
placenta, such as endothelial, immune or other mesenchymal cells, and by human fetal 
tissues. Besides energy production, acid soluble products may have other important 
actions in the placenta. For instance, short-chain fatty acids (e.g. acetate, propionate and 
butyrate) possess inflammatory modulation roles including inhibition of histone 
deacetylase (HDAC) and NF-kB activities, along with inhibition of cellular release of 
TNF-α and prostaglandin E2 (339). There is evidence that ketone bodies can also act as 
mediators of cellular signalling, including the suppression HDAC activity and indirect 
stimulation of histone acyltransferase activity, as well as the modulation of lipolysis and 
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cellular metabolic rates (340). Hence, placental acid soluble products may function as 
intermediates linking maternal nutrition, metabolism and inflammation, which may have 
consequences to the developing fetus. Whether the placental synthesis of acid soluble 
products is increased in pregnancies complicated by diabetes and obesity, and whether 
higher levels of these substances contribute to the pathophysiology of pregnancy 
complications are unclear. Even if a defined pathophysiological role for acid soluble 
products in pregnancy complications could not be established, they could still be used as 
biomarkers for the anticipation of adverse gestational outcomes in diabetic and obese 
gravidas (341). 
The differences between trophoblasts cultured for short or long-term need to be 
interpreted with caution since we have not done a time course study of metabolism across 
the process of syncytialisation. Thus, those studies are needed for establishing more 
robust conclusions about differences in the rates of glycolysis, lipid oxidation, glycogen 
pathways in trophoblasts with diverse levels of syncytialisation. In addition to metabolism 
studies, the investigation of relevant gene expression at mRNA and protein levels together 
with enzyme activity measurements are worthy to better understand glucose and lipid 
metabolic pathways at the molecular level.  
Our results show that trophoblasts have capacity to alter the partitioning of glucose 
metabolism through the various pathway options in the presence of excess glucose 
availability. In the short-term cultures, high media glucose stimulated glycogen synthesis 
that was further increased in the presence of NEFA. Therefore, this may be an adaptive 
mechanism that could occur in placentas from pregnancies complicated by diabetes and 
obesity. However, this extrapolation deserves prudence since the in vivo environment of 
pregnancy is much more complex than culture studies, with cross modulation between 
hormones, nutrients, cytokines and other factors between the mother and the feto-
placental unit. Moreover, these metabolic findings may be altered in trophoblasts from 
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abnormal placentas, as previous studies have demonstrated differential expression of 
enzymes involved in glycogen turn-over in GDM placentas (205). Also, a reduction in 
glucose uptake, glucose utilisation and lactate release in GDM placentas was evident in 
perfusion studies (176, 198). The same may be true for alterations in fatty acid 
metabolism in placentas from diabetic and obese pregnancies, as many studies have 
shown alterations in genes and protein expression of lipid metabolism enzymes and 
transporters, particularly when GDM is combined with obesity (205, 218, 230, 231).   
6.3 Future directions  
• Placental production of acid soluble products from fatty acid metabolism may be 
a substantial metabolic pathway in this organ. Therefore, it is important to further 
verify the presence of this pathway, as well as quantitate the chemical components 
of the acid soluble products using metabolomic approaches.   
• As the metabolism studies performed in long-term cultures were different from 
short-term cultures it would be valuable to complete the assessment of glucose 
and lipid metabolism pathways in time course studies with concomitant analysis 
of the syncytialisation.  
• Among the glucose metabolism pathways, the study of the oxidative and non-
oxidative branches of pentose phosphate pathway, is required in the short and 
long-term cultured trophoblasts at low and high glucose concentrations.  
• In the current research, the effects of high levels of glucose and NEFA on glucose 
metabolism were studied in human trophoblasts isolated from placentas donated 
by healthy mothers without obesity or diabetes. Thus, we believe that our results 
express the normal metabolism of glucose and NEFA in human trophoblasts. 
Consequently, the study of glucose and lipid metabolic pathways in trophoblasts 
isolated from placentas of pregnancies affected by diabetes and/or obesity could 
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bring beneficial information about the trophoblast role in the pathogenesis of 
gestational complications associated with diabetes and obesity.  
• To test the individual effects of saturated, monounsaturated and polyunsaturated 
NEFA, as well as other NEFA mixtures, on glucose metabolism pathways and 
morphology in trophoblasts with a dose and time-response curve would be 
worthwhile. The addition of carnitine to these experiments could be useful 
because long-chain fatty acids are unable to cross the mitochondrial membrane 
without adequate carnitine levels.    
• In addition, the study of glucose and NEFA metabolism in endothelial cells is 
needed as, together with the trophoblasts, these cells form part of the critical 
interface between the maternal and fetal hormonal and metabolic milieus.  
• A prospective study of gravidas of different BMI groups would also be valuable. 
Examining for associations between (i) maternal antenatal metabolic 
characteristics, (ii) placental development throughout pregnancy as assessed by 
ultrasound and post-delivery placental morphology and histology, (iii) trophoblast 
and endothelial cell glucose, lipid and amino acid metabolism, as well as 
metabolic gene expression, (iv) placental cytokine and adipokine production, (v) 
cord plasma nutrient levels, cytokines and adipokines, and (vi) maternal and fetal 
pregnancy outcomes, could help clarify the pathophysiological processes which 
link obesity/diabetes and adverse gestational outcomes.  
6.4 Final conclusions 
Human trophoblasts have high glucose and NEFA metabolism with adaptations to 
nutrient availability. Trophoblasts utilise a substantial amount of NEFA as fuel and 
produce a relatively large quantity of acid soluble products. Furthermore, the 
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characteristics of glucose and NEFA metabolism change according to the level of 
trophoblast differentiation from cytotrophoblast to syncytiotrophoblast.  
Since the prevalence of gestational complications associated with obesity and diabetes is 
a current major burden, the study of nutrient metabolism in the placenta is highly relevant 
and more research is needed. Understanding the underlying pathophysiological 
mechanisms of these complications may contribute to the development of future 
therapies.   
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Appendix 1: Material, reagents and solutions  
Material and reagents 
Table 1  
Reagents used in this research thesis, in alphabetic order, and their respective 
suppliers  
Reagent Supplier 
Antibiotic and antimycotic solution (100X), 
10,000 units/ml of penicillin, 10,000 µg/ml of 
streptomycin, and 25 µg/ml of amphotericin B 
Invitrogen, Mulgrave, VIC, Australia 
Calcium and magnesium free Hank’s Balanced 
Salt Solution (HBSS)  
Sigma, Castle Hill, NSW, Australia 
Calcium and magnesium free phosphate 
buffered saline (PBS)   
Sigma, Castle Hill, NSW, Australia 
CD68 antibody clone KP1  DakoCytomation, Campbellfield, VIC, 
Australia 
Cell conditioning 1 (CC1) reagent buffer  
pH 8-8.5 
Ventana/Roche, Castle Hill, NSW, 
Australia 
Cell lifter polyethylene Corning, New York, NY, USA 
Cell scraper  TPP, Trasadingen, Schaffhausen, 
Switzerland 
Cell strainers, nylon mesh, 100 µm Falcon BD Bioscience, Durham, NC, 
USA 
Cheese cloth Fisher Scientific, Scoresby, VIC, 
Australia 
Connaught Medical Research Laboratories 
(CMRL) medium 1066, without L-glutamine 
Sigma, Castle Hill, NSW, Australia 
Cytokeratin antibody monoclonal-clone 
AE1/AE3  
DakoCytomation, Campbellfield, VIC, 
Australia 
Dade thrombin reagent 100 NIH unit/ml Siemens Health Care, Marburg, Hesse, 
Germany 
Dispase II, 5,000 caseinolytic units/100 ml 
bottle 
BD Biosciences, Bedford, MA, USA 
DNase 1 Type IV, from bovine pancreas,  
≥ 2,000 KU/mg protein  
(for trophoblast isolation-protocol 1) 
Sigma, Castle Hill, NSW, Australia 
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DNase 1 grade II, from bovine pancreas, 
 ≥ 2,000 KU/mg protein  
(for trophoblast isolation-protocol 2) 
Roche, Castle Hill, NSW, Australia 
Dulbecco's Modified Eagle Medium (DMEM), 
Low Glucose (5.56 mM glucose), GlutaMAX ™ 
(3.97 mM L-alanyl-L-glutamine), sodium 
pyruvate (1 mM) 
Invitrogen, Mulgrave, VIC, Australia 
EDTA, BioUltra, anhydrous, ≥ 99% (titration) Sigma, Castle Hill, NSW, Australia 
Epidermal growth factor (EGF)  Invitrogen, Mulgrave, VIC, Australia 
Fetal bovine serum, heat inactivated, US origin Invitrogen, Mulgrave, VIC, Australia 
Filter 0.22 µm–for solution sterilization Millex GP, Carrigtwohill, Cork, IRL 
HEPES (25 mM)  Sigma, Castle Hill, NSW, Australia 
L-glutamine (99-100%) Sigma, Castle Hill, NSW, Australia 
Sodium chloride (NaCl) Sigma, Castle Hill, NSW, Australia 
Sodium bicarbonate (NaHCO3) Sigma, Castle Hill, NSW, Australia 
Penicillin-Streptomycin-Neomycin (PSN), 
Antibiotic Mixture (100X), 5 mg/ml of 
penicillin, 5 mg/ml of streptomycin, and 10 
mg/ml of neomycin 
Invitrogen, Mulgrave, VIC, Australia 
Percoll (for trophoblast isolation-protocol 1) Sigma, Castle Hill, NSW, Australia 
Percoll (for trophoblast isolation-protocol 2) GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden 
Phosphate buffered saline (PBS) tablets Medicago, Uppsala, Sweden 
Protease 1 Ventana/Roche, Castle Hill, NSW, 
Australia  
Rat tail collagen  Roche, Castle Hill, NSW, Australia 
Trypsin 2.5% solution, from porcine pancreas 
(for trophoblast isolation-protocol 1) 
Invitrogen, Mount Waverley, VIC, 
Australia 
Trypsin type XII-S, from bovine pancreas, 
1,32 x 106 BAEE unit/100 mg bottle 
(for trophoblast isolation-protocol 2) 
Sigma, Castle Hill, NSW, Australia 
0.4% Trypan blue Sigma, Castle Hill, NSW, Australia 
ultraView Multimer Ig Ventana/Roche, Castle Hill, NSW, 
Australia 
ultraView Universal DAB Detection Kit Ventana/Roche, Castle Hill, NSW, 
Australia  
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Vimentin Pre-dilute antibody (V9) Ventana/Roche, Castle Hill, NSW, 
Australia 
KU: Kunitz units; BAEE: Na–benzoyl–L–arginine ethyl ester; DAB: 3, 3′-diaminobenzidine; 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; EDTA: ethylenediaminetetraacetic 
acid. 
 
Solutions 
0.22 µm filters were used for all sterile filtered solutions.  
Trophoblast isolation-protocol 1 solutions 
Sterile saline solution (0.9% NaCl) 
9 g of NaCl was added in 1 l of Milli-Q water and autoclaved. 
L-glutamine (100X, 205 mM) 
200 ml of Milli-Q water was warmed up (37°C) and 6 g of L-glutamine was dissolved. 
The solution was sterile filtered, aliquoted in 5 ml and stored at -20°C. 
NaHCO3 (7.5%) 
7.5 g of NaHCO3 was dissolved in 100 ml of Milli-Q water. The solution was sterile 
filtered and kept at 4°C. 
HEPES (1 M, pH 7.4) 
23.83 g of HEPES was dissolved in Milli-Q water, the pH adjusted to 7.4 and the final 
volume made up to 100 ml. The solution was sterile filtered and kept at 4°C. 
Calcium and magnesium free HBSS (1X) with HEPES (1 M, pH 7.4) 
100 ml of calcium and magnesium free HBSS (10X) was mixed with 25 ml of HEPES (1 
M, pH 7.4) and 875 ml of Milli-Q water. The solution was filtered and stored at 4°C. 
Percoll (90%) 
117 ml of Percoll was mixed with 13 ml of calcium and magnesium free HBSS (10X) and 
stored at 4°C. 
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NaOH (1 M) 
1 ml of 50% NaOH was mixed in 9 ml of Milli-Q water. The solution was kept at room 
temperature.  
Complete CMRL media 
Table 2  
Reagents added to complete CMRL media-trophoblast isolation-protocol 1  
Reagent Volume (ml) 
CMRL 1066 medium-without L-glutamine 427.5  
HEPES (1 M, pH 7.4) 12.5 
PSN (100X) 5 
L-glutamine (100X) 5 
Fetal bovine serum  50 
Total volume 500  
 
Serum free CMRL media 
Table 3  
Serum free CMRL media reagents -trophoblast isolation-protocol 1  
Reagent Volume (ml) 
CMRL 1066 medium-without L-glutamine 477.5 
HEPES (1M, pH 7.4) 12.5 
PSN (100X) 5 
L-glutamine (100X) 5 
Total volume 500 
 
Digestion buffer 
Reagents used for digestion buffer preparation (Table 4). The solution was prepared fresh 
on the experiment day, stored in a 1 l sterile glass bottle and kept at 37ºC until use. 
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Table 4  
Digestion buffer-trophoblast isolation-protocol 1  
Reagent Volume (ml) 
Calcium and magnesium free HBSS (10X) 70 
NaHCO3 (7.5%)  3.3 
HEPES (1 M, pH 7.4) 17.5 
Milli-Q water 532.2 
Total volume 623 
 
Enzyme digestion solution   
Buffer and enzymes were distributed into two 500 ml Erlenmeyer flasks containing the 
placental harvested tissue (Table 5).  
Table 5  
Enzymatic digestion solution-trophoblast isolation-protocol 1  
Reagent 1st digestion (ml) 2nd digestion (ml) 3rd digestion (ml) 
Digestion buffer 134.1 89.7 67.275 
Trypsin (2.5%)  15 10 7.5 
DNase 1 (375 KU/15 ml)  0.9 0.3l 0.225 
Total volume 150 100 75 
KU: Kunitz units.  
 
Percoll gradient  
Percoll concentrations were prepared mixing 90% Percoll solution and calcium and 
magnesium free HBSS (1X) with HEPES (1 M, pH 7.4) in 50 ml Falcon tubes (Table 6). 
The concentrations were stored at 4°C. Gradients were prepared using a 5 ml pipette within 
18 h of trophoblast isolation. 3 ml of each Percoll concentration was added, starting from 
70 and going to 5% (Table 6). The layers were added at a constant and low speed. The 
gradient was not disturbed and kept at room temperature until use.   
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Table 6  
Percoll concentrations for Percoll gradients-trophoblast isolation-protocol 1 
Final Percoll (%) Volume of 90% Percoll (ml) Volume of HBSS (1X) with HEPES (ml) 
70 15.6 4.4 
65 14.4 5.6 
60 13.3 6.7 
55 12.2 7.8 
50 11.1 8.9 
45 10.0 10.0 
40 8.9 11.1 
35 7.8 12.2 
30 6.7 13.3 
25 5.6 14.4 
20 4.4 15.6 
15 3.3 16.7 
10 2.2 17.8 
5 1.1 18.9 
 
Collagen-coated plates 
10 mg of rat tail collagen was resuspended in 5 ml of sterile 0.2% acetic acid. The 
reconstituted collagen was distributed into plates according to the well surface (5 µl/cm2). 
The solution was spread on the wells with a cell scraper and allowed to dry under sterile 
conditions. Plates were covered with aluminium foil and stored at 4°C no more than 15 
days before use.  
Trophoblast isolation-protocol 2 solutions  
Calcium and magnesium free PBS 
5 PBS tablets were dissolved in 1 l of Milli-Q water. The solution was autoclaved and 
stored at 4oC.  
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L-glutamine (50 mM) 
1.461 g of L-glutamine 99-100% was dissolved in 200 ml of warm Milli-Q water. The 
solution was filtered, aliquoted in 5 ml and stored at -20°C.  
Calcium and magnesium free HBSS (10X) with HEPES (250 mM) pH 7.4 
29.8 g of HEPES was dissolved in 500 ml of calcium and magnesium free HBSS (10X). 
The pH was adjusted to 7.4 with NaOH (1 M). The solution was filtered and stored at 
4°C. 
Complete DMEM 
Table 7  
Complete DMEM reagents-trophoblast isolation-protocol 2 
Reagent Volume (ml) 
DMEM Low glucose (5.56 mM) GlutaMAX TM, pyruvate 430 
HEPES (1 M, pH 7.4) 10 
Antibiotic and antimycotic solution (100X)  5 
L-glutamine (50 mM) 5 
Fetal bovine serum  50 
Total volume 500 
For long-term cultures (> 3 days), epidermal growth factor (EGF) was added to complete media. 
EGF vial was briefly centrifuged and re-suspended in 1ml sterile PBS (stock concentration: 100 
µg/ml). 50 µl was added to each 500 ml complete media (final dilution: 10 ng/ml) no more than 
24 h before use. 
 
Digestion Buffer–Dispase/HBSS/HEPES (DHH)  
A total DHH volume of 500 ml was prepared for < 120 g of villous tissue to be digested 
and a total volume of 750 ml was prepared for > 120 g of villous tissue. 50 or 75 ml of 
calcium and magnesium free HBSS (10X) with HEPES (250 mM, pH 7.4) was mixed 
with Milli-Q water to make up 480 ml or 720 ml, respectively. The pH was adjusted to 
7.4 with NaOH (1 M). 20 ml of dispase II (1,000 caseinolytic units) was added for a final 
 230
solution of 500 ml. 30 ml of dispase II (1,500 caseinolytic units) was added for a final 
solution of 750 ml. The solution was sterile filtered and stored at 37°C for same day use. 
Percoll gradient  
Percoll was mixed with calcium and magnesium free HBSS (1X) and HEPES (pH 7.4) to 
make different concentrations (Table 8). Tubes were capped and the solution mixed by 
inversion. Percoll (stock and gradients) was stored at 4°C and removed from the fridge 
before manipulation to equilibrate at room temperature. Percoll layering was prepared 
with a 5 ml pipette within 24 h of trophoblast isolation. The layering started adding 5 ml 
of each Percoll concentration from 60 to 20% (Table 8). 5% gradient was not added at 
this stage. Layers were added at a slow and constant speed. Gradient was not disturbed 
and kept at 4°C until use. 
Table 8  
Percoll concentrations for Percoll gradients-trophoblast isolation-protocol 2  
Gradient (%) Percoll (ml) HBSS (1X) with HEPES (ml) 
60 30 20 
50 25 25 
45 22.5 27.5 
40 20 30 
35 17.5 32.5 
30 15 35 
20 10 40 
5 2.5 47.5 
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Erythrocyte lysis buffer (ELB)  
ELB was prepared (Table 9), sterile filtered, distributed in 45 ml aliquots, sealed and 
stored at room temperature. 
Table 9 
Erythrocyte lysis buffer reagents-trophoblast isolation-protocol 2  
Reagent Weight/volume 
NH4Cl (50 mM) 1.34 g 
NaHCO3 (10 mM) 0.42 g 
EDTA (0.1 mM) 0.0145 g 
Milli-Q water 500 ml 
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Appendix 2: Material, reagents and solutions  
Material and reagents 
Table 1  
Reagents used in this research thesis, in alphabetic order, and their respective 
suppliers  
Reagent  Supplier 
Amyloglucosidase, from Aspergillus 
niger lyophilized powder, 30-
60 units/mg protein (biuret), ≤ 0.02% 
glucose 
Sigma, Castle Hill, NSW, Australia 
BCA protein assay kit acid-Pierce TM Thermo Scientific, Rockford, IL, USA 
Bovine serum albumin, fatty acid 
(BSA-FA free), ≥ 96% 
Sigma, Castle Hill, NSW, Australia  
D-Glucose Sigma, Castle Hill, NSW, Australia 
DMEM, no glucose no glutamine  Invitrogen, Mulgrave, VIC, Australia 
Filters GF/B Glass Circles, 25 mm 
diameter 
Whatman, Rydalmere, NSW, Australia 
Glucose assay kit Wako, Osaka, Japan 
Glycogen from bovine liver Type IX Sigma, Castle Hill, NSW, Australia 
[5-3H]-D-glucose Perkin-Elmer Life Sciences, Waltham, MA, USA 
HEPES powder Sigma, Castle Hill, NSW, Australia 
[5-3H]-water  Perkin-Elmer Life Sciences, Waltham, MA, USA 
Isopropanol Ajax Finechem, Taren Point, NSW, Australia 
KOH Sigma, Castle Hill, NSW, Australia 
Lactate Colorimetric Assay Kit II BioVision, Milpitas, CA, USA 
L-carnitine hydrochloride synthetic, 
≥ 98% 
Sigma, Castle Hill, NSW, Australia 
Methanol  Selby-BioLab, Clayton, VIC, Australia 
NaHCO3 Sigma, Castle Hill, NSW, Australia 
NEFA C (ACS-ACOD method) kit Wako, Osaka, Japan 
Nunc™ Lab-Tek™ II Chamber Slide™ 
System, culture area of 0.7 cm², 8 wells  
Thermo Scientific, Scoresby, VIC , Australia 
Perchloric acid (PCA), ACS reagent, 
70% 
Sigma, Castle Hill, NSW, Australia 
PermaFluor Aqueous Mounting Medium  Thermo Scientific, Scoresby, VIC , Australia 
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PVC tubing-I.D. x O.D.: 3/16 x 5/16 
inch 
Thermo Fisher Nalgene, Scoresby, VIC, Australia 
Read Safe cocktail (scintillation liquid)  Beckman Coulter, Fullerton, CA, USA 
Rubber stoppers size 14.5, 7/16 LN Thermo Fisher Nalgene, Scoresby, VIC, Australia 
Scintillation vials Super polyethylene vial, 20 ml, Perkin Elmer, 
Waltham, MA, USA 
Sodium acetate  Sigma, Castle Hill, NSW, Australia 
Sodium dodecyl sulphate (SDS) Sigma, Castle Hill, NSW, Australia 
Sodium oleate (C18:1)   Nu-chek-Prep, Elysian, MN, USA  
Sodium palmitate (C16:0)  Nu-chek-Prep, Elysian, MN, USA  
T25 culture flask, canted neck, slim type IWAKI, Asahi techno glass, Shizuoka, Japan 
Triglyceride Determination kit Sigma, Castle Hill, NSW, Australia 
Tris (hydroxymethyl) aminomethane Sigma, Castle Hill, NSW, Australia 
[(U) 14C]-2-deoxy-D-glucose  Perkin-Elmer Life Sciences, Waltham, MA, USA 
[(U)14C]-D-glucose  Perkin-Elmer Life Sciences, Waltham, MA, USA 
[(U)14C]-palmitic acid  Perkin-Elmer Life Sciences, Waltham, MA, USA 
Urea Ajax Finechem, Auburn, NSW, Australia 
HEPES: 4-(2-hydroxyethyl hydroxyethyl)-1-piperazineethanesulfonic acid. BCA: bicinchoninic 
acid. 
 
Solutions 
0.22 µm filters were used for all sterile filtered solutions.  
HEPES (1 M, pH 7.4) 
23.83 g of HEPES was dissolved in Milli-Q water, the pH adjusted to 7.4 and the final 
volume made up to 100 ml. The solution was sterile filtered and kept at 4°C. 
NaHCO3 50X (100 mM) 
0.84 g was dissolved in 100 ml of Milli-Q water. The solution was sterile filtered and kept 
at 4°C. 
Glucose solution (1 M) 
18.016 g of glucose was added to Milli-Q water to make up a 100 ml final solution. The 
solution was sterile filtered, aliquoted and kept at -20°C. 
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KOH (30%) 
30 g of KOH was added to Milli-Q water to make up a 100 ml final solution. The solution 
was kept in a sealed glass bottle at room temperature.  
KOH (0.5 M) 
5.6 g KOH was dissolved in 200 ml of 95% ethanol. The solution was kept in a glass 
bottle at room temperature.    
MgSO4 (0.15 M) 
11.07 g of MgSO4.7 H2O was added to 300 ml of Milli-Q water. The solution was kept 
in a glass bottle at room temperature.    
Na2SO4 (6%) 
6 g of Na2SO4 was added to Milli-Q water to make up a 100 ml final solution. The solution 
was kept in a glass bottle at room temperature.    
L-carnitine (100 mM) 
0.197 g of L-carnitine was diluted in 10 ml of Milli-Q water. The solution was sterile 
filtered, aliquoted in 20 µl into 0.5 ml sterile microtubes and stored at -20°C. 
Na-Acetate buffer (0.5 M, pH 4.8)   
21 g Na-acetate (anhydrous) was dissolved into 300 ml of Milli-Q water. The pH was 
adjusted to 4.8 with acetic acid and Milli-Q water added to make up a 500 ml final 
solution. Fresh solution was prepared for each experiment.  
Amyloglucosidase solution (2 mg/ml) 
This solution was freshly prepared in each experimental day. Amyloglucosidase was 
weighed and added to 0.5 M Na-acetate buffer (pH 4.8) to make up a 2 mg/ml final 
concentration. The final volume was calculated according to each assay.  
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5X Krebs-Ringer Bicarbonate (KRB) Buffer 
5X KRB buffer was prepared in advance according to Table 2. Final solution was filtered 
and stored in a 500 ml sterile glass bottle at 4ºC until use. 
Table 2  
5X Krebs- Ringer Bicarbonate (KRB) Buffer 
Reagent Weight/volume 
CaCl2 0.55 g 
NaCl   19.72 g 
KCl 0.67 g 
NaH2PO4 0.15 g 
MgCl2 0.25 g 
Milli-Q water  Up to 500 ml 
Total  500 ml  
 
Krebs-Ringer Bicarbonate HEPES (KRBH)  
KRBH was freshly prepared fresh in each experimental day. After mixing the reagents 
(Table 3), the pH was adjusted to 7.4 with NaOH (1 M) and the solution was kept inside 
a 5% CO2 incubator at 37°C until use. 
Table 3 
Krebs-Ringer Bicarbonate HEPES (KRBH)  
Reagent Volume (ml) 
NaHCO3 (100 mM) 2 
HEPES (1 M, pH 7.4) 1 
KRB 5X 20 
Milli-Q water 77  
Total 100  
 
NEFA stock preparation  
Palmitate and oleate stocks were prepared according to method described by Roche et al. 
(342) with modifications. 5 g of BSA-FA free was resuspended in 100 ml of KRBH 
solution to obtain KRBH-5% BSA-FA free (wt/vol), and later sterile filtered. 70 ml was 
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taken for NEFA stock preparation and the remaining was kept at 4°C under sterile 
conditions. 200 mg of sodium palmitate was added to 30 ml of KRBH-5% BSA-FA free 
and 25 mg of sodium oleate was added to 40 ml of KRBH-5% BSA-FA free. Both 
solutions containing palmitate or oleate were gazed with nitrogen gas for a couple of 
minutes, sealed with parafilm M and incubated overnight on a rocker/shaker at 37°C. 
Following overnight incubation, NEFA-5% BSA solutions were filtered under sterile 
conditions. An aliquot of 200 µl was then taken for measurement of fatty acid 
concentration. Samples were serial diluted and measured using NEFA C kit according to 
manufacture instructions. The solution containing oleate and palmitate were adjusted to 
4 mM concentration using KRBH-5% BSA. NEFA stocks were stored at -20°C in small 
aliquots to avoid repetitive thawing and freezing cycles. The stocks were used within 6 
months of their preparation.  
Complete DMEM with 1 mM glucose  
Complete DMEM plus 1 mM glucose was prepared (Table 4) on the experimental day 
for pre-incubation of glycogen total content experiment (Chapter 3) 
Table 4  
Complete DMEM with 1 mM glucose 
Reagent Volume  
HEPES 1 M (pH 7.4) 2 ml 
L-glutamine (50 mM) 1 ml  
Antibiotic and antimycotic solution (100X) 1 ml  
Fetal bovine serum 10 ml  
Glucose (1 M) 100 µl 
DMEM, no glucose no glutamine  85.9 ml 
Total  100 ml 
Refer to Appendix 1 for reagent details.  
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Glucose and palmitate oxidation–material preparation 
PVC tubing were cut into 3 cm length and filter papers were cut into 3 equal pieces. Then, 
one end of 3 cm of tubing piece was wrapped in parafilm without covering the lumen and 
the tubing was firmly fitted into the underside of the rubber stopper.  
In order to improve 14CO2 fixation, 150 µl of 5% KOH was applied on each filter paper 
which was later inserted into the tubing with tweezers in a position to let the tubing 
opening clear.  
Protein lysis buffer  
The reagents listed on Table 5 were one by one added to 80 ml of Milli-Q water. The pH 
was adjusted to 7.5 using NAOH (1 M). The final volume was finally completed to 100 
ml and the solution was filtered and stored at room temperature. 
Table 5  
Protein lysis buffer 
Reagent Weight/volume 
Urea 36.04 g 
20% SDS (Sodium dodecyl sulphate) 10 ml  
2 M TRIS base solution (pH 7.5) 3.13 ml 
Milli-Q water  Up to 100 ml  
Total  100 ml  
 
Oil Red O stock solution 
500 mg of Oil Red O dye powder was dissolved into 100 ml of isopropanol and allowed 
to stand overnight at room temperature.  
Oil Red O working solution  
Oil red O working solution was freshly prepared on the experimental day. 3 ml of Oil red 
O stock was mixed with 2 ml of diluted with ddH2O [3:2 (vol/vol) ratio; Oil red O: 
ddH2O]. The solution was allowed to stand for 10 minutes at room temperature and later 
filtered through a 0.22 µm filter into 50 ml Falcon tubes.   
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